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 Summary 
 
 
 
Both the immune and the thyroid hormone systems are integral to human physiology and 
health. They are also important for normal development from early in fetal life, but 
simultaneously vulnerable to chemical exposures and disruption during fetal and early 
postnatal life. If disrupted during development, both systems can become compromised 
leading to negative consequences later in life. This includes effects on immune function, 
neurobehavior and cognitive abilities. In fact, since thyroid hormones are crucial for brain 
development there are correlations between low maternal serum thyroxine (T4) levels and 
subsequent adverse effects on child neurobehavior and intelligence quotient (IQ). 
Poly- and perfluoroalkylic substances (PFAS) are compounds linked to immunotoxicity 
and thyroid hormone disruption. They are ubiquitous and persistent in the environment and 
human exposure is universal, hence a potential risk to human health. Yet the toxicity 
potential of several PFASs, including perfluorohexane sulfonate (PFHxS), remains largely 
unknown. This PhD project therefore aimed at investigating the developmental toxicity of 
PFHxS, with an emphasis on the reproductive, the thyroid hormone and the immune 
systems. PFHxS toxicity was further investigated in combination with exposure to a 
human-relevant mixture of 12 endocrine disrupting chemicals. These studies showed that, 
for some endpoints, there was increased sensitivity to PFHxS exposure when it was 
combined with the mixture and that PFHxS and the mixture could potentiate the effect of 
each other. This indicates that the current European approach for regulating chemicals, 
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relying on risk assessment of one chemical at a time, may underestimate the risk to humans 
who are exposed to a multitude of chemicals on a daily basis. 
The main finding in these studies was that PFHxS reduced maternal and offspring thyroid 
hormone levels. This happened without apparent activation of the compensatory feedback 
responses. We were not able to correlate the decreased thyroid hormone levels to behavior-
al effects in the offspring, but the literature suggests that the employed tests are insensitive 
measures of altered brain development due to developmental thyroid hormone reductions. 
In humans, however, even smaller reductions in thyroid hormone levels during develop-
ment, may affect complex functional parameters as language development and IQ, 
endpoints which are not measurable in rodents. Hence, in order to protect human brain 
development there is a strong need for development of new test methods for identification 
of adverse effects on brain development due to disruption of the thyroid hormone system. 
Preferably, these would include assays that are sensitive to more moderate reductions of 
thyroid hormone levels (reduction in T4<50%). Such tests are necessary because the 
legislative framework for regulating the use of chemicals relies on assays showing 
downstream adverse outcomes. Until a suitable test for adverse effects due to developmen-
tal thyroid hormone disruption has been identified, a compromise designed to protect 
human cognition could be to regard decreased serum T4 as an adverse outcome in itself. 
PFHxS exposure had limited effects on the immune system in our study; however, a faulty 
study design impedes conclusions on especially functional immune endpoints, which in 
theory should be the most sensitive measure of immune competence. At the highest tested 
dose, PFHxS may reduce immune organ weights, but this could not be replicated in the 
larger study that investigated lower doses. Hence, further studies of immunotoxicity of 
PFHxS are warranted. 
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 Resumé 
 
 
 
Både immun- og thyreoideahormon-systemerne er vigtige for human fysiologi og sundhed. 
Fra tidligt i fosterstadiet er de også vigtige for en normal udvikling, men samtidigt yderst 
sårbare over for påvirkning fra kemikalier. Hvis der sker forstyrrelser under udviklingen 
kan begge systemer blive påvirkede, og det kan blandt andet have negative konsekvenser 
for immunfunktionen, adfærd og kognitive evner senere i livet. De rette niveauer af 
thyreoideahormonerne er afgørende for hjernens udvikling, og mange studier har vist 
sammenhænge mellem lave thyroxin(T4)-niveauer i gravide og skadelige effekter på deres 
børns adfærd og intelligenskvotient (IQ). 
Poly-og perfluorerede stoffer (PFAS) er blevet kædet sammen med immuntoksicitet og 
thyreoideahormonforstyrrelser.  Stofferne udgør en potentiel sundhedsrisiko for menne-
sker, da de findes overalt i miljøet, er persistente, og menneskers udsættelse for stofferne er 
universel. På trods af dette, er der stadig adskillige PFASer, hvis toksicitet er stort set 
ukendt. Det gælder også perfluorhexansulfonat (PFHxS). Dette PhD-projekt har derfor haft 
til formål, ved hjælp af rotteforsøg, at undersøge PFHxSs toksiske effekter på udviklingen,  
med et særligt fokus på effekter i reproduktions-, thyreoideahormon- og immunsystemet. 
Derudover blev PFHxS undersøgt for kombinationseffekter ved at udsætte rotterne for 
både PFHxS og en blanding af 12 hormonforstyrrende kemikalier, som er repræsentative 
for, hvad mennesker udsættes for i dagligdagen. Studierne viste, at udsættelse for PFHxS i 
kombination med blandingen af miljøkemikalier førte til øget toksicitet af PFHxS for nogle 
effekter, og at PFHxS og blandingen af miljøkemikalier kunne potentiere effekten af 
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hinanden. Dette indikerer, at den nuværende europæiske metode til regulering af kemikali-
er, hvor risikovurdering foretages for et kemikalie ad gangen, kan undervurdere risikoen 
for mennesker, som jo i dagligdagen udsættes for en kompleks blanding af kemikalier. 
Det vigtigste fund i de udførte dyrestudier var at PFHxS nedsatte niveauet af thyreoi-
deahormoner hos både mødre og unger. Der sås ikke nogen tydelig aktivering af hormon-
aksens feed-back mekanismer. Der var ikke nogen klar sammenhæng mellem de nedsatte 
thyreoideahormonniveauer under udviklingen og adfærdseffekter i ungerne, men ud fra 
litteraturen tyder det på, at de anvendte tests er ufølsomme over for ændret hjerneudvikling 
der er opstået som konsekvens af thyreoideahormonforstyrrelser under udviklingen. Hos 
gravide kvinder ses mindre nedsættelser i T4 niveauerne imidlertid at have en effekt på 
komplekse funktionelle parametre som sprogudvikling og IQ hos deres børn, hvilket jo 
ikke kan måles i rotter. For at kunne beskytte hjerneudviklingen hos mennesker er der 
derfor et stort behov for udvikling af nye testmetoder, så man i dyreforsøg kan måle 
effekter på hjerneudviklingen som følge af påvirkning af thyreoidea-hormonsystemet. Der 
er især et behov for tests som er følsomme overfor moderate nedsættelser i thyreoideahor-
monniveauet (T4 reduktion<50%). Sådanne tests er helt nødvendige, fordi brugen af 
hormonforstyrrende kemikalier reguleres på baggrund af anerkendte tests, der påviseligt 
har ført til skadelige effekter i dyr. Indtil sådanne tests for skadelige effekter i forsøgsdyr er 
udviklet, kan et kompromis for at beskytte hjerneudvikling hos mennesker være, at anse 
nedsættelse af T4-niveauet som en skadelig effekt i sig selv. 
I vores studie viste udsættelse for PFHxS begrænsede effekter på immunsystemet. Men et 
ikke optimalt studiedesign forhindrede desværre, at der kunne drages konklusioner på især 
de funktionelle parametre, som i teorien skulle være de mest følsomme indikatorer for 
immunfunktionen. Ved den højest undersøgte dosis tydede det på, at udsættelse for PFHxS 
nedsatte vægten af immunorganer, men dette kunne ikke bekræftes i det store forsøg, som 
blev udført med lavere doser. Derfor vil yderligere studier af PFHxS’s mulige immuntok-
sicitet være nødvendige.  
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1 Introduction 
 
This chapter introduces the topic of the thesis (1.1), the rationale and aims (1.2) and 
provides an outline (1.3) of the following chapters.  
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1.1 Introduction 
 
The last decades have witnessed a rising prevalence of disorders of the immune and 
thyroid systems such as asthma, allergies, autoimmune disorders and thyroid cancers [A. 
C. Gore et al., 2015; Lim et al., 2017; McFadden et al., 2015; WHO/UNEP, 2013]. 
Neurobehavioral disorders are also increasing, and in the U.S. an estimated 1 in 59 
children are currently being diagnosed with autism spectrum disorders and 9.4% with 
attentive hyperactivity disorders [Baio et al., 2018; Danielson et al., 2018]. The rate at 
which this surge in incidents have occurred excludes genetic factors as the primary cause, 
but rather suggests a combination of changing diagnostic patterns and environmental 
factors to be the cause. Early life exposure to environmental chemicals could constitute 
such an environmental factor as both the immune and thyroid hormone systems seem 
particularly vulnerable to xenobiotic disruptions during development [Dietert, 2008; 
Gilbert & Zoeller, 2011].  
Both the thyroid hormone and immune systems are essential for maintaining organismal 
homeostasis and health in adult life, but to function optimally they rely on a complex 
network of tissues, organs and inter-related signaling pathways. The foundation for this 
network is set down during fetal and early postnatal life as the simple zygote grows and 
develops into a fully formed organism. Exposure to xenobiotics during these sensitive life-
stages can disrupt the process and cause life-long consequences [A. C. Gore et al., 2015; 
WHO/UNEP, 2013]. With regard to the immune system, disrupted development could 
render the offspring predisposed to immune dysfunction and non-communicable diseases. 
As for the thyroid hormone system, a primary concern is that the brain does not develop 
optimally, since thyroid hormones are crucial for development of the central nervous 
system. 
Perfluorinated compounds are one class of chemicals that have been implicated in immu-
notoxicity and thyroid hormone disruption. Much of the available data comes from human 
epidemiological studies however, and empirical cause-effect relationship data remain 
largely lacking. This knowledge gap was a major motivation for this PhD project, which 
sought to better explain how, and if developmental exposure to perfluorinated chemicals 
can have detrimental consequences for the offspring’s immune- or neurocognitive status. 
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1.2 Rationale and aims 
 
The aim of this project was to investigate the developmental toxicity of perfluorohexane 
sulfonate (PFHxS), using the rat as a model. Focus was on the immune and thyroid 
hormone systems, guided by epidemiological studies. For instance, correlations between 
PFHxS and human immune function has implicated the immune system as a potential 
target of PFHxS, whereas studies on thyroid function and the importance for brain 
development has shown the need for increased understanding of thyroid hormone disrup-
tors and their adverse effects on brain development in animal studies.  
 
 
1.3 Outline 
 
With chapter 1 providing the introduction to this thesis, chapter 2 contains the background 
for the scientific work. It introduces the perfluorinated compounds, reviews the literature 
that prompted us to perform the studies on PFHxS. Additionally it contains an introduction 
to the thyroid hormone system and thyroid hormone disrupting compounds, and reviews 
the literature on human thyroid hormone status and implications for brain development. 
Chapter 3 contains the scientific paper on developmental toxicity of PFHxS where the 
most important finding was effects on thyroid hormone levels in serum. In chapter 4, the 
manuscript focuses on this identified effect and studies the thyroid hormone system and 
potential adverse effects in response to thyroid hormone disruption by PFHxS. Chapter 5 
contains the study report on the immunotoxicological work. In chapter 6 the results of the 
presented work are discussed and contrasted to previous work on thyroid hormone 
disrupting chemicals and the potential implications for human brain development. Finally, 
chapter 7 contains the conclusions of this project. 
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2 Background 
 
This chapter introduces the concept of environmental chemicals and endocrine disruptors 
(2.1), the perfluorinated compounds (2.2), the thyroid hormone system and thyroid 
hormone disruptors (2.3) and the importance of thyroid hormones during brain develop-
ment (2.4). It concludes with a description of the influence of perfluorinated compounds on 
thyroid status (2.5) and the developing immune system (2.6).  
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2.1  Environmental chemicals and endocrine 
disruptors 
 
Thousands of industrial chemicals are produced and a large number are now ubiquitous in 
the environment. Consequently, the combined human exposure to chemicals via foods, 
textiles, dust, and so forth, make up a complex mixture that potentially can influence 
development and health [Kortenkamp, 2014; Svingen & Vinggaard, 2016; WHO/UNEP, 
2013].  
Human exposure to environmental chemicals may cause a plethora of effects, including 
disruption of endocrine functions and adverse effects on the developing immune system. 
The World Health Organisation (WHO) has defined an endocrine disrupting chemical 
(EDC) to be “an exogenous substance or mixture that alters function(s) of the endocrine 
system and consequently causes adverse effects in an intact organism, or its progeny, or 
(sub)populations” [WHO/IPCS, 2002]. The identification of a chemical as an endocrine 
disruptor hence relies on both an identified endocrine mode of action causing a physiologi-
cal change, and a subsequent adverse effect.  
The majority of industrial chemicals have not been thoroughly tested for their potential 
endocrine disrupting potential prior to market introduction, and testing them all is extreme-
ly resource demanding [Svingen & Vinggaard, 2016]. In order to increase knowledge on 
toxicological pathways and make better use of knowledge generated via alternative 
approaches (e.g. non-animal tests), the Organisation for Economic Co-operation and 
Development (OECD) initiated a toxicological knowledge framework programme; 
Adverse Outcome Pathways (AOPs) to “support chemical risk assessment based on 
mechanistic reasoning” [OECD, n.d.]. An AOP describes causally linked events leading to 
an adverse health or ecotoxicological effect.  
The work on thyroid hormone disruption performed in this thesis builds on the AOP 
framework and parallels some of the work performed at the US Environmental Protection 
Agency (EPA) for the AOP number 42 “Inhibition of Thyroperoxidase and Subsequent 
Adverse Neurodevelopmental Outcomes in Mammals” (Fig. 1) [Crofton et al., 2018; 
Hassan et al., 2017]. This AOP initiates with inhibition of thyroid hormone synthesis 
(through thyroperoxidase inhibition) resulting in decreased serum thyroxine (T4) levels 
leading to reduced thyroid hormone mediated gene transcription in the brain, and subse-
quent effects on brain development and cognition. Decreased serum T4 was our point of 
entry into the AOP, it is a central Key Event shared by many thyroid hormone disrupting 
chemicals acting through different targets. 
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Figure 1 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals. The 
AOP describes the sequential relationship of events following inhibition of thyroperoxidase by a xenobiotic. The 
molecular initiating event leads to reduced serum thyroxine, reduced thyroxine in the developing brain, reduced thyroid 
hormone mediated gene expression and altered morphology and function resulting in the adverse outcome defined as 
decreased cognitive function. KER: Key event relationship, TH: Thyroid hormones. From [Crofton et al., 2018]. 
  
 
 
  
2.2 Perfluorinated compounds 
 
Poly- and perfluoroalkylic substances (PFAS) comprise a large group of industrial 
chemicals used as surfactants since the 1950s, largely for their ability to repel oil and 
water. There are hundreds of PFAS that have been, or still are used in a variety of consum-
er products, from food contact materials and Teflon-coated frying pans, to upholstery and 
outdoor adventure gear. The industrial uses include firefighting foams, lubricants, paints 
and emulsifiers for fluoropolymer production [Lindstrom et al., 2011].  
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Although PFAS are desired for their oil and water repellency, it is exactly these properties 
that make them problematic environmental pollutants; they are persistent and bioaccumu-
late in animals and humans. The perfluorinated compounds are fully fluorinated on the 
carbon chain and the strength of these carbon-fluorine bonds prevent metabolism in 
humans. Instead it appears that they, unlike many other Persistent Organic Pollutants 
(POPs), are not stored in fatty tissues but instead bind to proteins and are distributed in 
blood, liver and peripheral tissues [Kerstner-Wood et al., 2003; Pérez et al., 2013]. 
The longstanding use and persistence of the compounds have ensured widespread envi-
ronmental contamination. They are found at the bottom of the ocean, at the top of the 
atmosphere and in polar bears of remote arctic regions, as well as in virtually all tested 
individuals in tissues including brain, blood, milk, lungs, and liver [Calafat et al., 2007; 
Giesy & Kannan, 2001; Greaves et al., 2012; Gützkow et al., 2012; Kärrman et al., 2007; 
Mørck et al., 2015; Nøst et al., 2014; Smithwick et al., 2005]. 
Considerable efforts have been made to restrict the use of PFAS, and the use of especially 
the long-chained compounds now appear to have been reduced due to measures taken by a 
number of governments, users and the industry producing the compounds [Blum et al., 
2015; Lindstrom et al., 2011; Stockholm Convention, 2009; US EPA, 2006, 2015]. This 
reduction in use has been confirmed by some epidemiological studies [Axmon et al., 2014; 
Bjerregaard-Olesen et al., 2016; Eriksson et al., 2017; Nøst et al., 2014; Schröter-Kermani 
et al., 2013; Seo et al., 2018], whereas it is not (yet) evident in a few others [Glynn et al., 
2012; Kato et al., 2011; E. Okada et al., 2013]. Some uncertainties with regard to changing 
production patterns also exist and it has been suggested that production has moved to Asia 
and shifted to some of the more unknown compounds [Axmon et al., 2014; Eriksson et al., 
2017; Nøst et al., 2014; Seo et al., 2018]. Nevertheless, contamination of the general 
environment and point sources and exposure of the general population will continue for 
years to come [Wang et al., 2017].  
 
 
2.2.1   PFOS, PFOA and PFHxS 
The human exposure to PFAS is widely documented. Perflurooctane sulfonate (PFOS) is 
typically found at the highest concentrations, often followed by perfluorooctanoic acid 
(PFOA) and PFHxS. PFOS and PFOA are by far the most studied perfluorinated com-
pounds and also those that generally appear to be the most toxic (Fig. 2). Toxicities in 
vitro, in animals and in humans include effects on the metabolic-, immune-, and thyroid 
hormone systems. PFHxS with its C6-chain is at the boundary between what is classified 
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as short or long-chain compounds, since its acid counterpart perfluorohexanoic acid 
(PFHxA) is a short chain PFAS, while PFHxS is usually termed a long-chained PFAS 
[Buck et al., 2011]. PFHxS is interesting with regard to human toxicity for a number of 
reasons. It is usually in the top 3 of human exposures and its half-life stands out in, likely 
comparison to the other PFAS where it does not follow the norm with decreasing chain 
length predicting decreased half-life. Rather, the order is PFHxS>PFOS>perfluorobutane 
sulfonate (PFBS). The half-life of PFHxS is longer than 7 years in humans [Axmon et al., 
2014; Gao et al., 2015; Olsen et al., 2007; Yang et al., 2016] due to enterohepatic circulati-
on of PFAS [Genuis et al., 2013; Zhao et al., 2015, 2017]. There are also reports suggest-
ing that some sites are contaminated with the compound [Gyllenhammar et al., 2015; Hu et 
al., 2016; Norström et al., 2015] and PFHxS has recently been classified according to the 
European chemicals legislation, REACH, as a substance of very high concern, due to its 
very persistent and very bioaccumulative (vPvB) properties [ECHA, 2017a, 2017b, 
2017d]. Furthermore, it is proposed for listing as a persistent organic pollutant (POP) 
according to the Stockholm Convention [UNEP, n.d.]. In spite of this, the toxicity of 
PFHxS is not well described [Danish Ministry of the Environment, 2015; FSANZ, 2016] 
and at the initiation of this project only one developmental toxicity study in rats could be 
identified [Butenhoff, Chang, et al., 2009], warranting further studies into how PFHxS 
might affect exposed individuals in the future. A study in mice has recently been published 
[S. Chang et al., 2018]. 
Figur 2 Figure 2 | Chemical structures of Perflurooctane sulfonate (PFOS), perfluorohexane sulfonate (PFHxS) and perfluoro-
butane sulfonate (PFBS). 
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2.3 The thyroid hormone system and thyroid 
hormone disruptors 
 
The main function of the two thyroid hormones is to regulate metabolism. They exert their 
actions in most tissues and organs of the mammalian organism. During development their 
function is more dynamic and they have a crucial role in the development of the central 
nervous system where they help regulate neurogenesis, migration, synaptogenesis and 
myelination [Gilbert & Zoeller, 2011; Howdeshell, 2002; Moog et al., 2017]. Because of 
the complexity of the thyroid hormone system, chemicals can interfere with thyroid 
hormone action in many different ways and in various target tissues.  
 
 
2.3.1  The thyroid hormone system 
Thyroid hormone action is controlled by an intricate system making up the thyroid 
hormone system. Central is the hypothalamic-pituitary-thyroid axis (HPT-axis) (fig. 3). 
Here thyrotropin-releasing hormone (TRH) from the hypothalamus stimulates the release 
of thyroid-stimulating hormone (TSH) from the pituitary. TSH stimulates the thyroid 
follicular cells through the TSH-receptor to increase activity of the thyroid gland. This 
includes all steps of TH synthesis and secretion and both increased expression and activity 
of enzymes. Iodide uptake is increased through the Sodium-Iodide Symporter (NIS), and 
hormone production and excretion is stimulated. Thyroperoxidase (TPO) performs the 
rate-limiting step of hormone synthesis that occurs in the thyroid follicle lumen [Ortiga-
Carvalho et al., 2016]. TPO incorporates iodine into thyroglobulin (Tg) forming iodothyro-
sine scaffolds, on which the thyroid hormones (TH) thyroxine (T4) and triiodothyronine 
(T3) are built and released to the circulation in a ratio of 80:20 [Laurberg, 1976]. T4 and 
T3 in turn exert negative feedback on release of TRH and TSH from the hypothalamus and 
pituitary, to control thyroid hormone homeostasis [Ortiga-Carvalho et al., 2016]. 
THs are released to the circulation from the thyroid gland, where they bind to the serum 
distributor proteins albumin, transthyretin (TTR) and thyrosin-binding globulin (TBG). 
These proteins are believed to transport and shield thyroid hormones from metabolism and 
transport them to their target cells [Alshehri et al., 2015; Mendel et al., 1987]. The fraction 
(<1%) of unbound free hormone is in equilibrium with the much larger pool of protein 
bound hormones [Alshehri et al., 2015]. Assays measuring free T4 (fT4) intends to  
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Figure 3 | Overview of the hypothalamic-pituitary-thyroid axis and the thyroid hormone system with points of 
regulation. See text for details. TR: Thyroid Receptor, TRH: Thyrotropin-Releasing Hormone, TSH: Thyroid-Stimulating 
Hormone (thyrotropin), NIS: Sodium-Iodide Symporter (mediates uptake of Iodide into the thyroid follicular cells), I-: 
Iodide, T4: Thyroxine, T3: Triiodothyronine, TH: Thyroid Hormone, TPO: Thyroid Peroxidase (oxidation of Iodide to 
iodine, TSHR: TSH receptor, TBG: Thyroxine-binding globulin, TTR: Transthyretin, MCT8: Monocarboxylate Transporter 
(specific T3 transporter), OATP: Organic Anion Transporting Polypeptide, D1: Deiodinase type I, D2: Deiodinase type II, 
D3: deiodinase type III, UDPGT: Uridinediphosphate-Glucoronosyl Transferases, SULT: Sulfotransferases. Modified from 
[Gilbert et al., 2012]. 
  
Peripheral tissues 
UDPGT, SULT 
Deiodinases 
Peripheral tissues 
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determine the amount of fT4 while measurements of total T4 include both the free and 
protein bound T4.  
Thyroid hormones are actively transported into cells through membrane transporters as 
monocarboxylate transporter (MCT) 8 and organic anion transporters (OATPs) [Bernal et 
al., 2015; Landers & Richard, 2017; Wirth et al., 2014]. Here, deiodinases convert T4 to 
the active T3 which acts on the nuclear thyroid hormone receptors (TR)s in target cells, 
these are ligand-regulated transcription factors working with accessory proteins to repress 
or promote gene transcription [Schroeder & Privalsky, 2014]. Accordingly, lack of 
receptor ligand has a function and as such can have a more detrimental effect on develop-
ment than simple lack of the entire receptor [Gil-Ibañez et al., 2013; Sjögren et al., 2007]. 
Differential expression of the receptor isoforms secures some of the regulation of TH 
tissue action during development [Bradley et al., 1992]. 
The complexity of the thyroid system ensures tight control and extensive possibilities of 
spatiotemporal action of the hormones. This can be observed in the developing brain where 
action is tightly controlled for both time and place on a single cell level [Zoeller, 2010]. 
However, this also provides ample opportunity for environmental chemicals and drugs to 
interfere with thyroid hormone action. Chemicals and drugs have been shown to act on 
various targets as TPO, NIS, serum distributor proteins, transporters, liver enzymes, 
deiodinases, and TRs [Crofton, 2008; A. C. Gore et al., 2015; Howdeshell, 2002; 
WHO/UNEP, 2013; Zoeller, 2007].  
 
 
2.3.2  Metabolism of thyroid hormones 
Deiodinases 
The deiodinases are involved in TH metabolism by activating and deactivating TH (fig.4). 
Most peripheral tissues are dependent upon peripheral activation of T4 to T3 by deiodinase 
type 1 (D1), the brain being an exception (see below). As deiodinases also degrades TH, 
the expression and activity of the enzymes are used spatiotemporally to ensure TH action 
locally, irrespective of the circulating hormone levels, and to secure against hormone 
excess [Bates et al., 1999; Hernandez et al., 2010, 2012; Zoeller, 2010]. 
The deiodinases forms part of the compensatory mechanisms of the thyroid system. D1 
expression in liver is negatively regulated by TH, so that expression is increased in 
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hypothyroidism [Zavacki et al., 2005]. Whereas D1 expression in thyroid is proportional to 
serum T4 levels and hence is impaired in hypothyroidism. Hypothyroidism also increases 
brain D2 to maintain T3 levels as seen by PCB induced hypothyroxinemia in fetal rats and 
iodine deficiency [Morse et al., 1993; Peeters et al., 2001]. 
 
Liver enzymes 
Degradation and excretion of thyroid hormones are taken care of by uridine 5'-diphospho-
glucuronosyltransferases (UDP-glucuronosyltransferases, UGTs), sulfotransferases 
(SULTs) and deiodinases (D1, D2 and D3) working in concert (fig. 4). While sulfation 
primarily marks T3 and T4 for inactivation by D1 [Visser, 1994], glucuronidation facilitate 
direct biliary excretion of the hormones. It is believed that the UGT1A family of enzymes 
perform glucuronidation of T4 while the UGT2Bs have T3 as substrate [T. A. Richardson 
& Klaassen, 2010a, 2010b]. 
Some thyroid hormone disrupting compounds act as microsomal enzyme inducers which 
can increase the activity of UGTs and SULTs resulting in increased excretion of TH with a 
subsequent fall in serum levels of primarily T4 [Hood & Klaassen, 2000a; Klaassen & 
Hood, 2001; McClain, 1989; Visser et al., 1993].  
With some microsomal enzyme inducers the HPT axis is activated and TSH is increased 
leading to effect on the thyroid gland: follicular cell differentiation, hypertrophy, reduced 
colloid, and increased gland weight [Hood et al., 1999; Klaassen & Hood, 2001] as would 
be expected based on the theory of the negative feedback loop. However, the reason for 
this increase in TSH remains elusive as not all microsomal enzyme inducers actually cause 
this expected effect on TSH. Instead, comparative studies of enzymes inducers have shown 
that the increased TSH is not correlated with decreased circulating levels of T4 or T3, and 
not to T4 glucuronidation. Potentially, it is mediated through increased biliary excretion 
following glucuronidation of T3 by unknown enzymes that are induced by pregnenolone-
16α-carbonitrile (PCN) but not by 3-methylcholanthrene (3-MC) or Arochlor 1254 (a 
polychlorinated biphenyl, PCB). These compounds all reduce T4, but cause no effect on 
TSH [Hood & Klaassen, 2000a; T. A. Richardson & Klaassen, 2010b; Vansell & Klaassen, 
2001, 2002a, 2002b]. These studies also showed marked differences in the effect patterns 
by microsomal enzyme inducers: serum total and free T4 and T3, TSH, T4 glucuronidation 
and half-life, T3 glucuronidation, thyroid gland effects, D1 activity in liver, kidney and 
thyroid, and D2 activity in brown adipose tissue, pituitary and brain, can all be differential-
ly affected by different compounds [de Sandro et al., 1991; Hood et al., 1999; Hood & 
Klaassen, 2000a, 2000b; Klaassen & Hood, 2001; T. A. Richardson & Klaassen, 2010a, 
2010b; Visser et al., 1993]. Additionally, there is a wide range of compensational effects 
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Figure 4 | Major pathways for thyroid hormone metabolism. See text for details. T4: thyroxine, T3: tri-iodothyronine, 
rT3: reverse T3, T2: diiodothyronine, D1,D2 and D3: deiodinase type 1,2 and 3, SULT: sulfotransferases, UGT: uridine 
diphosphate glucuronosyltransferases, T4G: T4-glucuronide, T4S: T4-sulfate, T3G: T3-glucuronide, T3S: T3 sulfate. 
 
and additional pathways that may be activated as shown by studies of Ugta1 deficient 
Gunn rats and Ugt2b2 deficient Fischer rats [T. A. Richardson & Klaassen, 2010a, 2010b]. 
This clearly shows that there is not one prototypic microsomal enzyme inducer, but rather 
indicates that the different compounds either directly cause the observed differences or that 
the organism responds differentially to different chemical insults. Furthermore, additional 
compensatory responses in other parts of the thyroid system may also be affected. Effects 
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on hepatic transporters, MCT8, D3, thyroid gland genes, distributor protein levels and 
TRH and TSH receptors in hypothalamus and thyroid [Liu et al., 2015; V. M. Richardson 
et al., 2008; Wu et al., 2016] may all contribute to the observed phenotype. 
Compounds which can displace TH from the serum distributor proteins are also believed to 
cause increased thyroid hormone metabolism. Binding of compounds to distributor 
proteins can displace thyroid hormone form the proteins, increasing the free fraction of the 
hormones and making them available to metabolizing enzymes [Alshehri et al., 2015; 
Chanoine et al., 1992]. It is not known whether this displacement of TH in turn can cause 
liver enzyme induction, potentially further decreasing circulating hormone levels; many 
distributor protein binders appear to both cause enzyme induction and displace T4 but it is 
uncertain whether this is due to multiple modes of action or just the protein binding with 
derived additional effects. 
 
 
2.3.3   Transport of thyroid hormones to the fetal brain 
Thyroid hormones are functional from early in gestation. They are potentially available to 
the rat fetus from GD 9 and to the human fetus as early as week 5 and there are biological-
ly relevant levels of fT4 in the first trimester [Calvo et al., 2002; Contempré et al., 1993; 
Woods et al., 1984]. The thyroid receptors appear in the brain around gestation day (GD) 
14 in rats and week 10 in humans [Bernal & Pekonen, 1984; Ferreiro et al., 1988]. 
However, as fetal thyroid function does not initiate until GD 17 in rats and week 18 in 
humans, thyroid hormones are supplied via the maternal thyroid gland and transported 
across the placenta to the fetal circulation (fig. 5) [Calvo et al., 2002; Fisher et al., 1976; 
Patel et al., 2011b]. Many transporters may be implicated in placental transfer, including 
TTR [Landers & Richard, 2017; Patel et al., 2011a]. In the fetal circulation TTR distributes 
TH to tissues, with the fetal brain relying exclusively on maternal T4 and not T3 [Calvo et 
al., 1990; Grijota-Martínez et al., 2011]. T4 is proposed to enter the brain via two mecha-
nisms: across the blood-brain barrier by MCT8 uptake into endothelial cells and then into 
astrocytes via organic anion transporter 1C1 (OATP1C1), and across the blood-
cerebrospinal fluid barriers via MCT8 and OATP1C1 in choroid plexus epithelial cells, 
followed by intracellular complexation with TTR and export into the cerebrospinal fluid 
where TTR distributes T4 to the brain [Chanoine et al., 1992; Landers & Richard, 2017; 
Wirth et al., 2014]. In astrocytes T4 is deiodinated by D2 and T3 is sent to neurons through 
MCT8 for receptor binding, with subsequent degradation performed by D3 [Freitas et al., 
2010; Zoeller, 2010]. It has also been suggested that T4 exerts direct action on TRα1 
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Figure 5 | Transport of thyroid hormones from the maternal circulation to the fetal brain. See text for details. T4: 
thyroxine, T3: tri-iodothyronine, D2 and D3: deiodinase type 2 and 3, MCT8: Monocarboxylate transporter 8, OATP: 
organic anion transporting polypeptide. TTR: transthyretin. 
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[Schroeder & Privalsky, 2014]. 
This intricate system of distributors, transporters and metabolizing enzymes allows for 
careful spatiotemporal timing of thyroid hormone action and some compensatory capacity 
to ensure important hormone action in times of insufficiency or excess [Morreale de 
Escobar et al., 1988]. Nevertheless, there are plenty of examples of insufficient compensa-
tion in both the fetal and neonatal brain resulting in irreversible effects on brain develop-
ment in humans [Berbel et al., 2009; Haddow et al., 1999; Henrichs et al., 2010; Korevaar 
et al., 2016] and rats [Ausó et al., 2004; Gilbert et al., 2014; Lavado-autric et al., 2003; 
Sharlin et al., 2010; Shibutani et al., 2009].  
 
 
2.3.4  The rat as model in thyroid hormone disruptor research 
The thyroid hormone system is highly conserved across species and in mammals the 
molecular similarities are significant. The ontogenesis of the system is similar in rats and 
humans, albeit temporal differences as the final stages of maturation happen postnatally in 
rats (Fischer 1976). Nevertheless, rats and humans share roughly the same thyroid 
hormone system, but with some distinct differences in especially metabolic rates. The rat 
thyroid hormone system runs at a faster pace with a shorter thyroid hormone half-life, than 
the human system. Consequently, the adult rat appears to have impaired compensatory 
capabilities, in response to thyroid hormone disruptors compared to adult humans [Fisher 
et al., 2012; McClain, 1989]. However, during pregnancy, the maternal human thyroid 
system, supplying the fetus, is already vulnerable and hormone production increased to 
meet increased demands, for some beyond capacity (see section 2.3.6). Also neonates are 
uniquely vulnerable with high hormone turnover and no stored iodine or hormone 
[Ginsberg et al., 2007; Glinoer, 1997]. At the same time, just slightly inadequate thyroid 
function during the fetal and neonatal periods may have consequences for child brain 
development (See 2.4.2 and 6.4). This suggests that a potential increased relative sensitivi-
ty of the rat thyroid system could make the rat a good model for human thyroid function 
during development. On the other hand, with regards to brain development, the rat brain 
cannot model the full spectrum of complex human neurobehavior and cognition [Berbel et 
al., 2014].  
The relative distribution between serum distributor proteins is different between rats and 
humans with TTR being predominant in the rat and TBG mostly being present during rat 
development. In humans TBG is the most abundant, binding 70% of thyroid hormones in 
the serum. However, 15% of the hormones are bound to TTR, and this fraction appear to 
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be the biologically active as the affinity to TTR is just enough to protect thyroid hormones 
from degradation, yet low enough to release thyroid hormones at target cells [Alshehri et 
al., 2015]. Thus underscoring the similar hormone systems in the two species. 
The differences between human and rat thyroid systems complicates the risk assessment 
process and warrants further studies. At the same time, thyroid disorders are one of the 
most frequent human endocrine disorders with 11% of the European population affected 
[Madariaga et al., 2014] and a rising frequency of thyroid cancer [Enewold et al., 2009], 
suggesting that the human thyroid system is not infallible. 
 
 
2.3.5  Thyroid hormone balance in the rat during development 
The origin of thyroid hormone supply varies throughout fetal development and early 
postnatal life. The rat fetal thyroid gland is not fully functional until GD 21 and hence T4 
is transferred across the placenta from the dam until late gestation where the fetal gland 
gradually takes over production. Towards the end of gestation dam TSH is suppressed and 
circulating TH falls steadily. Around birth ca 17% of the thyroid hormones in the neonate 
are of maternal origin [Morreale de Escobar et al., 1990]. After birth rising TSH levels 
stimulate T4 production to a steady increase from around PND 5 towards PND 17 where it 
reaches a maximum, before a gradual decline towards the adult equilibria reached around 
PND 35 [Dussault & Labrie, 1975; Fisher et al., 1976; Howdeshell, 2002]. 
 
 
2.3.6  Thyroid hormone economy during pregnancy  
and breastfeeding  
 
In humans, pregnancy brings on physiological changes that include changes to the thyroid 
hormone system and increase the demand of hormone from the gland. Both total and fT4 
rise during the 1st trimester, approximating steady state conditions from gestational week 
12 until term. Throughout pregnancy circulating levels of T3 do not seem to change much 
or they follow the fT4 levels with a modest rise early in pregnancy and later a small 
reduction [Patel et al., 2011a]. The changing hormone levels fall within normal reference 
intervals but it complicates evaluation of thyroid hormone balance because different stages 
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of pregnancy has their individual reference intervals that varies with the laboratory 
performing the measurements [Lazarus & Mestman, 2012].  
These more modest changes to the circulating hormone levels masks more marked 
physiological changes. From early in pregnancy plasma TBG rise due to increased 
synthesis and a stabilizing effect of estrogen, leading to increased T4 levels [Brent, 1997]. 
While T4 levels rise during the first trimester, it suppresses TSH levels, but human 
chorionic gonadotropin (hCG) seems to replace TSHs thyroid stimulating role during these 
first 12 weeks, and its works to further activate the gland [Mestman, 1998]. Later in 
gestation these stimulatory events are followed up by changes in the peripheral metabolism 
of thyroid hormones, especially in the placenta [Lazarus & Mestman, 2012]. Additionally, 
pregnancy brings plasma expansion and increases renal excretion of iodine, potentially 
reducing the iodine available to the thyroid gland. All of these factors work together for a 
net result of increased demand of thyroid hormone [Alexander et al., 2004]. Healthy 
thyroid systems can meet these requirements, but impaired systems may not be able to, and 
the combination of pregnancy and conditions as autoimmune thyroid disorders and 
selenium, iron and iodine deficiency may decrease thyroid capacity and interact with 
pregnancy to cause thyroid insufficiency [Thilly et al., 1992]. 
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2.4 The importance of thyroid hormones during 
brain development 
 
For thyroid hormone disruptors the primary area of concern is potential effects on neuro-
development. Here, the evidence for associations between low thyroid hormone function 
and effects on neurodevelopment will be reviewed. 
 
 
2.4.1  Thyroid hormones and brain development in  
animal studies  
 
Thyroid hormones are essential for both fetal and postnatal brain development and their 
functions during brain development has been extensively reviewed, including: [Bernal, 
2005, 2015, 2017; Demeneix, 2014; Dussault & Ruel, 1987; Gilbert & Zoeller, 2011; 
Howdeshell, 2002; Moog et al., 2017; Morreale de Escobar et al., 2004; Porterfield & 
Hendrich, 1993; Williams, 2008; Zoeller & Rovet, 2004]. 
 
In the rat, thyroid hormones are necessary for neurogenesis from around GD 12 in the 
developing brain. While some areas primarily have neurogenesis during gestation it 
stretches at least until weaning in the cerebellum, hippocampus and olfactory bulb 
[Howdeshell, 2002; Mohan et al., 2012]. Thyroid hormones influence migration so that 
insufficiency results in densely packed neurons and migration defects [Gilbert et al., 2014; 
Mohan et al., 2012; Shibutani et al., 2009]. Later in gestation it is followed by synaptogen-
esis also influences by thyroid hormones. In hypothyroidism, neural connections are 
impaired by decreased axonal growth and branching of neurons. The circuitry is further 
impaired by postnatal effects on oligodendrocyte differentiation and myelination with the 
developmental hypothyroid brain lacking myelination and white matter volume [Berbel et 
al., 1994; Powell et al., 2012; Sharlin et al., 2008]. In the cerebellar cortex lack of thyroid 
hormone results in maturation defects of the purkinje cells with decreased arborization and 
a permanent impairment of neuronal connectivity [Legrand, 1979].  
The effects of developmental hypothyroxinemia and hypothyroidism on brain development 
are well established. However, the majority of studies relied on animal models of severe 
thyroid hormone deficiency. These studies used doses of antithyroid drugs as 10 ppm 
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propylthiouracil (PTU)/200 ppm methimazole (MMI) (and above) in drinking water, 
thyroidectomy or radioiodine treatment. They report a range of effects on the developing 
brain at the highest doses; structure, morphology, function, and behavior including learning 
and memory are all affected [Akaike et al., 1991; Berbel et al., 1994; Dussault & Ruel, 
1987; Gilbert & Zoeller, 2011; Goldey et al., 1995; Iniguez et al., 1996; S. Y. Kim et al., 
1998; Ruiz-marcos et al., 1979]. Models of milder and transient forms of thyroid hormone 
insufficiency are sparser but effects such as migration errors, synaptic transmission, and 
plasticity, and subtle impairments in learning has been found [Gilbert, 2011; Gilbert et al., 
2013, 2016, 2017; Hassan et al., 2017; Mohan et al., 2012; Powell et al., 2012]. Also, 
transient (3 days) exposure to MMI has resulted in a significant proportion of, primarily, 
neurons in aberrant and inappropriate places matched to their birth date, this deranged 
migration resulted in blurred cell layers of both cortex and hippocampus. Additionally, the 
migration was correlated to wild runs and audiogenic seizures in the adult offspring and it 
could be rescued with concurrent T4 treatment [Ausó et al., 2004; Lavado-autric et al., 
2003].  
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Table 1. Thyroid conditions   
Serum fT4 TSH 
 
Reference range of population 
 
Overt hypothyroidism fT4 < 0th percentile elevated 
Subclinical hypothyroidism normal elevated 
Hypothyroxinemia 0th percentile < fT4 < 10th percentile normal 
 
 
 
2.4.2 Thyroid hormones and brain development in humans  
The importance of thyroid hormones for human development has been established through 
studies of congenital hypothyroidism and in areas of endemic iodine deficiency. Congeni-
tal hypothyroidism is a condition in which the neonate cannot produce thyroid hormones of 
their own, they are born with very low levels of thyroid hormones but appear normal due 
to a sufficient supply of thyroid hormones from the mother during pregnancy. However, 
without treatment the continued development of the children is severely inhibited and they 
suffer from severe mental retardation, spasticity, incoordination and hearing loss [Delange, 
1994; Gilbert & Zoeller, 2011]. The symptoms can largely be avoided with early and 
sufficient treatment, but suboptimal neurodevelopment can still be observed [Zoeller & 
Rovet, 2004].  
Severe iodine deficiency during fetal development has even more detrimental consequenc-
es as motor milestone retardation, deaf-mutism, squint and mental deficiency, but endemic 
cretinism is preventable with adequate iodine supply before conception [Pharoah et al., 
1971].  
While the effects of pronounced thyroid hormone deficiency during development are 
detrimental, milder forms of thyroid hormone deficiency at different stages of fetal and 
postnatal brain development may result in many less severe effects that have been studied 
in association studies usually correlating maternal hypothyroidism or hypothyroxinemia 
(Table 1) with child cognition and behavior. 
IQ scores is a common end-point in thyroid studies and effects are often reported. E.B. 
Man was the first to study the effect of maternal hypothyroxinemia on child brain devel-
opment. In one trial with multiple follow-ups they showed that inadequately treated 
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hypothyroxinemia was correlated to decreased child IQ at age 7 and conversely, that 
adequately treated hypothyroxinemia was correlated to increased IQ [Man, 1972; Man & 
Serunian, 1976].  Hypothyroidism during pregnancy resulted on average in a loss of 7 IQ 
points at age 7-9 with 19% of the children falling below 85 IQ points (5% in the matched 
controls) and effects within all 5 parameters of the neuropsychological test; intelligence, 
attention, language and school performance [Haddow et al., 1999]. Some of the women 
were treated for hypothyroidism during pregnancy and despite serum levels of TSH not 
returning to normal, it improved the outcome in the children. Henrichs et al., (2010) 
studied both mild (fT4<10th percentile) and severe (fT4<5th percentile) maternal hypothy-
roxinemia. Mild hypothyroxinemia was associated with an increased risk of expressive 
language delay in the children at age 18 months and severe hypothyroxinemia with verbal 
and nonverbal cognitive delay at 36 months [Henrichs et al., 2010]. Ghassabian et al. 
(2014) showed a mean reduction in IQ of 4.3 points due to maternal fT4<5th percentile 
with normal TSH but found no correlations between brain morphology and volume 
measures in a potentially underpowered sub-analysis [Ghassabian et al., 2014]. Korevaar 
found a similar reduction in IQ between 1.4-3.8 points associated with both low and high 
maternal fT4 levels, and in addition an u-shaped correlation to grey matter and cortex 
volume [Korevaar et al., 2016]. 
Autism, Attention Deficit Hyperactivity Disorder (ADHD), and schizophrenia have also 
been linked to low thyroid hormone during development. Maternal hypothyroxinemia with 
iodine supplementation from 12-14 weeks of gestation or not at all was associated with 
lower developmental quotient in the children at 18 months compared to the quotient in 
children whose mothers were euthyroid and who had received iodine supplementation 
from week 4-6 [Berbel et al., 2009]. Additionally, there was effects on gross and fine 
motor skills and socialization but not on language; a pattern suggesting predisposition to 
development of autism [Berbel et al., 2009]. In a nationwide Danish cohort study hypothy-
roidism during pregnancy was associated with diagnosis of a child with autism spectrum 
disorders [Andersen et al., 2014], and the Dutch generation R study also found that severe 
maternal hypothyroxinemia increased the odds ratio with about 4 for having a child that 
was scored as “probably autistic” [Román et al., 2013]. Vermiglio et al. (2004) studied 
ADHD up until age 8-10 in a moderately iodine insufficient area compared to a marginally 
iodine sufficient area [Vermiglio et al., 2004]. They found that 11 out of 16 children from 
the iodine deficient area had ADHD (vs 0 out of 11 in controls) and that IQ in the iodine 
insufficiency area was 92 vs 110 in controls. In addition, overall ADHD prevalence in the 
iodine deficient area was higher and fT4 levels below normal [Vermiglio et al., 2004]. A 
less pronounced effect, but still significant, was found on ADHD in a study of mild 
maternal hypothyroxinemia and ADHD at age 8 [Modesto et al., 2015], whereas only 
maternal TSH, and girls ADHD was associated in another study [Päkkilä et al., 2014]. 
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Recently, another study found that maternal hypothyroxinemia was associated with later 
life development of schizophrenia [Gyllenberg et al., 2016]. 
Overall, studies show concordance between low thyroid hormones during development and 
impaired neurobehavioral development of the child [Berbel et al., 2009; Gyllenberg et al., 
2016; Haddow et al., 1999; Henrichs et al., 2010; Korevaar et al., 2016; Modesto et al., 
2015; Pop et al., 2003] and this is supported by recent systematic reviews and meta-
analysis [Fetene et al., 2017; Thompson et al., 2018]. However, to date, the two random-
ized controlled trials investigating the effect of maternal levothyroxine treatment on child 
neurobehavioral development have not found an effect [Casey et al., 2017; Lazarus et al., 
2012] and another study  raises concerns for adverse effects arising from overtreatment 
with levothyroxine resulting in high-normal fT4 levels [Korevaar et al., 2016]. This indi-
cates that our understanding of the complex relationships between thyroid function and 
brain development is limited and that further studies are needed. These inconsistencies 
between adverse effects of inadequate T4 supply, yet lack of apparent effect of treatment, 
could arise due to underlying confounding factors and relationships causing or obscuring 
effects in studies of thyroid function. The epidemiological studies point to several areas of 
concern for further studies, also for their potential influence on the results of studies 
investigating associations between chemical exposures and thyroid function.  
 
 
2.4.3 Confounding factors in epidemiologic studies of thyroid 
function and neurobehavioral development 
 
Epidemiological study designs can influence the outcome. Study population, hormone 
limits and values, reference intervals, and time of hormone assessment during gestation are 
all parameters that can influence the results. The definition of impaired thyroid function 
has implications for the outcome; more effects were present in “severe” hypothyroxinemia 
defined as fT4<5th percentile and fewer effects in “mild” hypothyroxinemia 5th percen-
tile<fT4<10th percentile [Henrichs et al., 2010]. Outcomes have been different depending 
on whether data was analyzed as the hypothyroxinemic group compared to the rest of the 
population [Ghassabian et al., 2014] or by linear regression [Korevaar et al., 2016]. 
As described previously, thyroid function changes over the course of pregnancy and 
associations to neurobehavior may vary according to which point in time TH measure- 
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1[Andersson et al., 2012; Bath et al., 2013; Bath & Rayman, 2013; WHO, 2007] 
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4[Berg et al., 2017; Brucker-Davis et al., 2012; Glinoer, 1997; WHO, 2007]  
 
ments are performed. Pop et al., (2003) found that Maternal fT4<10th percentile at week 12 
of gestation was associated with impaired motor and mental development of the child at 
age 1 and 2. Interestingly, this effect was attenuated by higher fT4 at week 24 and 32 and 
increased by lower values later in pregnancy. Yet, lower fT4 at week 24 and 32 had no 
effects in the control population [Pop et al., 2003]. These results suggest that effects 
observed in studies with only a single thyroid function determination during gestation may 
under or overestimate the effects depending on the subject’s thyroid status over the course 
of pregnancy and that time of assessment is critical.  
Studies usually assess a child’s postnatal neurobehavioral development and the relationship 
to thyroid hormones during development. However, a range of factors, in addition to 
thyroid hormone, can impact on a child’s neurobehavioral development and may influence 
it from birth and until assessment. These include parental education level, household 
income, marital status, urbanization at birth, smoking, siblings, ethnicity, birth weight, sex, 
Iodine and thyroid function 
Iodine deficiency is the most common dietary deficiency  that can give rise to neurode-
velopmental problems, with almost 2 billion worldwide at risk, including >40% of the 
European population1. 
The iodine deficiency disorders (IDDs) span the endemic and severe iodine deficiency 
giving rise to endemic cretinism with severe mental retardation, deaf-mutism and motor 
spasticity but also the milder forms of iodine deficiency which gives rise to neurological 
impairments on a population scale. Due to these effects, the importance of adequate 
supplies of iodine for optimal neurodevelopment cannot be understated2. 
Iodine status of a population is tricky to assess as both inter-individual and intra-
individual variation in urinary iodine concentration is high, necessitating measurements 
from ca 10 days to determine iodine status of an individual with ca. 20% precision3.  
Mild and moderate iodine insufficiency may result in higher T3 and lower T4 levels but 
it is an insensitive measure as hormone levels may be within reference intervals and 
they have a large overlap with iodine sufficient populations4.  
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gestational time, breastfeeding, hospitalizations, environmental and psychosocial factors 
[Ghassabian et al., 2014; Gyllenberg et al., 2016; Haddow et al., 1999; Korevaar et al., 
2016; Pop et al., 1995, 2003]. In addition to these factors related to the individual child and 
study population, variability between studies also arise from the applied assessment: type 
of test, test performer, age of child at assessment, and the measurement of different 
endpoints may all give rise to different outcomes. 
Variation also arises from the physiological conditions of thyroid function. Sometimes 
there are associations between effects and TSH irrespective of fT4 [Ghassabian et al., 
2014; Päkkilä et al., 2014] and sometimes not [Gyllenberg et al., 2016; Henrichs et al., 
2010; Korevaar et al., 2016]. Studies also suggest the existence of a subpopulation of TPO-
antibody (ab) positive individuals which are uniquely sensitive to disturbances of the 
thyroid hormones [Brown et al., 2015; Nøhr et al., 2000; Pop et al., 1995, 1999; Webster et 
al., 2014]. Iron deficiency can interfere with the iron dependent TPO enzyme and selenium 
deficiency with the iodothyronine deiodinases both potentially exacerbating effects of 
thyroid hormone disturbances and levels [Bastian et al., 2014; Köhrle, 2015; Preston et al., 
2018; Webster et al., 2014].  
Last is the influence of individual and population iodine status. Production of thyroid 
hormones is dependent upon iodine and milder forms of deficiency has modified the 
outcome of studies investigating thyroid hormone deficiency and neurobehavioral devel-
opment, with or without a measurable effect on thyroid status [Bath & Rayman, 2012; 
Berbel et al., 2009; Lazarus et al., 2012; Taylor et al., 2014; Vermiglio et al., 2004]. Thus, 
controlling for iodine status in studies of thyroid function is important, albeit complicated 
[Bath & Rayman, 2012; König et al., 2011; Lazarus et al., 2012](see also box “Iodine and 
thyroid function).  
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2.5 Perfluorinated compounds and  
thyroid status 
 
Exposure to perfluorinated compounds consistently affects circulating levels of thyroid 
hormones in animal studies. However, the potential effects of PFHxS in vivo was unclear, 
and thus investigated in chapters 3 and 4. Here, the potential mode of actions of PFHxS on 
the thyroid system of experimental animals and humans will be reviewed. 
 
 
2.5.1  Mode of action of PFAS in the thyroid hormone system 
The Hypothalamic-Pituitary-Thyroid axis 
The HPT axis contains the central compensatory feedback loops of the thyroid hormone 
system (section 2.3.1) that maintain TH levels within narrow concentration levels. Hence, 
traditionally, we expect the HPT axis to increase TSH production when serum T4 is 
decreased [Bansal et al., 2014; Goldey et al., 1995; Klaassen & Hood, 2001; Kortenkamp 
et al., 2017; Yu, Liu, & Jin, 2009]. However, some environmental chemicals seem to 
circumvent the feedback loops and decrease hormone levels without increasing TSH levels 
and activating the compensatory responses of the endocrine system (chapter 4) [Bansal et 
al., 2014; Goldey et al., 1995; Klaassen & Hood, 2001; Kortenkamp et al., 2017; Yu, Liu, 
& Jin, 2009]. The underlying physiology and consequences of this atypical response is still 
elusive [Kortenkamp et al., 2017]. 
A similar pattern of effects is seen after PFOS exposure [Bjork et al., 2008; Chang et al., 
2008, 2009; Lau et al., 2003; Luebker et al., 2005; Thibodeaux et al., 2003]. Direct damage 
of the HPT axis is not the cause as co-exposure to PTU induced the expected compensato-
ry increase in TSH levels [Chang et al., 2008]. Another study, where PFOS was adminis-
tered in drinking water to male rats for 91 days, found no significant effect on TSH, 
although levels were nominally doubled (0.72±0.30 IU/L in controls versus 1.62±0.67 
IU/L in 15 mg/L group) while serum T4 was decreased to 20% of control levels [Yu, Liu, 
& Jin, 2009]. However, in contrast, the Butenhoff et al., (2009) study indicated a potential 
activation of the axis in the males receiving the highest dose as they found histopathologi-
cal changes in the thyroids of the male rats [Butenhoff, Chang, et al., 2009]. Possibly, due 
to a high internal exposure of male rats compared to females [Butenhoff, Chang, et al., 
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2009; S.-J. Kim et al., 2016; Ramhøj et al., 2018; Sundström et al., 2012]. Later, Chang et 
al., 2018 reported no effects on histopathology or TSH in mice receiving a rather low 
exposure to PFHxS [S. Chang et al., 2018]. The effect of PFHxS on the HPT axis is further 
investigated in chapter 4.  
 
 Thyroid hormone distributor proteins  
One of the classical targets of thyroid hormone disrupting chemicals are TTR, TBG and 
albumin; three plasma proteins involved in distributing thyroid hormones to target tissues. 
These proteins have a high affinity to thyroid hormones, but can also bind to a range of 
chemicals, including PFHxS and other PFASs.  For instance, PFHxS can bind to both TTR 
and albumin, but not TBG [Kerstner-Wood et al., 2003; Ren et al., 2016; Weiss et al., 
2009]. Amongst PFASs, PFHxS and PFOS have high affinities to TTR, albeit still 4-20 
times lower than the affinity for T4 [Ren et al., 2016; Weiss et al., 2009]. Despite the 
limited affinity relative to T4, both PFOS and PFOA have theoretically been shown 
capable of binding to almost all of the available TTR in occupationally exposed workers 
(5.3µM chemical-bound TTR vs. 5.4µM TTR in normal human serum) [Ren et al., 2016]. 
Taking mixture effects from all chemicals binding to TTR [Crofton et al., 2005; Flippin et 
al., 2009; Weiss et al., 2009] into account it shows the potential for effects in humans.  
The precise implications of chemicals binding to TH distributor proteins remains uncertain, 
but it can be speculated that the end result will be less TH available to target tissues, 
including the developing fetal brain. Furthermore, TTR could directly transport chemicals 
from the maternal circulation, across the placenta to the fetal compartment and into the 
fetal brain where PFOS have been found [Alshehri et al., 2015; Chang et al., 2009; 
Chanoine et al., 1992].  
Distributor proteins also act to shield TH from hepatic elimination, thereby prolonging TH 
half-life. Displacement of TH from distributor proteins could increase biliary excretion 
leading to decreased circulating TH levels, as for instance is the case for PFOS. Within 2-6 
h of PFOS exposure there are transiently increased free T4 levels inducing expression of 
the thyroid hormone responsive gene malic enzyme and reducing TSH levels. Concurrent-
ly, an upregulation of the T4 glucuronidation enzyme UGT1A1 messenger ribonucleic acid 
(mRNA)  increases turnover and loss of T4 resulting in persistently reduced total T4 levels 
[Chang et al., 2008; Yu, Liu, & Jin, 2009]. Hence, evidence supports the view that reduced 
serum protein binding of T4 increases hepatic enzyme activity and elimination, and that 
fT4 drives TH responsive gene expression. The similarities between PFHxS and PFOS and 
the affinity to TTR suggest that also PFHxS could act through this mechanism in vivo. 
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Liver metabolism 
Another classical target of thyroid hormone disrupting chemicals is the liver enzymes that 
eliminate thyroid hormones by glucuronidation and sulfation. The expression and activity 
of UGTs and SULTs can be induced by both drugs and environmental chemicals resulting 
in loss of TH. Indeed, the liver is a target organ of both PFHxS and PFOS. Findings 
include upregulation of UGT1A1 mRNA along with reduced liver D1 and activation of 
both peroxisome proliferator-activated receptor (PPAR) α, constitutive androstane receptor 
(CAR) and pregnane X receptor (PXR) pathways [Bjork et al., 2008; Butenhoff, Ehresman, 
et al., 2009; S. Chang et al., 2018; Chang et al., 2009; H. Dong et al., 2016; Rosen et al., 
2017; Yu, Liu, & Jin, 2009; Yu, Liu, Jin, et al., 2009]. However, the exact effects on UGT-
activity and mRNA are unknown for PFHxS and it should be noted that, in general, effects 
on mRNA levels are not always reflected in enzyme activities and vice versa [Bárez-López 
et al., 2017; Glanemann et al., 2003; Ohtsuki et al., 2011]. Furthermore, it appears that the 
effects on TH are evident at doses lower than the doses at which effects in the liver are 
detected (also see chapter 4). This shows either a lack of sensitivity of applied liver 
investigations or that increased hepatic elimination of thyroid hormone is not the primary 
mechanism of PFOS/PFHxS mediated thyroid hormone reductions. 
 
 
2.5.2  Human epidemiology studies of PFAS and thyroid status 
Multiple epidemiological studies have investigated the relationship between exposures to 
various PFAS and thyroid hormones in different populations. In many studies, the adjust-
ment for confounders attenuates associations, sometimes allegedly due to correlations 
between exposures to the different compounds. Yet, most studies are not designed to assess 
joint exposures to PFAS or effects are not significant in a model of all exposures [Berg et 
al., 2015; S. Kim et al., 2011]. The studies are of heterogeneous design, as are the results 
with significant effects associated to PFHxS: increased fT4 and total T4 in adults [Liu et 
al., 2018], increased T4 in adults [Jain, 2013], increased fT4 in adults [Seo et al., 2018],  
increased T3 in newborn girls [Shah-Kulkarni et al., 2016], increased T3 in 60-80 year old 
females, increased T4 in 20-40 year females [Lewis et al., 2015], reduced fT4 in TPO-ab 
positive pregnant women [Webster et al., 2014], inversely associated to maternal fT4 
[Preston et al., 2018],  negatively to fT4 [Webster et al., 2016], decreased T4 in male 
adolescents [Lewis et al., 2015], and decreased T4 in 60-80 year females [Lewis et al., 
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2015]. There is also studies [Berg et al., 2015; Chan et al., 2011; S. Kim et al., 2011; Wang 
et al., 2013; Yang et al., 2016] and endpoints in the above mentioned studies that show no 
significant correlations to PFHxS. Identification of some effects seems to depend and vary 
according to exposure level, sex, age, TPO-ab status, iodine status, smoking, body mass 
index (BMI), mother versus fetal, and hormones assessed. The heterogeneity of results is 
not surprising if comparing to epidemiological studies of other thyroid disrupting com-
pounds [Boas et al., 2009, 2012; Ghassabian & Trasande, 2018; Mughal et al., 2018], but 
suggest some of the challenges associated with epidemiological studies of both thyroid 
status and chemical exposures. Despite this, recent reviews and meta-analysis conclude 
that, overall, there is evidence suggesting that PFAS modifies thyroid hormone homeosta-
sis (primarily hypothyroidism) in especially pregnant women [Ballesteros et al., 2017; 
Coperchini et al., 2017; Lee & Choi, 2017] whereas others did not find that in a subanaly-
sis of pregnant women [M. J. Kim et al., 2018]. Specifically Ballesteros et al., (2017) 
found correlations between PFHxS and TSH in maternal blood and Kim et al., (2018) that 
PFHxS is negatively correlated to T4 in the general population [Ballesteros et al., 2017; M. 
J. Kim et al., 2018]. 
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2.6 Perfluorinated compounds and  
the develoing immune system 
 
Allergic, autoimmune and inflammatory diseases are reaching epidemic proportions in 
these years [Minihane et al., 2015; H. Okada et al., 2010; Patterson et al., 2009; Pearce et 
al., 2007]. Mutual for them all are a dysregulation of the immune system, leading to 
hyperactivation, inadequate activation, or even activation towards the organisms own 
components. The resulting disorders may be fatal and can have serious impacts on the 
quality of life of the individual and presents a considerable economic burden on societies 
[Global Asthma Network, 2014; NIH, 2005; AARDA, 2011]. The prevalence has been 
increasing in a pace that indicates environmental causes and it is possible that early life 
insults on the developing immune system [Dietert, 2008; Pollard et al., 2010; Tonk et al., 
2012; WHO/UNEP, 2013] can result in altered developmental programming causing 
impaired immunological function later in life [Dietert, 2008; Dietert & Zelikoff, 2008]. 
Within risk assessment and toxicology the immune system presents a special case due to its 
presence in virtually every tissue and to its functional nature. Consequently, it can be 
assumed that every chemical exposure will result in exposure of some components of the 
immune system, but also, that it is crucial to test whether the function of the immune 
system, is altered by an exposure [IPCS, 2012]. This, in combination with an exposure 
taking place during development of the immune system, presents a special challenge to 
toxicology [Dietert, 2008]. It is necessary to consider both the acute effect of an exposure 
during development, as well as any latent future effects on the different components and 
functions of the immune system [Tonk et al., 2010]. 
 
 
2.6.1   Perfluorinated compounds and immunotoxicity 
In 2012, Dewitt and collegues concluded that exposure to perfluorinated compounds can 
adversely affect immune function [DeWitt et al., 2012]. This was based on observations in 
turtles and dolphins, in vitro to in vivo data correlations, and overall concordance between 
results from animal studies. Since then, especially more human studies have been pub-
lished and in 2016 a 3M (previous producer of PFOS and PFOA) sponsored review 
concluded that “epidemiological evidence does not establish a causal effect of PFOA or 
PFOS on immune conditions in humans” [E. T. Chang et al., 2016]. While the National 
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Toxicology Program (NTP) concluded that exposure to both PFOA and PFOS are “pre-
sumed to be an immune hazard to humans” [NTP, 2016]. 
Studies of PFOA and PFOS immunotoxicity indicate that they share some, but not all, 
properties and show differential effects and modes of action in vivo and in vitro [Corsini et 
al., 2011, 2012, 2014; Midgett et al., 2015; Mogensen, Grandjean, Nielsen, et al., 2015; 
Qazi et al., 2009]. PFHxS may possess similar properties [Rosen et al., 2017; Wolf et al., 
2014]. Some of the hallmark effects are altered antibody production [Grandjean et al., 
2012; Grandjean, Heilmann, Weihe, Nielsen, Mogensen, & Budtz-Jørgensen, 2017; 
Grandjean, Heilmann, Weihe, Nielsen, Mogensen, Timmermann, et al., 2017; Grandjean & 
Budtz-Jørgensen, 2013; Granum et al., 2013; Keil et al., 2008; Kielsen et al., 2016; Looker 
et al., 2014; Mogensen, Grandjean, Heilmann, et al., 2015; Peden-Adams et al., 2008] and 
skewing of the immune system towards a T helper cell type 2 (Th2) response [G.-H. Dong 
et al., 2011, 2013; Keil et al., 2007; Midgett et al., 2015; Timmermann et al., 2014, 2015, 
2017; Zheng et al., 2011; Zhou et al., 2017; Zhu et al., 2016]. Decreased Immunoglobulin 
M (IgM) production was found in male mice after exposures down to 1.66 µg 
PFOS/kg/day for 28 days, bringing the mice’s serum levels within the range of human 
serum levels [Peden-Adams et al., 2008]. Gestational exposure (GD 1-17) of mice to PFOS 
resulted in decreased natural killer (NK) cell activity and decreased IgM response to sheep 
red blood cells at 8 weeks of age [Keil et al., 2008]. Corsini et al 2014 suggested some 
PFAS mediated immunity to be through PPARs and the nuclear factor-κB (NF-κB) 
pathway. This has been confirmed in humans where the PPARδ and NF-κB pathways were 
enriched in a transcriptomics study linking prenatal PFAS (PFOS, PFOA, perfluoronona-
noic acid (PFNA), and PFHxS) exposure with childhood immunological events [Pennings 
et al., 2016]. Overall, immunological and developmental pathways were affected by both 
prenatal PFAS exposure and occurrences of the common cold and rubella antibody titers in 
early childhood. In addition the specific linkage of PPARδ and NF-κB provides a mecha-
nistic explanation for the observed immunotoxic effects, also in humans, and strengthens 
the notion that also prenatal PFAS exposure affects human immunological health 
[Pennings et al., 2016]. 
In humans there may be consistent correlations between PFAS and immune effects overall. 
However, what specific compounds that show statistically significant effects after adjust-
ment for confounders differ, including exposure to the other perfluorinated compounds 
usually correlated to each other. Mogensen et al., 2015 performed a joint analysis on 
PFOA, PFOS and PFHxS exposure in 7-year old children and found a doubling of serum 
PFAS resulted in a 54% decrease in protective antibodies after vaccination towards difteria 
and tetanus [Mogensen, Grandjean, Heilmann, et al., 2015]. The authors considered these 
strongly decreased antibody concentrations to reflect an immunological deficit which 
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should be regarded as adverse and their calculations showed that current exposure levels to 
PFOA and PFOS can cause impaired immune function in Faroese children [Grandjean & 
Budtz-Jørgensen, 2013; Mogensen, Grandjean, Heilmann, et al., 2015]. When looking at 
the compounds individually, it appears that PFHxS had the biggest effects on tetanus 
antibodies compared to diphtheria [Mogensen, Grandjean, Heilmann, et al., 2015].  
Furthermore, exposure to PFHxS has been statistically significantly associated to self-
reported food allergies in adolescents [Buser & Scinicariello, 2016], childhood atopic 
dermatitis in girls [Chen et al., 2018], asthma and asthma biomarkers [G.-H. Dong et al., 
2013; Zhou et al., 2017; Zhu et al., 2016], asthma in 5-year old measles mumps and rubella 
(MMR)-unvaccinated children [Timmermann et al., 2017], total infectious diseases in girls 
[Goudarzi et al., 2017], common cold [Granum et al., 2013], gastroenteritis [Granum et al., 
2013], anti-tetanus antibodies [Grandjean, Heilmann, Weihe, Nielsen, Mogensen, 
Timmermann, et al., 2017; Mogensen, Grandjean, Heilmann, et al., 2015], anti-diphtheria 
antibodies [Grandjean, Heilmann, Weihe, Nielsen, Mogensen, Timmermann, et al., 2017; 
Mogensen, Grandjean, Heilmann, et al., 2015],  anti-rubella antibodies [Granum et al., 
2013; Stein et al., 2016] but also to less sensitization to cockroach and shrimp [Stein et al., 
2016]. Significant finding thus show overall tendencies for increased disease susceptibility, 
increased asthma and allergic disease and decreased protecting antibodies after vaccina-
tions. 
Not surprisingly there were also endpoints in the above mentioned studies that showed no 
correlations to PFHxS. Other studies found no significant associations between PFHxS 
exposure and fever [Dalsager et al., 2016], common cold [Impinen et al., 2018], respiratory 
tract infections at 0-10 years [Impinen et al., 2018], immediate post-booster tetanus and 
difteria antibodies [Kielsen et al., 2016], eczema and allergic disease [E. Okada et al., 
2014; Smit et al., 2015], asthma and allergy biomarker at birth [Ashley-Martin et al., 2015] 
and asthma in adolescents [Humblet et al., 2014]. 
The large variability studies and the investigated endpoints make it difficult to draw any 
conclusions about the specific details of PFAS effects in humans. Critical exposure 
windows, effect modulation by sex, vaccine-type to be affected and specific effects of 
single compounds, will all be hard to specify with epidemiological studies alone. The 
recent study by Timmermann et al., (2017) also clearly shows the importance of correct 
adjustment for confounders and how important external influences on the dynamic immune 
system may be. They found a positive correlation between PFAS levels in children and risk 
of asthma only in the small subgroup of 22 unvaccinated children in a cohort study of 559 
children [Timmermann et al., 2017]. This association was reversed in MMR-vaccinated 
children. The authors suggest that PFAS skew the immune system towards a TH2-type 
response increasing the risk of asthma. However, in the study population the skewing does 
not happen when a previous MMR vaccination has skewed the immune system towards a 
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Th1 type response. This potential skewing has been suggested by other recent human 
studies [Buser & Scinicariello, 2016; G.-H. Dong et al., 2013; Zhou et al., 2017; Zhu et al., 
2016], but also not seen in others [E. Okada et al., 2014; Smit et al., 2015; Stein et al., 
2016]. It raises further questions about the long term implications of PFAS mediated 
immunomodulation, not only for decreased resistance against infectious diseases but also 
for allergic, autoimmune and non-communicable diseases [Dietert, 2014; McFadden et al., 
2015]. 
   
 
2.6.2  Testing for developmental immunotoxicity 
In a regulatory context, testing for developmental immunotoxicity is only performed as 
part of the Extended One Generation Reproductive Toxicity Study (EOGRTS), OECD test 
guideline 443 [OECD, 2011]. Here, the assessment of a cohort 3 for assessment of 
developmental immunotoxicity is the standard: “decision (…) to omit the developmental 
(…)  immunotoxicity cohort should reflect existing knowledge for the chemical being 
evaluated, as well as the needs of various regulatory authorities”. However, in REACH, 
cohort 3 is only included if existing knowledge reveal triggers (signs) that indicate a 
“particular concern” of a “certain level of severity” that a compound has developmental 
immunotoxic properties [ECHA, 2017c]. Thus, the inclusion of the cohort primarily 
depends on effects found in less sensitive systems than the developing immune system. 
When included, the information requirement for cohort 3 requires assessment of the 
primary immunoglobulin M response to a T-cell dependent antigen (TDAR), usually using 
either sheep red blood cells or keyhole limpet hemocyanin (KLH) as antigens (as done in 
chapter 5. This measure is designed to give “a holistic view of IgM synthesis” and will 
detect suppression of the immune system, It may also be able to detect stimulation, of the 
immune response [OECD, 2013]. In addition to this functional immune test, lymphoid 
organ weights and histopathology, and lymphocyte subset analysis are assessed in the 
resting immune system of adult F1 offspring. The outcomes of these tests may require 
further testing of cell mediated immunotoxicity; the delayed type hypersensitivity (DTH) 
response (as done in chapter 5). If evidence for effects is found, further testing to deter-
mine underlying mechanisms can be conducted, these could include immunoglobulin G 
(IgG) response and regulatory cytokines. In certain cases investigations of resistance to 
infection, allergic hypersensitivity and autoimmune diseases can be performed in animal 
disease models [OECD, 2013]. Hence, even though functional immune test are considered 
the most sensitive and predictive tests [Boverhof et al., 2014; Dietert & Burns-Naas, 2008; 
Holsapple, 2002; IPCS, 2012; Luster et al., 1992, 1993; OECD, 2013; Tonk et al., 2010] 
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only the primary IgM response is assessed by default when cohort 3 is included in the 
EOGRTS study. Despite the TDAR assays being sensitive and predictive of immunotoxi-
cology [Boverhof et al., 2014; Cooper et al., 2006; Luster et al., 1992, 1993] especially 
related to immunosuppression, it seems that there could be a risk of not detecting devel-
opmental immunotoxicity resulting in immune dysfunction and/or disrupted immune 
regulation. i.e. a risk of missing effects ultimately resulting in increased risks for autoim-
mune and allergic diseases, viral infections, cancer and misregulated inflammation 
[Dietert, 2008, 2014; IPCS, 2012] although with increasing chance of detecting such 
effects when multiple test are combined [Dayan et al., 1998; Dietert & Holsapple, 2007; 
Holsapple, 2005; Luster et al., 1992, 1993; White et al., 2007]. 
 
The implementation of testing for developmental immunotoxicity in each lab should be 
done with assay optimization for both day and dose of immunizing agent as these may 
influence results [OECD, 2013; White et al., 2007]. It is also stressed that laboratories 
should have experience with functional immune testing, be able to deliver accurate and 
consistent results, and that a positive control study is useful in results interpretation (agents 
could be e.g. cyclophosphamide, cyclosporine). This seems especially important consider-
ing that interindividual variation in TDAR response is a natural feature of the functioning 
immune system [E. R. Gore et al., 2004; Lebrec et al., 2014]. Examination of validation 
studies for immunotoxicity testing also show that variation may be high for some assays 
[Dayan et al., 1998; E. R. Gore et al., 2004; Kawai et al., 2013; Loveless et al., 2007; 
White et al., 1994]. Furthermore, from comparisons between laboratories with immuno-
suppressing agents some studies find that although the assays detect immunotoxicity 
overall, there are still laboratories that do not detect significant effects on some parameters 
[Dayan et al., 1998; Loveless et al., 2007; Richter-Reichhelm et al., 1995]. White et al., 
(1994) find more consistency between laboratories on some endpoints. Depending on the 
agent tested it may be that sheep red blood cells or KLH induces the most sensitive 
immune response and also that both animal strain and species have an influence on the 
detected response [Dayan et al., 1998; Kawai et al., 2013; White et al., 2007], also 
stressing the need for validated test protocols, which can be optimized for reliability [E. R. 
Gore et al., 2004; Lebrec et al., 2014]. 
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ABSTRACT
The developmental toxicity of perfluorohexane sulfonate (PFHxS) is largely unknown despite widespread environmental
contamination and presence in human serum, tissues and milk. To thoroughly investigate PFHxS toxicity in developing rats
and to mimic a realistic human exposure situation, we examined a low dose close to human relevant PFHxS exposure, and
combined the dose-response studies of PFHxS with a fixed dose of 12 environmentally relevant endocrine disrupting
chemicals (EDmix). Two reproductive toxicity studies in time-mated Wistar rats exposed throughout gestation and
lactation were performed. Study 1 included control, two doses of PFHxS, and two doses of PFHxSþEDmix (n¼5–7). Study 2
included control, 0.05, 5, or 25 mg/kg body weight/day PFHxS, EDmix-only, 0.05, 5, or 25 mg PFHxS/kg plus EDmix (n¼13–20).
PFHxS caused no overt toxicity in dams and offspring but decreased male pup birth weight and slightly increased liver
weights at high doses and in combination with the EDmix. A marked effect on T4 levels was seen in both dams and
offspring, with significant reductions from 5 mg/kg/day. The EDmix caused antiandrogenic effects in male offspring,
manifested as slight decreases in anogenital distance, increased nipple retention and reductions of the weight of
epididymides, ventral prostrate, and vesicular seminalis. PFHxS can induce developmental toxicity and in addition results
of the co-exposure studies indicated that PFHxS and the EDmix potentiate the effect of each other on various endpoints,
despite their different modes of action. Hence, risk assessment may underestimate toxicity when mixture toxicity and
background exposures are not taken into account.
Key words: perfluoronated agents; endocrine disruptors; thyroid; androgens; Reproductive & Developmental Toxicology.
Pre- and postnatal development is under the control of a com-
plex network of tightly regulated processes that ensures health
at later adult stages, and disruption of these processes may re-
sult in irreversible changes or increased disease susceptibility in
adult life. Some of the changes may arise from endocrine dis-
rupting chemicals (EDC), that is, chemicals that can interfere
with the hormonal systems and consequently adversely affect
numerous organs and organ systems (Bergman et al., 2013).
Because human EDC exposure is likely to occur as combined
exposures, mixture investigations are relevant to include, when
performing animal studies on endocrine disruption
(Christiansen et al., 2012; Hass et al., 2012).
Poly- and perfluoroalkyl substances (PFAS) are a diverse
group of chemicals that have been used in industrial applica-
tions and consumer products, for example, as surfactants since
the 1950s (Lindstrom et al., 2011). They are persistent, resist
VC The Author(s) 2018. Published by Oxford University Press on behalf of the Society of Toxicology.
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degradation in the environment, and bioaccumulate in humans
(Blum et al., 2015; Scheringer et al., 2014). PFASs can act on vari-
ous endpoints within the mammalian body, including the met-
abolic, immune, and endocrine systems (DeWitt, 2015; USDHHS,
2016). There are indications from the industry and biomonitor-
ing studies that the use of the three most commonly found
PFAS, perfluorooctane sulfonate (PFOS), perfluorooctanoic acid
(PFOA), and perfluorohexane sulfonate (PFHxS), has decreased
(Kato et al., 2011; Schro¨ter-Kermani et al., 2013; U.S. EPA, 2006).
Nonetheless substantial human and environmental exposure to
these compounds will continue for some time, due to their long
half-lives of 3–-7 years (Olsen et al., 2007). In vivo studies have
shown that PFOS can cause pup death and thyroid hormone dis-
ruption (Lau et al., 2003; Yu et al., 2009a), leading to a classifica-
tion as a reproductive toxicant category 1B (ECHA, 2018).
Epidemiologic studies show inconsistent associations between
serum T4 levels and PFOS exposures (Ballesteros et al., 2017;
Jain, 2013). PFHxS has recently been classified as a substance of
very high concern, due to its very persistent and very bioaccu-
mulative (vPvB) properties, and it is proposed for listing as persis-
tent organic pollutant (POP) according to the Stockholm
Convention (ECHA, 2017; UNEP, 2017). In spite of this, surpris-
ingly little is known about the potential toxicity of PFHxS (Danish
Ministry of the Environment, 2015; FSANZ, 2016). In vitro studies
with PFHxS have shown that it can bind to the serum thyroid
hormone transport protein transthyretin releasing the hormones
to the circulation for hepatic metabolism (Ren et al., 2016; Weiss
et al., 2009). As with PFOS, epidemiologic studies investigating
PFHxS exposure and human T4 levels find inconsistent associa-
tions (Jain, 2013; Wang et al., 2014; Webster et al., 2016).
To our knowledge only one developmental toxicity study
with PFHxS has been published (Butenhoff et al., 2009). Toxicity
was observed in parental males, with minimal to moderate hy-
pertrophy in liver and thyroid gland appearing at the two high-
est doses (3 and 10 mg/kg body weight/day). No adverse effects
were observed in dams and offspring, however, due to sex dif-
ferences in elimination of this compound, serum PFHxS were
approximately 75% lower in dams than in the parental males re-
ceiving the same dose. Additionally dams only showed a mini-
mal PFHxS accumulation in the liver. Hence, we hypothesized
lower internal exposures to be the cause of the lack of effects in
the dams and offspring.
Due to the evidence of toxicity of PFAS and especially PFOS,
the continued human exposure to these compounds and the
limited knowledge of developmental toxicity of PFHxS, we de-
cided to conduct a developmental toxicity study of PFHxS in
Wistar rats. We focused especially on assessment of endpoints
sensitive to endocrine disruption; anogenital distance (AGD), nip-
ple retention (NR), male reproductive organ weights and thyroid
hormone levels. Moreover, to investigate internal exposures,
PFHxS levels were measured in dam serum. To mimic a more real-
istic human exposure situation a low dose, closer to human rele-
vant PFHxS exposure, was included, and we also combined the
dose-response (Christiansen et al., 2012) studies of PFHxS with a
fixed dose of a mixture of 12 environmentally relevant EDCs
(EDmix). A similar mixture has previously been investigated by
our research group (TotalMix100 in Axelstad et al., 2014; Johansson
et al., 2016; Mandrup et al., 2015), and it was administered at a dose
reflecting a hundred fold high-end human exposure.
MATERIALS ANDMETHODS
Chemicals
Perfluorohexane sulfonate (PFHxS) purity>98% was purchased
from Sigma-Aldrich (Tridecafluorohexane-1-sulfonic acid po-
tassium salt, CAS-No: 3871-99-6, lot #BCBC3545V, Sigma-
Aldrich, Copenhagen, Denmark). The powder was tested for
other PFAS impurities by LC-MS, but none were identified (data
not shown). Corn oil (Sigma-Aldrich) was used as vehicle for all
treatments and dosing in the control group. The mixture of 12
EDCs (EDmix) (chemicals and doses are shown in Table 1) and
the rationale behind choosing these compounds and exposure
levels has previously been described in detail (Christiansen
et al., 2012). Briefly, the mixture consisted of 12 environmental
endocrine disruptors, given at a dose reflecting 100 times high
end human intakes. For some of the chemicals, the intake esti-
mates were adjusted to reflect the joint exposure to several
chemicals of the same class, for example, the dose of epoxico-
nazole was increased to reflect the exposure to all antiandro-
genic azole fungicides. Together the DEHP and DBP doses
represented exposure to all antiandrogenic phthalates, whereas
for BP and 4-MBC the dose was decreased to adjust for a high in-
take in specific population groups. However, the TotalMix100
described previously also included acetaminophen (paraceta-
mol) which in the studies presented herein was omitted from
the EDmix, resulting in a total mixture dose of 32.11 mg/kg body
weight (bw)/day (Table 1).
Table 1. Composition of the Mixture of EDCs (EDmix)a
Chemical CAS Registry Number Purity Dose (mg/kg bw/Day)
DBP (dibutyl phthalate) 84-74-2 >99.0% 1.00
DEHP (di-2-ethylhexyl phthalate) 117-81-7 >99.5% 2.00
Vinclozolin 50471-44-8 >99.5% 0.90
Prochloraz 67747-09-5 >98.5% 1.40
Procymidone 32809-16-8 >99.5% 1.50
Linuron 330-55-2 >99.0% 0.06
Epoxyconazole 106325-08-8 >99.0% 1.00
4-MBC (4-methylbenzylidene camphor) 36861-47-9 >98.0% 6.00
OMC (octyl methoxycinnamate) 5466-77-3 >98.0% 12.00
p, p0-DDE (dichlorodiphenyldichloroethylene) 72-55-9 >98.5% 0.10
Bisphenol A 80-05-7 >99.5% 0.15
Butyl paraben 94-26-8 >99.0% 6.00
Total dose 32.11
bw, body weight.
aSee Axelstad et al. (2014) for details.
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Animals and Dosing
Study design of the two studies is presented graphically in
Figure 1A. In both studies, time-mated nulliparous, young adult
Wistar rats (HanTac: WH, Taconic Europe, Ejby, Denmark) were
received on gestation day 3 (GD) of pregnancy (the day of plug-
detection designated as GD 1) and randomly distributed for
pairwise housing. On the day after arrival (GD 4) animals were
pseudo-randomly allocated into groups with similar distribu-
tions in body weight. The expected day of delivery (GD 23) was
termed PND 1 for the pups. Hence, the age of the pups was
related to time of mating rather than day of birth, but the
two timepoints were rather similar as only 5 out of 30 births
in Study 1 and 13 out of 128 births in Study 2 did not occur on
GD 23.
Dosing of the dams was performed daily (between 8 and 10 AM)
by oral gavage at a constant volume of 2 ml/kg bw/day from GD 7
through postnatal day 22 (PND), except the day of delivery.
In the range-finding study (Study 1), 5 groups of 8 animals
were exposed to vehicle or 25 or 45 mg/kg bw/day PFHxS both
with and without a background EDmix exposure (32.11 mg/kg
bw/day) (Table 2). The main study (Study 2) consisted of 8 groups
of 16–20 animals (Table 2) dosed with lower doses of PFHxS:
0.05, 5 and 25 mg/kg bw/day, both with and without a back-
ground EDmix exposure. Besides a vehicle control group, a
group receiving only the EDmix was included in Study 2.
Study 1 was carried out in a single block, that is, dosing
started for all animals at the same day, whereas Study 2 was
subdivided into 4 blocks. Each block in Study 2 involved all
treatment groups.
The animals were housed in semi-transparent polysulfone
(PSU) type III cages (PSU 80-1291HOOSU Type III, Tecniplast,
Buguggiate, Italy) (15  27  43 cm) with aspen wood chip bedding
(Tapvei, Gentofte, Denmark), Enviro Dri nesting material
(Brogaarden, Lynge, Denmark), and Tapvei Arcade 17 (aspen wood)
shelters (Brogaarden). The animals were kept pairwise from GD 3
to GD 17 and alone thereafter. From the day of arrival the housing
standard controlled environmental conditions were: Reversed
light/dark cycles of 12 h (light from 9 PM to 9 AM, dark from 9AM to
9 PM), humidity 5565%, temperature at 216 1C, and ventilation
changing air 10 times per hour. All animals were fed ad libitum
on a standard diet with Altromin 1314 (soy and alfalfa-free,
Altromin GmbH, Lage, Germany) and were provided ad libitum
acidified tap water (to prevent microbial growth) in PSU bottles
(84-ACBTO702SU Tecniplast). The animals were inspected twice
a day for overt toxicity. The body weights were recorded on GD 4
and daily during dosing from GD 7 onward to adjust the dose, to
follow changes in weight gain, and to follow pregnancy status.
The animal experiments were carried out at the DTU National
Food Institute facilities (Mørkhøj, Denmark). Ethical approval
was given by the Danish Animal Experiments Inspectorate. The
authorization number given is 2015-15-0201-00553 C3. The
experiments were overseen by the National Food Institute’s in-
house Animal Welfare Committee for animal care and use.
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Figure 1. Study designs. A, Study design: Study 1 and 2. Two reproductive toxic-
ity studies were performed as shown. The endpoints for dams and offspring are
depicted along with timepoints. Exposure of dams to vehicle, perfluorohexane
sulfonate (PFHxS), and/or a mixture of EDCs (EDmix) from gestational day 7 (GD)
through postnatal day 22 (PND) except day of delivery. B, The full statistical
model in Study 2 was modelled on the 2  4 design matrix depicted, this model
allowed for comparisons of PFHxS dose against no PFHxS exposure (control and
EDmix groups) and for EDmix exposed groups against no EDmix groups (control
and PFHxS exposed groups). AGD, anogenital distance; NR, nipple retention; T4,
thyroxine. n ¼ time-mated dams.
Table 2. Dosing
Group PFHxS
(mg/kg bw/day)
EDmix
(mg/kg bw/day)
Time-Mated
Dams
Viable
Litters
Study 1
Control — — 8 5
25-Px 25 — 8 6
25-PxþED 25 32.11 8 5
45-Px 45 — 8 7
45-PxþED 45 32.11 8 7
Study 2
Control — — 20 20
EDmix — 32.11 16 13
0.05-Px 0.05 — 20 16
0.05-PxþED 0.05 32.11 16 13
5-Px 5 — 20 19
5-PxþED 5 32.11 16 15
25-Px 25 — 20 17
25-PxþED 25 32.11 16 15
Px, perfluorohexane sulfonate (PFHxS); ED, EDmix (mixture of EDCs, see Table 1).
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AGD and Nipple Retention
On the morning after delivery the pups were counted, weighed,
sexed, and checked for anomalies. Pups found dead were mac-
roscopically checked for anomalies when possible. AGD was
measured on all live pups with an ocular stereomicroscope. All
offspring were counted and weighed again on PND 6 and PND
14. The number of nipples/areolas of the pups was counted on
PND 14. The NR in male pups was defined as the number of are-
olas/nipples (a dark focal area with or without a nipple bud),
present where nipples are usually located in female offspring.
AGD and NR retention measurements were performed by the
same experienced technician blinded to exposure group.
Autopsy
Offspring. Autopsy in Study 1 took place on PND 16 where up to 1
male and 1 female pup from each litter were sacrificed, trunk
blood collected for plasma, and liver and adrenal glands excised
and weighed. In Study 2, sacrifice was performed on PND 16 and
PND 17 for male and female pups, respectively. If available, 1
pup per gender and litter was sacrificed for macroscopic exami-
nation, organ removal and blood collection. Liver, adrenal
glands, and one retroperitoneal fat pad was excised and
weighed from each pup, so was ovaries from female pups and
sex organs from male pups (testis, ventral prostate, epidydimis,
vesicular seminalis, musculus levator ani, and glandula bul-
bourethralis). On PND 22, up to 1 male and female pup per litter
was chosen for macroscopic examination and organ removal.
Liver and adrenal glands were excised and weighed.
Dams. In both studies dams with viable litters were sacrificed at
PND 22. Dams were weighed, anesthetized with CO2/O2, decapi-
tated, and trunk blood collected for thyroid hormone analysis
(see below). Uteri of the dams were excised and the number of
implantation scars was registered. Livers were excised and
weighed. All dams not giving birth were sacrificed, as described
above, on PND 3 and implantation scars registered to exclude
non-pregnant from the study and include dams with full-litter
resorption in the determination of postimplantation loss and
perinatal loss.
Thyroxine
In both studies trunk blood was collected from dams on PND
22 and from male and female pups on PND 16/17 in, respec-
tively, 10 and 4 ml vacutainer tubes with sodium heparin.
Additionally, on GD 15 in Study 2 tongue blood was drawn
from the dams without anesthesia in heparinized Eppendorf
tubes. All samples were stored on ice until centrifugation for
10 min at 4C and 4000 rpm (rounds per minute). The
plasma was collected and stored at 80C until analysis for T4
levels by electrochemiluminescence-immunoassay (ECLIA)—
photoncount at the Department of Clinical Biochemistry,
Rigshospitalet, Copenhagen, Denmark using a Cobas 8000
E-modul.
All dams in Study 1, and 15 dams from each exposure group
in Study 2 (20 controls) were sampled randomly for analysis. In
Study 1 pup T4, PND 16, was determined based on litter means
(from up to 1 male and 1 female pup per litter) and measured in
control and PFHxS-only groups. In Study 2 each litter was repre-
sented by either a male or female pup (the different sampling
times for male and female pups impedes conclusions on sex-
specific effects) and was determined in the control, all PFHxS-
only groups and the 25-PxþED group.
Chemical Analysis
Internal PFHxS levels in the serum from dams were determined
at the end of the dosing period (Study 1, sacrifice on PND 22), at
Environmental Medicine, University of Southern Denmark
(SDU), by online solid-phase extraction and analysis, using high-
pressure liquid chromatography with tandem mass spectrome-
try. The analysis was performed by a slightly modified version of
the method described by Haug et al. (2009) (Haug et al., 2009). The
serum samples were diluted 20–40.000 times prior to extraction
to quantify within the calibration range of the method, normally
used for human serum samples (Grandjean et al., 2012).
Statistical Analysis
Data from continuous endpoints were checked for normal dis-
tribution and homogeneity of variance and then analyzed by
analysis of variance (ANOVA). If assumptions were not fulfilled,
data was transformed accordingly. Body weight and litter size
was included as covariates in data analyses when considered as
relevant (e.g., organ weights, AGD, and birthweight). If data
from more than one pup per litter were available, litter was in-
cluded as an independent, random, and nested factor in
ANOVA or analysis was based on litter means.
The number of nipples/areolas (NR) was assumed to follow a
binomial distribution and analyzed according to Hass et al.
(2007) (Hass et al., 2007). Statistical significance were assessed us-
ing multiple contrast tests (global error rate a¼ 5%, two-sided)
(Bretz et al., 2005). Here we used Dunnett contrasts to detect any
dose-related effect and trend contrasts (linear, Helmert, reverse
Helmert) assuming different dose-response shapes.
In Study 2, effect differences between the PFHxS-only and
the control group and between PFHxSþED and the EDmix group
were tested by pairwise hypothesis testing, with the type I error
controlled by the two-tailed Dunnett test (continuous end-
points) and Dunnett contrast (NR). Outcomes from this pairwise
hypothesis testing were further investigated by integrating all
exposures and control groups into one full linear model (2  4
design matrix, Figure 1B), with PFHxS and EDmix exposures in-
cluding their interactions parameterized as indicator variables
(i.e., magnitude of exposure is not considered). The advantage
of the full model is not only a better control of false-positive
decisions, but by assuming an identical data variability across
all groups (which we consider fulfilled), it can result in more ro-
bust statistical outcomes. The chosen model parameterization
allows explicitly making a statistical decision whether (and to
which magnitude) EDmix changes in average the PFHxS
responses across the different exposure groups. Furthermore,
as a larger number of samples are considered in this full model,
the increased sample size can identify much smaller effect
changes than a simple pairwise comparison. The model was
tested by a main factor for EDmix and dose-dependent interac-
tion terms to account for non-parallelity between the PFHxS
and PFHxSþEDmix dose-response pattern.
Outcomes from the full model analysis are only reported if
they lead to different conclusions than the pairwise hypothesis
testing.
SAS Enterprise Guide 4.3 (2010), SAS Institute Inc, Cary, NC,
was used for statistical analyses.
RESULTS
Serum PFHxS
In Study 1, PFHxS was quantified in dam serum on PND 22
(n¼ 5–7, Figure 2). The average PFHxS concentration in the
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control group was<0.1 mg/ml whereas 139 and 174 mg/ml PFHxS
were measured in animals exposed at 25 and 45 mg/kg PFHxS,
respectively. In the groups co-exposed to EDmix and PFHxS the
PFHxS levels were slightly increased to 156 and 182 ug/ml, corre-
sponding to a 12.7% and 4.9% increase, respectively (not statisti-
cally significant).
Pregnancy Data, Postnatal Growth, and General Toxicity
PFHxS and EDmix alone or in combination did not affect mater-
nal weight gain during pregnancy, post-implantation loss, peri-
natal loss, litter size, and sex ratio (Tables 3 and Tables 4). In
Study 2, the EDmix significantly increased postnatal maternal
weight gain on PND 1–14 (p¼ .0140), whereas a reduced weight
gain was indicated by Study 1. Male pup birth weight was
slightly decreased by 25 mg/kg PFHxS in Study 2; in the full sta-
tistical model, exposure to a dose of 25 mg/kg decreased male
pup birth weight by 3.5% (p¼ .0351) and this effect was also sig-
nificant when comparing 25-PxþED with the background
EDmix group (p¼ .0070). In Study 1, birth weight was slightly re-
duced (6%, not statistically significant) in both the 25-PxþED
and 45-PxþED groups compared with control (adjusted for litter
size). There was no statistically significant effect on female pup
birth weight in any of the studies.
Pup growth and weights on PND 6, 14, and 22 were unaf-
fected in Study 1. In Study 2, slight significant decreases in body
weight were seen in female offspring on day 6 and 14 at 5 mg/kg
in the full statistical model (p¼ .0209 and p¼ .0274, respectively)
and in the 5-PxþED group compared with EDmix alone on day
6 (p¼ .0121). As decreased body weights were not seen at higher
doses (25-PxþED, 45-PxþED), we evaluate these body weight
changes as chance findings.
One pup from the EDmix group in Study 2 had a genital tu-
bercle with features in between male and female and it had 9
nipples on PND 14. Upon sacrifice on PND 16 it had an underde-
veloped testicle and an underdeveloped ovary. Having charac-
teristics of an intersex pup (the first ever to be identified in our
group), unrelated to exposure, it was excluded from the study.
Serum Thyroxine, T4
PFHxS clearly reduced total T4 levels in both dams and off-
spring. After only 7 days of gavage dosing (GD 15) the T4 levels
in dams were significantly reduced to about 80% of controls at
5 mg/kg PFHxS (p< .0001), and to about 60% of controls at the
highest dose (Figure 3A). These T4 reductions were similarly
strong with the EDmix co-exposure. At later stages (PND 22), the
T4 reductions were more pronounced, as they decreased to
ca.70 and 30% of control levels at 5 and 25 mg/kg PFHxS, respec-
tively (p< .0001). Furthermore, on PND 22 EDmix decreased sig-
nificantly T4 levels by approximately 10% if data were analyzed
Figure 2. Dam serum PFHxS concentrations on PND 22 (Study 1). Control
mean¼0.081 mg/ml, close to detection limit due to dilutions performed in the
assay. Px, perfluorohexane sulfonate (PFHxS); ED, EDmix. Data are shown as
mean þ SEM. n ¼ 5–7.
Table 3. Pregnancy and Litter Data: Study 1
Control 25-Px 25-PxþED 45-Px 45-Px-þED
Time-mated females (no.) 8 8 8 8 8
Viable litters (no.) 5 6 5 7 7
Maternal bw GD 7 (g)a 231.1 6 12.5 227.2 6 12.9 225.4 6 11.5 229.36 9.5 227.86 11.2
Maternal bw gain GD 7-GD 21 (g)a 80.7 6 19.6 86.4 6 18.0 85.2 6 13.7 77.0 6 8.4 71.0 6 17.6
Maternal bw gain GD 7- PND 1 (g)a 15.5 6 11.6 14.8 6 6.1 19.0 6 4.9 13.3 6 10.9 15.6 6 6.9
Maternal bw gain PND 1-PND 14 (g)a 40.8 6 14.5 41.0 6 17.0 34.4 6 8.0 43.0 6 8.9 33.9 6 15.7
Gestational length (days) 23.2 6 0.41 22.9 6 0.45 22.8 6 0.45 22.8 6 0.39 23.0 6 0.58
Litter size. Live pups PND 1 (no.) 10.0 6 4.1 9.4 6 4.6 10.8 6 2.5 10.0 6 2.3 7.9 6 3.4
Postimplantation loss (%) 29.6 6 40.1 13.9 6 19.4 16.2 6 6.7 26.9 6 31.4 20.3 6 17.1
Perinatal loss (%) 29.6 6 40.1 26.9 6 35.7 21.2 6 11.1 27.8 6 31.1 21.4 6 16.9
Birth weight. Male pups (g) 6.7 6 0.6 6.4 6 0.5 6.3 6 0.5 6.7 6 0.5 6.6 6 0.6
Birth weight. Female pups (g) 6.3 6 0.6 6.2 6 0.5 6.1 6 0.6 6.0 6 0.4 6.1 6 0.5
AGD. Males (unitsb) 22.1 6 0.6 22.2 6 1.4 20.9 6 0.4 22.5 6 0.9 23.0 6 0.8
AGD. Females (unitsb) 12.0 6 0.9 12.1 6 0.8 11.5 6 0.5 11.7 6 0.8 12.2 6 1.0
Body weight. PND 6. Male pups (g) 14.0 6 2.1 13.3 6 1.1 13.2 6 1.4 14.2 6 2.4 13.8 6 0.7
Body weight. PND 6. Female pups (g) 13.3 6 2.3 12.9 6 1.1 13.0 6 1.3 13.1 6 2.1 13.3 6 1.2
Body weight. PND 14. Male pups (g) 31.7 6 5.8 28.0 6 2.1 29.6 6 3.9 30.6 6 6.3 30.3 6 3.4
Body weight. PND 14. Female pups (g) 30.5 6 6.2 27.6 6 2.4 28.8 6 3.9 29.2 6 5.8 29.2 6 4.2
Body weight. PND 22. Male pups (g) 53.9 6 10.1 51.6 6 6.9 52.0 6 7.9 52.5 6 10.3 51.5 6 4.3
Body weight. PND 22. Female pups (g) 52.8 6 9.5 50.2 6 6.4 51.8 6 7.3 50.4 6 9.3 50.526 3.9
Data represent group means based on dam or litter means6SD. Px, perfluorohexane sulfonate (PFHxS); ED, EDmix (mixture of EDCs, see Table 1); PND, postnatal day;
GD, gestational day; AGD, anogenital distance.
aOnly pregnant dams giving birth to viable litters.
b1 unit¼0.164 mm (i.e. male AGD of 22.1 units corresponds to 3.62 mm).
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Figure 3. Serum thyroxine (T4) after exposure to PFHxS alone and in combination with a fixed dose of EDCs (EDmix). Dams were affected by both PFHxS and EDmix,
pups only by PFHxS. A, Dam serum T4 on GD 15 was reduced from 5 mg/kg bw/day PFHxS. B, Dam serum T4 on PND 22 were reduced in all 4 exposed groups, Study 1. C,
Dam serum T4 at PND 22, Study 2. The background EDmix exposure overall had a decreasing effect on T4 compared with no EDmix exposure (p¼ .0242). D, Pup serum
T4 based on litter means of up to 1 male and 1 female pup per litter, Study 1. Doses of 25 and 45 mg/kg body weight reduced serum T4 on PND 16. E, Pup serum T4 on
PND 16/17, Study 2. Doses of 5 and 25 mg PFHxS/kg body weight/day reduced serum T4 on PND 16/17. Px, perfluorohexane sulfonate (PFHxS); ED, EDmix, N/A, not
available. Data are shown as mean þ SEM. A and C, n ¼ 13–15 (except control with n ¼ 20) for each group. B, n ¼ 5–7. D, n ¼ litter means (from up to one male and one fe-
male pup per litter) of 5–7 litters. E, n ¼ 14–18 litters represented by either a male or a female pup. ** p < .01 compared with control, *** p < .001 compared with control,
þþþ p < .0001 for full model comparison of indicated dose of PFHxS compared with no PFHxS exposure in the control and EDmix group. Comparisons of PFHxSþEDmix
groups against EDmix not shown.
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in the full model (p¼ .0242) (Figure 3C). In Study 1, dam T4 levels
were only measured on PND 22. Here the effects followed the
same trend as in Study 2, however less pronounced, as the se-
rum T4 levels were only reduced to app. 40% of the controls in
all 4 exposure groups (Figure 3B).
T4 levels in the offspring were decreased after PFHxS expo-
sure (Figs. 3D and 3E). In Study 1, pup serum T4 levels on PND 16
were decreased to app. 60 and 50% of controls in the 25 and
45 mg/kg PFHxS groups, respectively (p< .0001) (Figure 3D).
In Study 2, pup serum thyroxine was measured at PND16/17
in the control, the three PFHxS-only groups and in the high dose
25-PxþED mix group. PFHxS significantly decreased serum T4
levels to app. 70% and 55% of control levels, in the 5 and 25 mg/
kg PFHxS groups, respectively (p< .001) (Figure 3E). The EDmix
had no additional decreasing effect on the T4 levels in the pups
(all groups were compared with control only, a full model analy-
sis was not possible as T4 was measured only in PFHxS-only
groups and in the high dose 25-Pxþ ED mix group).
Anogenital Distance and Nipple Retention
PFHxS and EDmix caused weak effects on AGD and NR. In the
smaller Study 1 no significant effects on AGD were observed
(Table 3). In Study 2, AGD in male pups was slightly but statisti-
cally significant decreased by about 2% after exposure to EDmix
(p¼ .0393, full model) (Figure 4A). No significant effects of PFHxS
exposure was seen on male and female AGD.
For male pups from Study 1 the average number of nipples
on PND 14 was significantly increased at highest PFHxS dose in
combination with the background EDmix exposure (45-PxþED,
p¼ .039, Dunnett contrast) (Figure 4B).
In Study 2, PFHxS weakly, but significantly, increased NR at
25 mg/kg PFHxS when using trend analysis (p¼ .01 using
Helmert contrast, and p¼ .04 using linear contrast) and in the
full model (p¼ .016). NR was significantly increased when PFHxS
exposure took place along with the background EDmix at the
two highest doses (5-PxþED and 25-Pxþ ED, p< .01, Dunnett
contrast compared with control), and compared with the EDmix
group (p¼ .02, linear contrast). When data from Study 2 were
analyzed by the full model including all dose-dependent inter-
action terms, a high statistical significance of EDmix was
revealed (p< .01, see Figure 1B for model visualization) indicat-
ing a strong overall effect of the EDmix on NR. NR in female
pups was not significantly affected by exposure to either PFHxS
or the EDmix.
Autopsy and Organ Weights PND 16 and PND 22
In both studies, no significant effects on dam or offspring
body weights were seen at sacrifice on PND 16 or PND 22
(Supplementary Tables S1A and B).
Reproductive Organs. PFHxS had no effect on the weight of male
reproductive organs examined on PND 16 in Study 2. EDmix ex-
posure reduced the weight of the epididymides, ventral prostate
and vesicula seminalis in the full statistical model (p¼ .0023,
p¼ .0055, and p¼ .0288, respectively) (Figs. 5A–C). The remaining
reproductive organ weights were not significantly affected by
the EDmix (Figs. 5D–G). In females, no significant effects on
ovary weights PND 17 or PND 22 were observed (Supplementary
Table S1B). No reproductive organ weights were assessed in
Study 1.
Retroperitoneal Fat Pad and Adrenals. Influences on weights of
adrenals and the retroperitoneal fat pat were examined in the
pups to evaluate potential influences on fat stores and steroido-
genesis. In males, the weight of the retroperitoneal fat pad with
body weight as a covariate was increased in male offspring ex-
posed to PFHxS at 25 mg/kg (p¼ .0309, full statistical model)
(Supplementary Table S1B). In a simple model the fat pad and
the adrenal gland weight in the 25-Px group was also increased
compared with control (p¼ .0154 and .0223, respectively).
Overall, effects were not judged to be of major importance as
the slightly lower body weights in the high dose group may
have influenced the statistics, and no effects were seen in
females, or in Study 1 males (Supplementary Table S1A), or at
PND 22 (Supplementary Table S1B).
Liver. In both studies liver weights in offspring on PND 16/17
were increased at high doses of PFHxS (Figs. 6A and 6B and
Supplementary Tables S1A and B). In Study 1, 25 and 45 mg/kg
bw/day PFHxS caused higher liver weights in male on PND 16
compared with control, (Supplementary Table S1A). In males
from Study 2 the effect of PFHxS was only significant when the
full statistical model was applied or when PFHxS exposure took
place along with EDmix exposure. This observation emphasizes
the increased statistical power of the full model including all
8 groups and may indicate increased sensitivity to PFHxS when
exposed to a background of chemicals (EDmix).
In Study 2 females, PFHxS increased liver weights in both the
5-Px and 25-Px groups compared with the control (p¼ .0182 and
Figure 4. Anogenital distance (AGD, A) and nipple retention (NR, B–C) in male pups following gestational exposure to PFHxS alone and in combination with a fixed dose
of EDCs (EDmix). EDmix significantly decreased AGD and NR was increased at high doses of PFHxS in the presence of the EDmix. Px, perfluorohexane sulfonate
(PFHxS); ED, EDmix. A, Data are shown as litter mean þ SEM. B and C, Data are shown as litter mean 6 SEM. A and C, n ¼ 13–20 litters; B, n ¼ 5–7 litters. AGD is
expressed as units (1 unit ¼ 0.1626 mm). Statistical analysis performed on data from all pups in each litter and adjusting for litter effects. * p < .05 compared with con-
trol, ** p < .01 compared with control.
586 | TOXICOLOGICAL SCIENCES, 2018, Vol. 163, No. 2
Downloaded from https://academic.oup.com/toxsci/article-abstract/163/2/579/4922959
by DTU Library - Technical Information Center of Denmark user
on 04 June 2018
p¼ .0478, respectively, Supplementary Table S1B) and in the full
model. At PND 22, similar, although less pronounced, increases
in liver weights were found in both sexes (Supplementary Table
S1B). Although the EDmix appeared to reduce liver weights in
Study 2 using the full statistical model, this may be due to a
chance finding of high liver weights in the 5-Px group (p¼ .0279,
Supplementary Table S1B).
No exposure-related effects on dam liver weight were observed
in any study apart from a reduction in Study 2 by the lowest dose
of PFHxS (compared with no PFHxS, full model p¼ .0329) and in
the .05-PxþED group compared with EDmix only (p¼ .0156,
Supplementary Table S1B). These effects were judged to be driven
by the rather high mean liver weight in the EDmix-only group and
do not appear to represent any toxicity of the chemicals.
Figure 5. Male reproductive organs in male pups on PND 16 following gestational exposure to PFHxS alone and in combination with a fixed dose of EDCs (EDmix).
PFHxS exposure had no effect on organ weights. The EDmix had an overall decreasing effect on the weights of the epididymides (A), ventral prostrate (B), and the vesic-
ular seminalis (C), but no effects on glandula bulbourethralis (D), levator ani (E) or testis weight (F and G). Px, perfluorohexane sulfonate (PFHxS); ED, EDmix. Data are
shown as mean þ SEM. n ¼ 10–16. * p < .05 compared with no EDmix exposure.
Figure 6. Pup relative liver weights after developmental exposure to PFHxS alone and in combination with a fixed dose of EDCs (EDmix). There was a linear relationship
between liver weight and body weight male (A) PND 16: R2¼0.85 and female (B) PND 17: R2¼ 0.91). Therefore, to ease visual inspection, relative weights of the livers are
depicted along with the results of the statistical analysis on relative weights, the absolute weights can be found in Supplementary Table S1A and B). Relative liver
weights PND 16/17 were increased by PFHxS in the presence of the background EDmix exposure (not shown) and when analyzed in the full statistical model comparing
PFHxS exposure at 3 levels against no PFHxS exposure in the control and EDmix groups. Px, perfluorohexane sulfonate (PFHxS); ED, EDmix. Data are shown as mean þ
SEM. n ¼ 11–16 for each group. þ <0.05 and þþ <0.01 for full model comparison of indicated dose of PFHxS compared with no PFHxS exposure in the control and EDmix
group.
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DISCUSSION
In the present study we have demonstrated that PFHxS can
cause endocrine disruption in the thyroid hormone system of
Wistar rats. Additionally, our results have shown that co-
exposure to PFHxS and a mixture of environmentally relevant
EDCs can affect NR, AGD and some reproductive organ weights,
even if PFHxS or the mixture of EDCs on their own, showed no
or only weak effects on these endpoints.
Thyroid Hormone Disruption
The consequences of decreased thyroid hormone levels or al-
tered action during human brain development can be serious,
even in the case of subclinical T4 reductions (Berbel et al., 2009;
Morreale de Escobar et al., 2000). Such alterations in neurodevel-
opment may result in adverse behavioral effects and low IQ,
outcomes with large consequences for healthcare expenses and
life-time income (Bellanger et al., 2015; Grandjean and
Landrigan, 2014). To our knowledge this is the first study that
demonstrates significantly decreased total serum T4 levels in
rat dams and their offspring after PFHxS administration. These
significantly lower T4 levels were seen at 5 mg/kg bw/day, after
only 7 days of exposure, indicating that PFHxS is an effective
thyroid hormone disruptor in rats.
The thyroid effects observed here are consistent with studies
showing decreased T4 levels in rats exposed to the structurally
similar compound PFOS (Chang et al., 2008; Yu et al., 2009a,b).
Furthermore, hypertrophy/hyperplasia of the thyroid follicular
epithelium was seen in male rats after 42 days of PFHxS expo-
sure (Butenhoff et al., 2009), supporting our findings of de-
creased T4 levels in dams. Butenhoff et al. suggested
microsomal liver enzyme induction to be the cause of the ob-
served effects, as marked increase in liver weight was seen in
their highest dosed animals (Butenhoff et al., 2009). Such liver
effects were not seen in our dams, and another likely mode of
action for the observed T4 reductions could be binding of PFHxS
to the thyroid hormone transport protein transthyretin (TTR), a
common mode of action for perfluorinated compounds (Ren
et al., 2016; Weiss et al., 2009).
Dam T4 reductions became more marked with time, with
further decrease at weaning (PND 22), compared with GD 15.
Data from Study 1 indicated that at higher doses, T4 reductions
plateaued around 40% of control levels.
The observed postnatal T4 decreases in offspring, seen at
PND 16/17, were likely due to lactational transfer of PFHxS. This
is supported by data from Butenhoff et al. showing that at doses
of 10 mg/kg, fetuses on GD 21 had serum concentrations 26%
lower than dams, whereas pups at later stages (PND 22) had se-
rum PFHxS concentrations 56% higher than dams at GD 21
(Butenhoff et al., 2009). Additionally some studies on human
PFHxS exposure find that breast milk is an important route of
exposure (K€arrman et al., 2007; Sundstro¨m et al., 2011).
The mixture of 12 environmentally relevant EDCs (EDmix)
contained some chemicals that on their own can affect the thy-
roid hormone system. However, the doses of the compounds in-
cluded in the EDmix were all well below the reported No
Observed Adverse Effect Levels (NOAELs) for T4 effects
(Klammer et al., 2007; Liu et al., 2015; O’Connor et al., 2002;
Schneider et al., 2011; Seidlova-Wuttke et al., 2006, 2005; Yamada
et al., 2004). Yet, in PND 22 dams the EDmix caused a small, but
statistically significant decrease in T4 levels, an effect which
may have been caused by combination effects of the single
chemicals in the EDmix.
Antiandrogenicity
PFHxS led to a slight but statistically significant positive trend
in male NR, indicating some endocrine activity. However, PFHxS
alone did not cause adverse effects on AGD or reproductive or-
gan weights at any dose. Interestingly, co-exposure to PFHxS
and EDmix significantly increased NR at 5 mg/kg PFHxS, and led
to overall significant effects of EDmix on male AGD and weight
of the epididymides, ventral prostrate, and seminal vesicle.
Thus, co-exposure of PFHxS to the EDmix seemed to enhance
the antiandrogenic action of the EDmix, possibly due to altered
toxicokinetics of EDmix as discussed further below.
In rats, alterations in AGD, NR, and prepubertal reproductive
organ weights are good markers of antiandrogenic action, and
predictive of adverse effects on the male reproductive system
later in life (Christiansen et al., 2008; van den Driesche et al.,
2011), with male NR often being the most sensitive marker of
antiandrogenic exposure during fetal sexual differentiation
(Christiansen et al., 2009; Laier et al., 2006).
A mixture of EDCs similar to the EDmix in this study has pre-
viously been shown to adversely affect reproductive develop-
ment. In our previous studies, the mixture also included
paracetamol, which in itself seems to possess antiandrogenic
properties (Axelstad et al., 2014; Kristensen et al., 2011). In those
studies, the lowest tested mixture dose contained 32.11 mg/kg
per day of environmental chemicals (corresponding to 100
times human high-end exposure) plus 80 mg/kg paracetamol
(close to maximally recommended human therapeutic doses)
given during two developmental windows sensitive to antian-
drogens. This mixture significantly affected the female repro-
ductive system at the lowest dose (Johansson et al., 2016)
whereas 2–4.5-fold higher doses affected male AGD, NR, and
prepubertal reproductive organ weights (Axelstad et al., 2014). In
the present study the EDmix consisted of only the 32.11 mg/kg
of environmental chemicals and although no statistical signifi-
cance was detected on male NR, AGD, and reproductive organ
weights if compared directly with the control, the full statistical
model on the basis of all data suggested that these endpoints
were weakly affected. In our typical experimental design the di-
rect effect comparison allows for the statistical detection of an
average AGD reduction of at least 5% (Christiansen et al., 2008;
Isling et al., 2014), whereas the full statistical model specifically
adapted to the experimental design in this study was able to de-
tect an approximately 2% decrease in AGD as statistically
significant.
General and Reproductive Toxicity
In the range-finding study, doses up to 45 mg/kg PFHxS did not
lead to overt systemic toxicity in dams or offspring. However, in
male pups doses of 25 and 45 mg/kg PFHxS increased liver
weights and induced modest but significant decreases in birth
weight. Additionally, we found female pup liver weight to be in-
creased already at 5 mg/kg PFHxS on PND 17 and at 25 mg/kg on
PND 22. This indicates a potential for PFHxS-induced develop-
mental toxicity at doses even below the 10 mg/kg that was pre-
viously reported as a NOAEL for effects in dams or offspring
(Butenhoff et al., 2009). The lack of other systemic toxicities of
PFHxS is in contrast to the effects of PFOS, which caused>95%
postnatal pup dead at 5 mg/kg (Lau et al., 2003), possibly by act-
ing as a surfactant in the lungs of the newborn rats (Lau, 2012).
Gender Differences and Toxicokinetics
Interestingly, Butenhoff et al. (2009) observed adverse effects on
liver and thyroid gland after repeated PFHxS administration (3
and 10 mg/kg) in the parental males, but not in dams, fetuses, or
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pups. They also found strong gender differences in internal
PFHxS levels, with serum levels in the males at least 4 times
greater than the adult females in the 10 mg/kg group. In addi-
tion their results indicate a gender difference in distribution of
PFHxS as the liver to serum ratio of PFHxS was greater than 2.5
in male rats and below 0.5 in females and offspring (Butenhoff
et al., 2009). In our study, external doses of 25 and 45 mg/kg
resulted in serum PFHxS concentrations in pregnant dams simi-
lar to those in adult male rats after exposure to 10 mg/kg
(Butenhoff et al., 2009). Indeed, the half-life of PFHxS in female
rats is lower than in males (Kim et al., 2016; Sundstro¨m et al.,
2012) with consequently less internal exposure. The major elim-
ination route for PFHxS is through the urine and for PFOA it has
been demonstrated that this secretion can be strongly increased
via organic anion transporter(s) in the renal tubules that appear
in female rats around puberty (Kudo et al., 2002). If also true for
PFHxS we can expect similar kinetics for prepubertal males and
females and that might explain why we see no clear gender dif-
ferences in thyroid and liver effects at PND 16/17.
Based on the observation of more marked effects on T4, anti-
androgenic endpoints and liver weight in the groups co-
exposed to EDmix and PFHxS, we hypothesize that co-exposure
could cause changes to absorption, distribution, and/or excre-
tion properties of either PFHxS or the EDmix (note that PFHxS is
not expected to be metabolized). This hypothesis can be exam-
ined indirectly via serum PFHxS determinations from Study 1,
where PFHxS serum levels appeared higher in groups with con-
comitant exposure to the mixture. The reason for the nonsigni-
ficant increase in internal serum PFHxS levels when
administered in combination with other EDCs is unknown to us
and we can only speculate that the EDC co-exposure may have
interacted directly with PFHxS-specific kinetic processes such
that more PFHxS was absorbed and/or less PFHxS eliminated.
Similarly, it is conceivable that the increased chemical load in
the animals exposed to both PFHxS and the EDmix may have
exacerbated the antiandrogenic effects of the EDmix by decreas-
ing the elimination of the mixture.
CONCLUSIONS
We have demonstrated that PFHxS can induce marked reduc-
tions in circulating serum T4 in rats, which at critical develop-
mental stages can lead to altered brain morphology and adverse
behavior. Additionally, we have shown that a mixture of envi-
ronmentally relevant EDCs can cause antiandrogenic effects at
a lower dose than previously reported. Interestingly, PFHxS and
the EDmix appear to exacerbate the effects of each other despite
different modes of action. This illustrates that risk assessment
may underestimate the toxicity of a chemical when mixture
toxicity and background exposures are not taken into account.
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Table S1A. Body and organ weights – Study 1 2 
 Control 25-Px 25-Px+ED 45-Px 45-Px+ED 
Autopsy PND 16      
Male, n 5 5 - 5 - 
Body weight (g) 35.8±5.8 30.5±1.2 - 33.4±9.3 - 
Liver (g) 0.90±0.15 0.84±0.05** - 0.90±0.27* - 
Adrenal glands (mg) 9.3±2.5 7.3±1.1 - 8.0±1.8 - 
Female, n 5 6 - 7 - 
Body weight (g) 33.7±8.0 31.8±3.2 - 32.7±8.5 - 
Liver, female (g) 0.86±0.20 0.88±0.12 - 0.92±0.22 - 
Adrenal glands, female 
(g) 
8.6±3.2 8.1±1.1 - 8.6±3.2 - 
Autopsy PND 22, dam, n 5 6 5 7 7 
Body weight, dam (g) 266.6±16.8 271.0±15.3 262.8±5.5 273.3±11.5 261.6±14.4 
Liver, dam (g) 11.9±1.5 14.5±4.4 13.0±1.0 13.3±0.5 12.2±2.3 
Absolute organ weights. Note that when relevant adjustment for body weight was included in the statistical analysis. Data are shown as mean ± SD. 3 
Px = Perfluorohexane sulfonate (PFHxS) 4 
ED = EDmix (mixture of endocrine disrupting  chemicals, see Table 1) 5 
PND = Postnatal day 6 
* p < 0.05 compared to control 7 
** p < 0.01 compared to control 8 
9 
2 
 
Table S1B. Body and organ weights – Study 2 10 
 Control EDmix 0.05-Px 0.05-Px+ED 5-Px 5-Px+ED 25-Px 25-Px+ED 
Effect in 
groups 
exposed to 
EDmix versus 
groups not 
exposed to 
EDmix 
Autopsy PND 16,  
male, n 
16 10 14 11 14 13 14 14 
Body weight (g) 33.7±4.8 31.6±2.0 34.1±5.6 34.1±6.8 32.4±3.5 32.3±5.6 30.5±4.9 31.4±3.2 
Liver (g) 0.86±0.12 0.76±0.08 0.87±0.15 0.88±0.18 0.83±0.11 0.86±0.18 0.82±0.14 0.85±0.09 #  
       ↑↑ compared to control + EDmix  
Retroperitoneal fat (mg) 57.2±18.4 60.9±9.7 70.5±27.0 66.4±21.6 60.9±15.5 63.6±24.6 62.0±23.0 * 62.3±12.0  
       ↑ compared to control + EDmix  
Adrenal glands (mg) 8.2±1.8 8.5±1.1 9.2±2.1 8.9±1.8 8.0±1.4 8.4±1.7 8.4±1.6 * 8.3±1.2  
Epididymides (mg) 25.9±3.6 22.1±1.8 26.4±3.9 23.8±3.9 22.6±3.5 22.8±3.1 24.9±3.2 23.3±2.8 ↓↓ 
Ventral prostrate (mg) 12.8±2.6 11.6±3.0 12.5±4.7 12.5±3.0 12.3±1.5 9.9±4.3 11.6±2.9 10.2±4.3 ↓↓ 
Vesicula seminalis (mg) 10.2±2.9 7.8±2.3 10.8±1.6 7.7±4.4 9.3±3.7 9.1±4.3 8.0±4.0 8.5±1.5 ↓ 
Gl. Bulbourethralis (mg) 1.5±0.6 1.5±0.4 1.9±0.8 1.7±0.7 1.6±0.6 1.7±0.7 1.7±0.5 1.7±0.6  
Levator Ani (mg) 27.6±9.9 25.3±6.3 25.1±11.8 28.3±4.2 24.2±7.7 20.2±9.9 28.5±5.7 25.4±9.7  
Left testis (mg) 55.7±9.2 53.9±2.7 58.6±9.6 58.2±13.3 52.7±5.2 52.3±6.1 53.1±8.7 51.6±4.4  
Right testis (mg) 56.8±6.4 54.7±4.3 58.3±9.3 57.2±11.9 52.6±5.9 49.6±16.2 54.0±8.9 52.3±4.5  
Autopsy PND 17, 
female, n 
16 13 11 13 16 12 16 15  
Body weight (g) 35.7±5.6 34.6±4.3 33.9±4.9 36.9±6.0 34.5±5.1 32.7±3.7 33.3±4.6 33.5±3.7  
Liver (g) 1.00±0.23 0.93±0.12 0.93±0.13 1.00±0.17 1.01±0.14* 0.91±0.12 0.96±0.17* 0.96±0.12 ## ↓ 
     ↑ compared to control + EDmix ↑↑ compared to control + EDmix  
Retroperitoneal fat (mg) 45.2±17.1 48.2±13.5 45.5±15.2 54.2±16.5 50.7±22.5 44.8±14.1 43.7±13.6 47.9±16.8  
Adrenal glands (mg) 10.8±2.2 10.5±1.5 10.4±1.7 10.5±2.1 10.2±1.7 9.2±2.1 10.0±2.1 10.2±1.9  
3 
 
Ovaries (mg) 6.7±1.5 7.2±1.9 6.6±1.4 6.8±1.6 7.3±1.1 6.4±0.8 7.3±2.1 7.0±1.4  
Autopsy PND 22 Control EDmix 0.05-Px 
0.05-
Px+ED 
5-Px 5-Px+ED 25-Px 25-Px+ED 
Effect in 
groups 
exposed to 
EDmix versus 
groups not 
exposed to 
EDmix 
Male, n 17 10 12 10 15 11 14 13 
Body weight (g) 51.0±6.3 48.8±4.0 50.7±8.0 53.1±7.0 50.3±5.4 49.2±5.6 48.6±6.5 50.8±5.6  
Liver (g) 1.73±0.27 1.63±0.12 1.76±0.29 1.81±0.25 1.76±0.21 1.73±0.18 1.75±0.33 ** 1.81±0.24 #  
       ↑↑ compared to control + EDmix  
Adrenal glands (mg) 15.0±3.2 14.4±2.3 14.1±2.9 14.0±2.1 14.2±2.7 13.9±2.2 13.8±2.3 13.7±1.7  
Female, n  17 13 11 12 16 11 15 15  
Body weight (g) 49.6±4.6 49.5±5.3 49.4±6.9 52.1±2.1 49.5±5.8 48.7±6.0 49.2±6.0 49.7±5.9  
Liver (g) 1.71±0.23 1.68±0.22 1.74±0.28 1.80±0.27 1.75±0.18 1.71±0.16 1.75±0.24 1.79±0.21 #  
       ↑ compared to control + EDmix  
Adrenal glands (mg) 16.0±2.7 15.8±1.7 14.8±2.3 16.4±2.9 14.7±3.4 15.2±1.7 15.0±3.0 15.2±2.3  
Ovaries (mg) 18.7±3.7 18.2±3.7 20.1±2.4 17.9±5.2 18.6±1.8 17.8±3.4 18.2±3.7 18.8±2.6  
Dam, n 20 11 18 14 18 15 17 14  
Body weight (g) 274.0±15.1 278.6±13.0 281.3±14.5 278.7±13.9 274.7±13.8 278.4±15.0 282.7±14.6 283.1±13.0  
Liver (g) 12.28±1.55 13.32±1.69 12.26±1.46 11.95±1.57 12.37±1.77 12.51±1.63 13.20±1.23 13.59±1.01  
Absolute organ weights. Note that when relevant adjustment for body weight was included in the statistical analysis. Data are shown as mean ± SD. 11 
* p < 0.05 compared to control 12 
** p < 0.01 compared to control 13 
# p < 0.05 compared to EDmix  14 
## p < 0.01 compared to EDmix 15 
↓ or ↑ p < 0.05 compared to indicated exposure 16 
↓↓ or ↑↑ p < 0.01 compared to indicated exposure 17 
 18 
 19 
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ABSTRACT 
Introduction 
Thyroid hormones (TH) are critical for mammalian brain development. In humans, low 
maternal serum thyroxine (T4) levels are associated with neurological deficiencies and 
cognitive impairment. Perfluorohexane sulfonate (PFHxS) is a widespread environmental 
contaminant found in human serum, tissues and milk. We have shown that PFHxS 
decrease serum thyroxine in pregnant rat dams and their offspring. Here, we further 
investigate effects on the thyroid system, neurodevelopment, and combination effects of 
PFHxS and a mixture of environmentally relevant endocrine disruptors. 
Methods 
Perfluorohexane sulfonate (PFHxS, 0, 0.05, 5 or 25 mg/kg/day with and without EDmix, a 
mixture of 12 endocrine disruptors e.g. phthalates, pesticides, UV-filters, Bisphenol A and 
butyl paraben) was administered (p.o.) to Wistar rat dams (n = 16-20/dose group) from 
gestation day (GD) 7 through postnatal day (PD) 22. Organs were removed on PD 16/17 
and PD 22 and a subset weaned for assessment in activity boxes at three life-satges and the 
radial arm maze in adulthood. 
Results/discussion 
PFHxS not only decreased serum T4 levels in dams and offspring but in the high dose also 
reduced T3 to 84% of controls in both dams (PD 22) and pups (PD 16). The hypothalamic-
pituitary-thyroid (HPT) axis was not activated based on lack of effect on serum TSH, 
thyroid gland histology, weight, and thyroid gene expression levels. Developmental 
hypothyroxinemia did not appear to increase physical activity levels in young and adult 
offspring. However, the expected sex difference was absent on PD 115 in low dose PFHxS 
(0.05 mg/kg) and at high doses in combination with EDmix (5 mg/kg + EDmix and 25 
mg/kg + EDmix). Slight effects on offspring learning and memory did not appear correlat-
ed to decreased TH levels during development. 
Conclusions 
PFHxS decreased circulating levels of T3 and T4 in pregnant rat dams and their offspring 
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without apparent compensation by the HPT axis. The thyroid hormone disruption was not 
associated with detectable learning and memory deficits. Rather, findings suggest that 
PFHxS may disrupt sexual differentiation of the brain. Standard behavioral assays appear 
insensitive to adverse effects on brain development caused by thyroid hormone disruption. 
Hence, there is a need for development of sensitive assays to protect human thyroid 
function and brain development.  
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Introduction 
Thyroid hormones (TH) are critical for normal brain development, as correct spatiotem-
poral action of THs ensures proper neurogenesis, migration, synaptogenesis and mye-
lination (Bernal, 2015; Zoeller et al., 2007). Hence, decreased thyroid hormone levels or 
altered TH action during development can affect human neurodevelopment, and it may 
result in adverse behavioral effects and low intelligence quotient (IQ) (Boas et al., 2012; 
WHO/UNEP, 2013). Outcomes which have serious consequences for the affected individ-
ual and which on a societal level have large consequences for healthcare expenses and life-
time income (Bellanger et al., 2015; Grandjean et al., 2014). Thyroid hormone balance can 
be altered by exogenous substances as chemicals, drugs and insufficient intake of iodide or 
by certain diseases. Disorders like congenital hypothyroidism and severe iodine deficiency 
have shown that absent or major reduction in thyroid hormone levels cause detrimental 
effects as cretinism and severe mental retardation. However, even subclinical T4 reduc-
tions in the mother can have effects on neurodevelopment and IQ of the child (Berbel et 
al., 2009; Ghassabian et al., 2014; Haddow et al., 1999; Henrichs et al., 2010; Korevaar et 
al., 2016; Morreale de Escobar et al., 2000) yet it has proven difficult to establish a clear 
relationship between low-grade developmental thyroid hormone disruption and adverse 
effects in rodent models (Axelstad et al., 2011b, 2011a, Gilbert et al., 2013b, 2008, 2013a; 
Harry et al., 2014; Kodavanti et al., 2010). This relationship is crucial for risk assessment 
and regulation of chemicals based on their potential for thyroid hormone disruption, as it 
appears that environmental chemicals often cause more subtle changes to the thyroid 
system than anti-thyroid drugs as propylthiouracil (PTU) (Boas et al., 2012; Gilbert et al., 
2012; WHO/UNEP, 2013). 
Fetal development encompasses development of the thyroid hormone system but the 
hormones have functions before the fetal thyroid gland is functional (Howdeshell, 2002). 
Hence, the fetus is dependent on placental transfer of thyroid hormones from early in 
gestation. By late gestation the fetus has a functional gland producing about 83% of T4 
found in its circulation with the rest being supplied by the dam (Morreale de Escobar et al., 
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1990). This means that both the thyroid homeostasis of the dam and the fetus have an 
influence on the thyroid status of the pup, and consequently, on fetal brain development. 
Not only general thyroid status but specifically T4 levels are strictly necessary for brain 
development as maternal T4 is the primary source of hormone in the fetus and because 
only T4, and not T3, is transported into the fetal brain (Bárez-López et al., 2017; Grijota-
Martínez et al., 2011; Landers et al., 2017; Morreale de Escobar et al., 1988, 1990). The 
HPT axis of the dam does not necessarily compensate adequately for low T4 to ensure 
optimal supply of T4 to the fetus and brain (Gilbert et al., 2013a; Hassan et al., 2017; 
Meerts et al., 2002; O’Shaughnessy et al.; Sharlin et al., 2010). 
After birth the neonate still have the T4 from the mother that it was born with, but the 
thyroid gland and the HPT axis is also functioning and supplies the necessary hormone 
(Howdeshell, 2002; Morreale de Escobar et al., 1990). Rodents are born at what corre-
sponds to late 2nd trimester of the human gestation, hence some of rodent brain develop-
ment take place during the postnatal period (Zoeller et al., 2004). Therefore, some adverse 
effects of TH insufficiency in rodents are dependent upon the xenobiotic being transferred 
from the milk to the pups and to give effects also on the pup TH system (Axelstad et al., 
2013, 2011b; Crofton, 2000; Crofton et al., 2005; O’Shaughnessy et al., 2018). 
Traditionally, we expect the feedback loops of the hypothalamic-pituitary-thyroid (HPT) 
axis to react with increased secretion of thyroid hormone stimulating hormone (TSH) in 
response to reduced serum T4 levels (Bansal et al., 2014; Fujimoto et al., 1999; Hood et 
al., 1999a; McClain, 1995; O’Shaughnessy et al.; Shibutani et al., 2009; Vansell et al., 
2004). However, in the case of several industrial chemicals, especially PCBs and PBDEs, 
it looks as if even high exposures for a prolonged time, which results in severe serum T4 
reductions, do not cause the expected activation of the HPT-axis with a subsequent 
increase in TSH (Bansal et al., 2014; Goldey et al., 1995; Klaassen et al., 2001; 
Kortenkamp et al., 2017; Yu et al., 2009).  
Poly- and perfluoroalkyl substances (PFAS) is one class of environmental chemicals which 
is frequently reported to cause TH disruption (Lau et al., 2007). PFHxS is repeatedly 
shown to be in the top three of PFAS in terms of human exposure 
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Fig. 1. Overview of the study. Time mated-rat dams were exposed to PFHxS and/or a mixture of 
environmentally relevant endocrine disrupting chemicals from gestation day 7 through pup day 22. 
Blood was taken from dams and pups for thyroid hormone assessments and organs were excised, 
weighed and stored for further analysis on PD 16 and 22. A subset of offspring was weaned (PD 
22) and used for testing of motor activity levels at 3 ages and learning and memory in the radial 
arm maze (4-5-months of age for the females and 8-9 months for the males). The litter was used as 
statistical unit for all analyses. PFHxS: Perfluorohexane sulfonate, GD: Gestation day, PD: Pup 
day. 
 
 
(Berg et al., 2014; Glynn et al., 2012; Kato et al., 2011). Presently, the Mode of Action 
(MoA) by which PFHxS is thought to cause reductions in circulating TH levels is by 
binding to the serum transport protein transthyretin (TTR) (Ren et al., 2016; Weiss et al., 
2009). This is also the case for other PFAS like PFOS and PFOA (Ren et al., 2016; Weiss 
et al., 2009), in addition other mechanisms may be relevant for PFHxS. 
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We recently reported (Ramhøj et al., 2018) that developmental exposure to PFHxS caused 
marked reduction in total serum thyroxine (T4) levels in both dams and offspring. Here we 
report on additional thyroid hormone-related parameters, including T3 and TSH levels, 
thyroid gland weight, histopathology, targeted gene expression profiling, as well as 
neurodevelopmental consequences on behavior.  
  
 
Materials and Methods 
 
Animals and treatment 
A developmental neurotoxicity study was performed with 144 time-mated wistar rat dams 
(See fig. 1). The study design has been described in details in Ramhøj et al., (2018, see 
Study 2). Briefly, the study consisted of 8 groups of 16-20 animals dosed with PFHxS 
(Perfluorohexane Sulfonate (PFHxS) purity >98 %, Sigma-Aldrich (Tridecafluorohexane-
1-sulfonic acid potassium salt, CAS-No: 3871-99-6, lot #BCBC3545V). PFHxS doses 
were 0.05, 5 and 25 mg/kg bw/day, given both with and without a fixed dose of back-
ground EDmix exposure as well as a control group and a group receiving only the EDmix. 
Corn oil (Sigma-Aldrich) was used as vehicle and dosing in the control group. The mixture 
of 12 endocrine disrupting chemicals (EDmix) consisted of 6 pesticides: Vinclozolin, 
Prochloraz, Procymidone, Linuron, Epoxyconazole, and Dichlorodiphenyldichloroeth-
ylene, 2 UV-filters: 4-Methylbenzylidene camphor and Octyl methoxycinnamate, 3 
plasticisers: Dibutyl phthalate, di-2-ethylhexyl phthalate and Bisphenol A, and 1 preserva-
tive: Butyl paraben. The composition was based on concentrations found in highly exposed 
humans and it has been described previously (Christiansen et al., 2012). However, 
acetaminophen (paracetamol) was omitted from the EDmix, which resulted in a total 
mixture dose of 32.11 mg/kg body weight (bw)/day (Ramhøj et al., submitted). 
Animals were received on gestation day (GD) 3 of pregnancy and dosing of the dams was 
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performed daily by oral gavage from GD 7 to postnatal day 22 (PD), except the day of 
delivery. The expected day of delivery (GD 23) was termed PD 1 for all pups. Hence, the 
age of the pups was related to time of mating rather than day of birth. 
From the day of arrival the housing standard controlled environmental conditions were: 
Reversed light/dark cycles of 12 hours (light from 9 pm-9 am), humidity 55 ± 5 %, 
temperature at 21 ± 1°C, and ventilation changing air ten times per hour. All animals were 
fed ad libitum on a standard diet with Altromin 1314 (soy and alfalfa-free, Altromin 
GmbH, Lage, Germany) and were provided ad libitum acidified tap water (to prevent 
microbial growth) in PSU bottles (84-ACBTO702SU Tecniplast). 
Necropsy of up to one male and one female per sex per litter took place on PD 16 and PD 
17, respectively, and again on PD 22 (see below). Also on PD 22 up to one male and one 
female pup from each litter were weaned and housed pairwise with an animal of the same 
sex and group (with a sibling if another animal of same sex and group were unavailable) 
and dams were sacrificed. This cohort of weaned offspring were subjected to behavioral 
assessment of motor activity levels at 3 ages and for the control and PFHxS-only groups 
learning and memory was tested in the radial arm maze. The study was terminated when 
the males were approximately 12 months and the females 13 months old. 
The animal experiments were carried out at the DTU National Food Institute facilities 
(Mørkhøj, Denmark). Ethical approval was given by the Danish Animal Experiments 
Inspectorate. The authorization number given is 2015-15-0201-00553 C3. The experiments 
were overseen by the National Food Institute’s in-house Animal Welfare Committee for 
animal care and use. 
 
Autopsies 
Dams 
On PD 22 dams were weighed, anesthetized with CO2/O2, decapitated, and trunk blood 
collected (see below). Livers were excised and saved for histopathological examination 
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(control and 25-Px). Thyroid glands were excised, weighed and saved for histopathology 
(control and PFHxS-only groups) in block 1-3. Thyroid glands from block 4 were stored in 
RNAlater at -80°C until extraction (see below) (control and PFHxS-only groups). 
Offspring 
On PD 16/17 and PD 22 pups were weighed, anesthetized with CO2/O2, decapitated, and 
trunk blood collected (see below). Livers from females were excised and saved for 
histopathology (PD 17). Male pup thyroid glands were excised with a piece of the thyroid 
cartilage for histopathology. Thyroid glands from females were weighed and from block 1 
and 2 they were stored in RNAlater at -80°C until RNA extraction (see below) (control and 
PFHxS-only groups).  
 
Thyroid hormones and thyroid stimulating hormone (TSH) 
On GD 15, tongue blood was drawn from the dams without anesthesia. Trunk blood was 
collected from male pups on PD 16 and female pups on PD 17. Dam trunk blood was 
collected at weaning on PD 22. The blood was collected in heparinized Eppendorf tubes 
(GD 15) or in 4 or 10 ml vacutainer tubes with sodium heparin for the pup blood and the 
dam blood, respectively. Samples were stored on ice until centrifugation for 10 min. at 4°C 
and 4000 rpm (rounds per minute). The plasma was collected and stored at -80°C until 
analysis for T3 levels by electrochemiluminescence-immunoassay (ECLIA) – photoncount 
at the Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark using a 
Cobas 8000 E-modul. 15 dams from each exposure group (20 controls) were sampled 
randomly for analysis. Each litter was represented by either a male or female pup (the 
different sampling times for male and female pups impedes conclusions on sex-specific 
effects). 
Thyroid Stimulating Hormone (TSH) was measured in rat plasma with the Luminex 
RTHYMAG-30 (Merck Millipore) according to the instructions of the manufacturer on 
randomly chosen male (n = 11-13) and female pups (n =5-7) PD 16/17 (control, 5-Px and 
25-Px groups only) and dams PD 22 (control and PFHxS-groups only). 
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Liver and thyroid gland histopathology 
Liver 
A predefined standardized slice of the liver was fixed in formalin, processed, embedded in 
paraffin, and 5μm sections were stained with haematoxylin and eosin. Livers from dams 
(on PD 22) and female offspring (PD 17) were evaluated for hepatocellular hypertrophy 
and vacuolation (macro- and microvesicular) in the control and high-dose (25 mg/kg 
PFHxS) groups.  
Thyroid gland 
Sections of thyroid glands from dams (PD 22) from control, Pax-25, EDmix, and Pax-
25+EDmix, and male offspring (PD 16) from control group and Pax-25, were fixed in 
formalin, embedded in paraffin, and 5μm sections were stained with haematoxylin and 
eosin. Histology of thyroid glands were assessed for signs of pathological changes and 
scored accordingly as described below. 
Thyroid glands from dams were assigned to one of the following four categories:  
A: No remarks 
B: Mild alterations with few irregular follicles or few follicles with multi-layered epitheli-
um.  
C: Follicular epithelial hypertrophy or hyperplasia, irregular follicles multi-layered 
follicular epithelium, papillary projections in follicular lumens and/or small peripheral 
follicles localized on the rim of the gland. 
 
Thyroid glands from male pups were assigned to one of the following four categories: 
A: No remarks – no changes  
B: Mild alterations with few irregular follicles or few follicles with multilayered epitheli-
um, increased cellularity. 
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C: hypertrophy or hyperplasia of follicular cells, irregular cells, multilayered follicular 
epithelium, papillary projections in follicular lumens 
 
Thyroid gland and cortical gene expression 
Both lobes of the thyroid gland from female PD 17 offspring were stored in RNAlater 
(Ambion AM7021) until RNA extraction. Thyroid glands from dams PD 22 were snap 
frozen in liquid nitrogen and stored at -80°C until analysis of one lobe. Upon sacrifice of 
male offspring on PD 16 an oblique slab of anterior to lateral cortex was stored in 
RNAlater at -80°C until RNA extraction. RNA was extracted with TRIreagent (Sigma 
T9424) according to manufacturer’s protocol and glycogen added to facilitate precipitation 
of the thyroid gland RNA. RNA pellets were resuspended in nuclease-free water, DNased 
(RQ1 DNase, Promega M6101) and quantitated with Quant-iT RiboGreen RNA assay kit 
(Life Technologies R11490e). 2 µg RNA was reverse transcribed (Life Technologies High 
Capacity cDNA Reverse Transcription Kit 4374966) and the resulting cDNA was ampli-
fied using TaqMan Gene Expression Assays (Life Technologies) and TaqMan Gene 
Expression PCR Master Mix (Life Technologies 4369510) according to manufacturer’s 
protocol. Amplification was performed on an ABI model 7900HT sequence detection 
system in duplicates. TagMan assays for thyroid glands were: Slc5a5 (NIS) (Solute carrier 
family 5, Rn00583900_m1), Nkx2.1 (TTF-1)(NK2 homeobox 1, Rn01512482_m1), Tpo 
(Thyroid peroxidase, Rn00571159_m1), Tshr (Thyroid stimulating hormone receptor, 
Rn00563612_m1), Pax8 (Paired box 8, Rn00579743_m1), Dio1 (iodothyronine deiodinase 
type 1, Rn00572183_m1) and for cortex samples: Agt (Angiotensinogen, 
Rn00593114_m1), Col11a2 (Collagen type XI alpha 2 chain, Rn01428773_g1), Gjb6 (Gap 
junction beta 6, Rn02042582_s1), Hr (Hairless, Rn00577605_m1), Itih3 (Inter-Alpha-
Trypsin Inhibitor Heavy Chain 3, Rn00569293_m1), Klf9 (Kruppel like factor 9, 
Rn00589498_m1), Ntf3 (Neurotrophin-3, Rn00579280_m1), Pvalb (parv) (Parvalbumin, 
Rn00574541_m1). B2M (Beta-2-microglobulin, Rn00560865_m1) and Gapdh (glycer-
aldehyde-3-phosphate dehydrogenase, Rn01775763_g1) were used as housekeeping genes 
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for thyroid gland and cortex, respectively. Data were analyzed by the 2-∆∆Ct method (Livak 
et al., 2001). 
 
Motor activity and habituation capability in offspring at 3 life stages 
Motor activity was assessed in one male and one female pup from each litter on PD 27. 
The same animals were tested in young adult life on PD 115 and again in late life on PD 
342/336. 
The animals were placed individually in clean, empty cages with a flat rack lid and the 
cages were placed in activity boxes with photocells recording horizontal activity for 30 
min. Neither food nor water was supplied during the testing. Movement was registered as 
interruption of a photobeam and data automatically collected by a computer in an adjoining 
room. The data collection started after 10 seconds habituation and continued for 10 periods 
of 3 minutes amounting to a total of 30 minutes observation. Data was collected as activity 
counts and break counts. Break counts being the total number of interrupted photobeams, 
and activity counts being disruption of adjacent photobeams, theoretically registering if the 
animal was moving around and not just continuously interrupting the same beam. The total 
activity during the 30 minutes was used as a measure of general activity. For habituation 
assessment data was divided into three periods: period 1 (1-9 min.), period 2 (10-21 min.), 
and period 3 (22-30 min.). 
 
Radial arm maze 
Offspring from the PFHxS-only groups: control, 0.05 mg PFHxS, 5 mg PFHxS and 25 mg 
PFHxS, were tested in the radial arm maze in adult life. One male and one female from 
each litter was tested, the females at 4-5 months of age and males at 8-9 months of age. 
Due to technical difficulties the radial arm maze was reduced to 7 arms. In the pre-testing 
week the animals were fed only 15 grams of chow a day in the afternoon and hand-fed a 
raw peanut (Brogaarden, Denmark) to accustom them to the taste. Following the pre-
testing week the animals were tested once a day in the radial arm-maze, the animals were 
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tested until they had reached the end of all arms or until 10 mins had been spent in the 
maze. Testing was performed for 5 consecutive days, followed by a 2-day break for a total 
of three weeks. Time spent in the maze, errors (a visit to an arm already visited) and 
sequences (visits to adjacent arms) were registered and analysis performed based on animal 
totals and as means per day for week 1, 2 and 3. 
 
Statistical Analysis 
Data with normal distribution and homogeneity of variance were analyzed using analysis 
of variance (ANOVA). Data were transformed if normal distribution and homogeneity of 
variance was not present. When relevant, body weight was included as a covariate in the 
analyses, e.g. when testing terminal organ weights. Histology results were analyzed with 
Fisher’s test when analyzing 2 groups and Chi square tests for more than two groups (dam 
thyroid glands). 
To avoid litter effects no more than one pup per litter was included in any analysis. Where 
an overall significant treatment effect was observed, Dunnet’s test was used for two-tailed 
comparison with the alpha level for statistical significance always set to 5%. Exposure 
groups were tested against the vehicle control and in addition a “full model” was con-
structed; the study design with dose response exposure to PFHxS and the addition of 
groups exposed to both PFHxS and the EDmix allowed for construction of a statistical 
model integrating all exposures and control groups into one full linear model depicted and 
described in detail in Ramhøj et al., 2018, it includes PFHxS and EDmix exposures 
including their interactions parameterized as indicator variables. The chosen model 
parameterization allows explicitly making a statistical decision whether (and to which 
magnitude) EDmix changes in average the PFHxS responses across the different exposure 
groups. Furthermore, as a larger number of samples are considered in this full model, the 
increased sample size can identify much smaller effect changes than a simple pairwise 
comparison.  
SAS Enterprise Guide 4.3 (2010), SAS Institute Inc, Cary, NC 27513, USA, was used for 
statistical analyses.  
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Results 
 
Thyroid hormones in dams and offspring 
We have previously reported dose-dependent reductions of dam and pup total serum T4 
levels after developmental exposure to PFHxS (Ramhøj et al., 2018), data are replicated 
here as % of control for reader discretion, Fig 2. Here we add T3 determinations to 
complement the characterization of the thyroid hormone system. On GD15 dam T3 levels 
were reduced to 97% at 25 mg/kg PFHxS using the full statistical model (p = 0.0024, data 
not shown). Whereas, on PD 22 dam T3 levels were further reduced to 84% of control 
levels in the 25 mg/kg PFHxS group. This reduction was statistically significant both using 
a simple statistical model and the full model (p =  0.0099 and p = 0.0054, respectively, fig 
2 A). 
As previously reported (Ramhøj et al., 2018) pup T4 levels were down to 70 and 55% of 
control in the 5 and 25 mg/kg group, respectively. 0.05 mg/kg PFHxS nominally increased 
T4 levels to about 105% of controls, but this was not statistically significant. Opposed to 
the situation in the dams the EDmix had no effect on pup T4 levels. Here we report that T3 
was dose-dependently affected in the pups with a reduction to 93% of control level at 5 
mg/kg PFHxS (not statistically significant) and reductions to 84 and 87% of control levels 
in the 25-Px and 25-Px+ED groups, respectively (p = 0.0002 and p = 0.0015, respectively, 
Fig. 2 B). EDmix had no effect on pup T3 levels. 
 
The hypothalamic-pituitary-thyroid axis 
Offspring 
TSH determinations on pups PD 16/17 showed no significant changes in any dose group 
compared to controls (Fig. 2 C, note the large control variability). 
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 Fig. 2. T3 and TSH after developmental exposure to PFHxS. A. T3 levels in dams on PD 22 after 
exposure since GD 7. Data shown as mean + SEM. n = 13-15. B. PFHxS decreased Pup T3 levels 
at 25 mg/kg on PD 16/17. Data shown as mean + SEM. n = 14-18 litters represented by either a 
male or a female pup. C. TSH in male pups PD 16. Each symbol represents one animal with line 
and whiskers showing mean ± SEM. n = 11-13. 
D. Dam serum T4 at PD 22 was reduced from 5 mg/kg PFHxS (absolute values previously reported 
in (Ramhøj et al., 2018). n = 13-15 (except control with n = 20). E. Pup T4 was reduced form 
5mg/kg PFHxS (absolute values previously reported in (Ramhøj et al., 2018). n = 14-18 litters 
represented by either a male or a female pup. ** p <0.01 compared to control, *** p <0.00 
compared to control, ++ p <0.01 for full model comparison of indicated dose of PFHxS compared 
to no PFHxS exposure in the control and EDmix group. +++ p <0.001 for full model comparison of 
indicated dose of PFHxS compared to no PFHxS exposure in the control and EDmix group. TSH: 
Thyroid stimulating hormone. T3: Tri-iodothyronine, N/A: not available. 
 
 
PFHxS dose-dependently reduced female thyroid gland weights at weaning on PD 22 (Fig. 
3 B), already from 0.05 mg/kg in the full model and from 5 mg/kg compared to control in a 
simple model. This effect was not statistically significant in the PD 17 glands (Fig. 3 A). 
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RT-qPCR on the PD 17 thyroid glands showed no effect on gene expression levels of 
Slc5a5(NIS), Nkx2.1, Tpo, and Tshr in the tested PFHxS-only groups (data not shown). 
Control and high dose (25-Px) male thyroid glands from PD 16 were evaluated histologi-
cally and smaller changes were found on PD 16 in the 25-Px group (Fig. 3 C-F) as 50% of 
the exposed animals received a B-score (reflecting one minor alteration that could be 
within the normal range) compared to 12.5% in the controls. By PD 22 this slight effect 
was no longer seen, possibly due to recovery. No animals were given the C-score at any 
time (reflecting hypertrophy and/or hyperplasia). 
We previously reported (Ramhøj et al., 2018) increased liver weight in both male and 
female offspring exposed to PFHxS and/or EDmix during development (from 5 mg/kg 
PFHxS in female offspring). Here we followed up on these observations and histological 
assessment of liver sections from female offspring showed no differences between controls 
and exposed animals (25 mg/kg PFHxS). Minimal midzonal microvesicular vacuolation 
was found in female offspring, but the change was evenly distributed between exposed and 
control animals. Morphological liver changes that could explain the changes in liver 
weight were not found.  
 
Dams 
TSH in dams on PD 22 was not altered by exposure to PFHxS (Fig. 2 F). 
There was no statistically significant effects on dam thyroid gland weights apart from a 
reduction by the EDmix (p = 0.0133, full model, data not shown). There was no changes to 
histopathology in the glands (data not shown) and gene expression levels of 6 genes 
involved in thyroid hormone economy (Slc5a5(NIS), Nkx2.1, Tpo, Tshr, Pax8 and Dio1, 
data not shown) showed no indications for an increase in thyroid gland activation to 
compensate for the reductions in serum thyroid hormones. 
Histological assessment of dam livers PD 22 showed no difference between control and 
high dose animals (25 mg/kg PFHxS). 
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 Fig. 3. Thyroid gland weight and histology PD 16/17 and 22, and histology on pup lives PD 16/17 
after developmental exposure to PFHxS. A. and B. Female pup thyroid gland weight at PD 16 and 
PD 22. Data shown as mean + SEM. * p <0.05 compared to control, ** p <0.01 compared to 
control. n = 11-16. 
D. and E. thyroid histopathology on male pup thyroid glands PD 16 and PD 22. Bars represents 
animals receiving indicated score. * p <0.05.  n = 13-17 animals per exposure group at each time. 
C. and F. representative images of thyroid tissue from a control male pup (C) receiving a score of A 
(no remarks) and a male pup from the 25-Px group (F.) receiving a score of B (1 mild alteration, 
potentially within natural variation) for increased cellularity (marked with arrowheads). 
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Brain development 
Cortical gene expression 
The cortical expression of 8 thyroid hormone responsive genes previously shown affected 
after developmental PTU exposure was assessed in male PD 16 pups: Agt, Col11a2, GJb6, 
Hr, Itih3 Klf9, Ntf3, and Pvalb (Fig. 4 A) (O’Shaughnessy et al.). No clear evidence for 
decreased expression due to lack of thyroid hormone were observed. Expression levels of 
Itih3 and Klf9 were significantly increased and decreased, respectively, however, the 
modest effect sizes of less than 0.25-fold warrant further studies of these potential effects 
on the developing brain. 
 
Motor activity  
Effects on motor activity levels in all of the three tested ages were sparse and did not 
correlate with thyroid hormone levels during development. The most notable changes at 
the 3 ages are described below. 
In prepuberty no sexual dimorphism was observed and no significant effects of PFHxS 
exposure were seen in either male of female offspring (Fig. 4 B). 
In young adulthood the most notable changes were reduced activity in the middle test 
period in 0.05 mg/kg females (p = 0.014, compared to control)(data not shown). In males 
increased initial activity was seen in the 5 mg/kg group (p = 0.018, compared to con-
trol)(data not shown). The EDmix appeared to increase activity levels, in young adult male 
offspring total activity (p = 0.0446, full model, Fig. 4 C) and activity in the last half of the 
testing period (p = 0.0297, full model) were increased (data not shown). 
Also in young adulthood the inherent sex-difference in activity had disappeared in the 
group exposed to low-dose PFHxS (both compared to control and in the full model) and in 
the higher exposure 5-Px+ED and 25-Px+ED groups (Fig. 4 C). Both indicating disrupted 
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sexual differentiation of the brain and observed at a very low dose of PFHxS or at higher 
doses in combination with the background mixture exposure. 
In old animals adding the EDmix to the PFHxS exposure caused some small but significant 
changes (data not shown). 25-Px+ED reduced activity compared to EDmix in the old 
female offspring.  
Whereas, again the EDmix appeared to increase activity, this time in the old female 
offspring  where the EDmix group were more active than controls in the initial phase of the 
testing (p = 0.0082, t-test versus control) (data not shown). 
 
Learning and memory in the radial arm maze 
No evidence of a thyroid hormone mediated impaired learning was seen in the adult 
offspring. The only statistically significant effects observed were at 0.05 mg/kg PFHxS, 
where the males made fewer errors during the first week of testing (Fig. 4 E) and the 
females both during the first week of testing and overall spent more time in the maze (Fig. 
4 D), both compared to their respective control. Conclusions on sex differentiation for 
learning and memory cannot be made due to the different ages at which females and males 
were tested. 
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Fig. 4 Effects on cortical gene expression, motor activity levels, and learning and memory after 
developmental exposure to PFHxS.  
A. Cortical gene expression levels for thyroid hormone mediated genes in male offspring PD 16. n 
= 8-9. 
B. and C. Motor activity levels in offspring PD 27 and PD 115. As expected there was an inherent 
sex difference in activity levels between control males and females in the young adult offspring, 
this sex difference was not found in the 0.05-Px, 5-Px+ED and 25-Px+ED groups, indicating 
disturbed sex differentiation of the brain. n = 11-19 animals per sex per litter. D. and E. Learning 
and memory assessed in the radial arm maze. n = 16-17 for the females, n = 15-19 for the males. 
Data shown as mean + SEM, * p <0.05 compared to control, ϕ p>0.05 for a sex difference within 
the indicated exposure group 
 
 
Discussion 
 
Reduction in TH and Mode of Action  
PFHxS exposure caused marked reductions in both T4 (reported previously) and T3. The 
effects were seen in both dams and offspring, and were significant already after 7 days of 
exposure, however longer exposure caused even more pronounced effects (i.e. larger 
reductions were seen on PD 22 than on GD 15). The most severe effect was the T4 
reduction in dams on day 22, which in study 2 was down to 30% of control levels (at 25 
mg/kg bw/day). In study 1, where a smaller group size was used, exposure to both 25 and 
45 mg/kg (Ramhøj et al., 2018) caused T4 reductions down to approximately 40% of 
control levels. 
The mode of action by which PFHxs causes such severe T4 reductions has not yet been 
investigated in depth, but PFHxS binds to both TTR and albumin (Kerstner-Wood et al., 
2003; Ren et al., 2016; Weiss et al., 2009). Therefore, displacement of thyroxine from 
serum transport proteins is expected to be the primary MoA for the PFHxS-induced 
hypothyroxinemia. This MoA has been further explored in rats for the similar perfluorinat-
ed compound PFOS, in a study where Chang et al., (2008) showed that transiently in the 
hours following administration of PFOS, free T4 rose dramatically, presumably due to 
displacement from transport proteins, followed by increased turnover and loss of thyroid 
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hormone through urine and feces (Chang et al., 2008). Total T4 remained low during the 
remaining 7 days of the study and it was not accompanied by HPT-activation. These 
observations are in line with our findings, and it can be hypothesized that a reached steady 
state between serum protein bound T4 and PFHxS could account for the observed maxi-
mum reductions in serum T4 to 30% of control levels. 
Another possible MoA is induction of the thyroid hormone glucuronidating enzyme 
UGT1A1 in the liver which in concert with increased thyroidal Dio1 mRNA, which the 
authors deemed responsible for the thyroid hormone effects after 91 days of PFOS 
exposure (Yu et al., 2009). However, the effects on thyroid and liver were only evident 
from 5 mg PFOS/L drinking water whereas T4 were down to 60% of control already at 1.7 
mg/L (Yu et al., 2009). Our studies could not confirm increased Dio1 mRNA levels in the 
dam thyroids on PD 22. Additionally, PPARα, CAR and PXR pathways were activated in a 
PFHxS mice study (Chang et al., 2018) and in a PFOS rat study (Dong et al., 2016). 
PFHxS did not appear to bind TR in an in vitro study (Ren et al., 2015),  whether other 
molecular initiating events as inhibition of TPO or NIS or effects on peripheral deiodinases 
could be contributing to the TH effects, has to our knowledge not yet been investigated.  
 
PFHxS reduced thyroid hormone levels in rats without activation of the HPT-axis 
In spite of the very marked decreases in circulating T4 levels, no significant effects on 
TSH levels were measured in dams (PD 22) or in offspring (PD 16). Based on our present 
understanding of thyroid physiology and the HPT-axis, reduced circulating T4 levels are 
expected to cause increases in TSH signaling. This leads to increased thyroid gland 
activation, with consequent changes in thyroid gland gene expression, hypertro-
phy/hyperplasia of the thyroid follicular cells, and increases in thyroid gland weight (Hood 
et al., 1999b; McClain, 1989; Vickers et al., 2012; Zoeller et al., 2007). The anti-thyroid 
drug PTU is a compound acting in this way, causing serum T4 levels to be reduced first, 
but soon followed by HPT axis activation. However, thyroid hormone disruptions by 
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environmental chemicals does not necessarily lead to an activation of the HPT axis 
(Kortenkamp et al., 2017). 
Here, the only effect in the thyroid system apart from reduced T4 and T3 were indications 
of adverse effects on male thyroid histopathology at PD 16. These were, however, transient 
(no longer seen on PD 22) and very mild, indicating that they could be chance findings 
within natural physiologic variation. 
It is presently unknown whether prolonged or increased exposure to PFHxS would have 
caused an activation of the HPT-axis. It seemed to be the case in male rats exposed to 3 
and 10 mg/kg PFHxS for 42 days as adverse effects on male rat thyroid gland histopathol-
ogy was found. This indicates a potential activation of the HPT axis at higher exposures. 
Unfortunately, TSH levels or thyroid gland weights were not obtained (Butenhoff et al., 
2009). The effects on male histopathology, compared to females, can be explained by a 
high internal exposure with high serum PFHxS levels, clear signs of toxicity and a 
different organ distribution of PFHxS, due to a poor renal elimination in males (Kim et al., 
2016; Sundström et al., 2012). In mice, at somewhat lower PFHxS internal exposures, 
there was no effect on serum TSH, thyroid gland weights or histopathology, but T3 and T4 
were not measured (Chang et al., 2018). Long term exposure to PFOS did not result in 
significantly increased TSH levels (Yu et al., 2009). 
It is thus clear that while we may be unsure of the long-term and high dose effects of 
PFHxS we know that it does not activate the HPT axis in a manner similar to PTU. It 
seems possible that the PFAS, like certain PCBs and PBDEs, can markedly reduce 
circulating T4 levels without a compensatory response within the HPT axis, even after long 
term exposure (Bansal et al., 2014; Goldey et al., 1995; Klaassen et al., 2001; Kortenkamp 
et al., 2017; Yu et al., 2009). 
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PFHxS induced hypothyroxinemia and effects on the developing brain 
There was no correlation between circulating T4 levels during development and behavioral 
effects measured in prepuberty or adulthood. While for PTU, MMI or thyroidectomy there 
is a correlation between developmental T4 levels and a wide range of behavioral effects in 
rats (Akaike et al., 1991; Axelstad et al., 2008; Crofton, 2004; Gilbert et al., 2006; Goldey 
et al., 1995; Kobayashi et al., 2005). On the other hand, despite validated developmental 
neurotoxicity behavioral protocols and sufficient group sizes, studies with other thyroid 
hormone disrupting compounds exist which have not shown any clear behavioral effects in 
the offspring (Axelstad et al., 2011b, 2011a, Gilbert et al., 2008, 2013a; Harry et al., 2014; 
Kodavanti et al., 2010). 
It seems likely that some of the apparent discrepancy between PTU and environmental 
chemicals can be found in the timing and severity of the fetal TH suppression. Data on the 
fetal T4 supply and in particular the fetal brain T4 supply are sparse, but indicate that PTU 
is very effective at restricting fetal T4 (Bastian et al., 2012; O’Shaughnessy et al.). 
The behavioral test employed in this study were designed to test for adverse effects, caused 
by a lack of thyroid hormone during development, which were irreversible, independent of 
concurrent effects on TH levels and which reflected altered brain function. We combined 
these tests with targeted gene expression profiling of the male pup PD 16 cortex. Tran-
script levels of TH responsive genes could potentially work as a direct molecular marker of 
thyroid hormone disruption in the developing brain (O’Shaughnessy et al.). The chosen 
genes have previously been implicated in PTU induced low T4 and some have been 
reduced dose-dependently by PTU (Bastian et al., 2012; Bernal, 2017; Gil-Ibañez et al., 
2017; O’Shaughnessy et al.; Royland et al., 2008). At this point in development the 
PFHxS-exposed pups had reduced serum T4 levels and assuming a direct correlation 
between serum and brain T4 levels (Gilbert et al., 2013a; Morreale de Escobar et al., 1988; 
O’Shaughnessy et al.; Porterfield et al., 1993; Ruiz de Oña et al., 1988; Schwartz et al., 
1997) levels it follows that thyroid hormone mediated gene expression in the cortex should 
be reduced. However, T4 levels were down to 55% of controls, close to the minimal 
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reduction required for effects on gene expression (O’Shaughnessy et al.), thus the effects 
on T4 by PFHxS may not have been above the limit of detection. Another possibility is 
that compensatory mechanisms lead to sufficient T4 levels in the developing pup brains so 
that cortical gene expression was indeed not altered, or simply that other genes than the 
ones examined here were affected by PFHxS exposure. 
 
Sensitivity of behavioral studies in rats and consequences to human health 
Adverse effects on human brain development have been shown in the children of women 
who fall within the low-normal range of T4 (Berbel et al., 2009; Gyllenberg et al., 2016; 
Haddow et al., 1999; Henrichs et al., 2010; Korevaar et al., 2016; Román et al., 2013). 
These results indicate that chemically induced changes to human serum T4 levels, during 
pregnancy, is a potential threat to human brain development. However, the testing of 
chemicals for effects on the developing nervous system relies on rather simple behavioral 
tests of rodents that do not appear to detect functional effects after more modest thyroid 
hormone disruption. Indeed, in humans, it is especially functional parameters as IQ and 
language which are affected after developmental hypothyroxinemia.  
 
Effects by low doses and effects on sex differentiation of the brain  
In addition to the marked disruption of thyroid hormones by PFHxS we found effects by 
PFHxS at the lowest tested dose, at 0.05 mg/kg. Although this is not correlated to the 
effects in thyroid hormones that were seen at higher concentrations, the effects on learning 
and memory at the lowest dose in both female and male adult offspring are concerning for 
primarily two reasons: First, this dose is far lower than the lowest tested dose would have 
been in a traditional developmental toxicology study design and hence, effects would have 
been overlooked, as the same effects where not seen at 5 and 25 mg/kg. Second, if effects 
are indeed present at 0.05 mg/kg in the rat, there is a much narrower safety margin between 
the current human exposure and what would be considered safe levels and a bigger risk 
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that some humans are exposed at levels that could be affecting them. This is especially 
true, if mixture toxicity is taken into account (Axelstad et al., 2014; Christiansen et al., 
2012; Hass et al., 2017; Howdeshell et al., 2017; Kortenkamp, 2014) and we assume most 
perfluorinated compounds to affect the thyroid hormone system in similar ways. Such 
assumptions seems warranted based on both the chemical and toxicological similarities 
between perfluorinated compounds and the existence of the possibility for mixture effects 
on serum T4 levels (Crofton et al., 2005; Flippin et al., 2009; Gomis et al., 2015; Lau et 
al., 2007; Ren et al., 2016). 
Other effects not clearly correlated to TH-disruption but related to both the concerns for 
low-dose and mixture toxicity are the effects on activity levels in the young adult off-
spring. Here, an inherent sex-difference in the rat brain had disappeared at both the low-
dose and higher doses of PFHxS in combination with the background EDmix. These 
effects appear to be due to increased activity in the males and reduced activity in the 
females, i.e. the males have been feminized and the females have been masculinized. 
These results further supports our previous studies of the sex hormone disrupting effects of 
a combination of PFHxS and EDmix exposure (Ramhøj et al., 2018), where we found 
weak signs that a combination effect of PFHxS and the EDmix was present as low as at 
0.05 mg/kg PFHxS. 
Since the low-dose effects observed do not follow a traditional dose-response relationship, 
chance findings are a possibility. Further studies confirming our observations and further 
characterizing the dose-response relationships for effects on sex differentiation and 
behavior are of great interest and could move the field forward by both expanding our 
understanding of these hard to study non-monotonic effects and improve our chances of 
safeguarding human health in the future. 
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Conclusion 
PFHxS reduces T3 and T4 in developmentally exposed dams and pups, but does not appear 
to activate the HPT-axis up to 25 mg/kg bw/day. The TH disruptions did not correlate with 
effects on behavior and learning and memory, rather the effects suggest that PFHxS 
disrupted sexual differentiation of the brain rather than caused thyroid hormone mediated 
effects. 
Human data show that T4 reductions during perinatal brain development can cause 
measurable reductions in child IQ. However, to regulate the use of thyroid hormone 
disrupting chemicals the current chemicals legislation is dependent upon the presence of a 
plausible link between a mode of action causing a physiologic effect and an adverse effect 
in animal studies. But, as we do not have sensitive tests for adverse effects of developmen-
tal hypothyroxinemia/hypothyroidism we risk not adequately protecting the developing 
brain in children. Therefore, to protect individuals and our societal collective cognition, we 
suggest using serum T4 as a marker of adverse effects until more sensitive tests are 
developed. 
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Introduction 
Integrity of the immune system is fundamental for health throughout life. However, 
associations between impaired immune function and serum levels of poly- and perfluoro-
alkylic substances (PFAS) have been seen in epidemiologic studies. The effects include 
asthma, susceptibility to infection, and poor long-term protection after vaccination (Dong 
et al., 2013; Goudarzi et al., 2017; Granum et al., 2013; Looker et al., 2014; Mogensen et 
al., 2015; Timmermann et al., 2017; Zhou et al., 2017). Especially correlations between 
serum antibody levels in response to childhood vaccinations in Faroese children seem 
strong (Grandjean et al., 2012, 2013, 2016; Mogensen et al., 2015). There is an inverse 
relationship between levels of several PFAS, in either maternal serum during pregnancy or 
in serum of the children at age 5 and 7, and serum vaccine antibody responses to tetanus 
and diphtheria vaccinations at age 5, 7 and 13. As these effects also results in an increased 
odds ratios for having no protective effect of the childhood vaccinations, the epidemiologi-
cal studies are highly concerning (Grandjean et al., 2012). Studies in animals of com-
pounds as perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) have 
confirmed their potential immunotoxic effects but animal studies of PFHxS are missing 
(Dewitt et al., 2008; FSANZ, 2016; Keil et al., 2008; Peden-Adams et al., 2008; Yang et 
al., 2002). In developmental toxicity studies of PFHxS we wanted to investigate the 
potential for developmental immunotoxicity of PFHxS on functional immune endpoints: 
antibody response to vaccination, delayed type hypersensitivity and avidity. To discern 
between effects induced by developmental exposure through the dam and effects caused by 
105 
 
direct exposure of young animals, these two exposure scenarios were investigated in 
separate studies.  
 
Materials and methods 
Animals and treatment 
Two developmental toxicity studies were performed with time-mated Wistar (HanTac: 
WH) rat dams (Taconic, Denmark). The study designs have been described in details in 
Ramhøj et al., (2018, see Study 1 and 2). Briefly, in Study 1 the immunotoxicity part of the 
study consisted of 3 groups of 8 animals dosed with vehicle (corn oil), 25 or 45 mg/kg 
bw/day of PFHxS (Perfluorohexane Sulfonate (PFHxS) purity >98 %, Sigma-Aldrich 
(Tridecafluorohexane-1-sulfonic acid potassium salt, CAS-No: 3871-99-6, lot 
#BCBC3545V). In Study 2 the immunotoxicity part of the study comprised 4 groups of 20 
animals dosed with PFHxS; 0.05, 5 and 25 mg/kg bw/day. Corn oil (Sigma-Aldrich) was 
used as vehicle and dosing in the control group. 
Animal were received on gestation day (GD) 3 of pregnancy and dosing of the dams was 
performed daily by oral gavage from GD 7 through postnatal day 22 (PND), except the day 
of delivery. The expected day of delivery (GD 23) was termed PND 1 for the pups. Hence, 
the age of the pups was related to time of mating rather than day of birth. 
From the day of arrival the housing standard controlled environmental conditions were: 
Reversed light/dark cycles of 12 hours (light from 9 pm-9 am), humidity 55 ± 5 %, 
temperature at 21 ± 1°C, and ventilation changing air ten times per hour. All animals were 
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fed ad libitum on a standard diet with Altromin 1314 (soy and alfalfa-free, Altromin 
GmbH, Lage, Germany) and were provided ad libitum acidified tap water (to prevent 
microbial growth) in PSU bottles (84-ACBTO702SU Tecniplast). 
Weaning was performed on PND 22. In Study 1, 8 males and 8 females per group were 
weaned (representing 5-7 litters, not adjusted for litter effects in the analysis). In Study 2, 
up to one male and one female pup from each litter were weaned and housed pair- or 
triple-wise with animal(s) of the same sex and group, and dams were sacrificed. These 
cohorts of weaned offspring were used for functional immune testing as described below.  
A study with the positive control compound cyclophosphamide was conducted with 40 
young adult Wistar rats from Charles River, Germany. Animals were received on PND ~24 
randomly allocated to 5 groups of 8 animals with equal weight distributions and housed 
pairwise under standard conditions as in Study 1 and 2. Animals were dosed once daily 
from PND ~30 with vehicle (saline), 5 mg PFHxS/kg bodyweight (bw)/day in corn oil or 
cyclophosphamide at 1, 3 or 10 mg/kg bw/day. Immunizations were performed as de-
scribed below. The high dose of cyclophosphamide caused weight loss and toxicity in the 
animals so the dose was halved to 5 mg/kg bw/day on PND ~48 and stopped at PND ~51. 
1 animal was killed ~49 because of ill health, one died ~51 and 3 were euthanized on PND 
~53, toxicity persisted even after reduction of exposure, so the remaining animals from the 
high dose group were sacrificed on PND ~57. 
The animal experiments were carried out at the DTU National Food Institute facilities. 
Study 1 and 2 in Mørkhøj, and the cyclophosphamide study in Lyngby Denmark. Ethical 
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approval was given by the Danish Animal Experiments Inspectorate. The authorization 
number given is 2015-15-0201-00553 C3. The experiments were overseen by the National 
Food Institute’s in-house Animal Welfare Committee for animal care and use. 
 
 
Autopsies, immunizations and blood samples 
Procedures were equal in Study 1 and 2 unless specified. Necropsy took place on 
PND16/17 and PND 22 where up to one male and one female pup per litter was macro-
scopically evaluated. On PND 16/17 thymus, spleen and popliteal lymph nodes were 
excised and weighed. On PND 22 spleen and thymus were excised and weighed. 
Weaned offspring were immunized twice (14 days apart) with 0.3 mg KLH intraperitone-
ally (i.p.) (200 µl of 1.5 mg/ml KLH) (Hemocyanin from Megatura crenulata (keyhole 
limpet) from Sigma-Aldrich, H7017-20 mg, Lot 065M4834V). In Study 1, Immunizations 
were performed on PND 23 and PND 37 and in Study 2 on PND 29 and PND 43. In the 
cyclophosphamide study immunizations took place on PND ~44 and PND ~58.  
Blood samples were taken from the tongue vein without anesthesia in Eppendorf tubes. In 
Study 1, sampling took place on PND 28, 37 (before immunization) and PND 43, in Study 
2, on PND 34, PND 43 (before immunization) and PND 48. In the cyclophosphamide 
study on PND ~49, PND ~58 (before immunization) and PND ~63. Blood was allowed to 
clot at room temperature for 1 h and stored in refrigerator (5℃) overnight. After overnight 
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storage clots were removed and tubes centrifuged at 3000 rpm for 20 min and the clear 
serum supernatant stored at -20℃ until analysis. 
 In Study 1 and 2, necropsy of all animals took place on PND 44 and PND 50, respectively. 
Thymus, spleen, popliteal lymph nodes, left medial mediastinal lymph node, liver and 
adrenals were excised and weighed. In the cyclophosphamide study necropsy was per-
formed on PND ~63 with excision and weighing of liver, thymus, and spleen. 
 
Specific IgG1 and IgM  
Levels of specific serum IgG1 and IgM was determined via enzyme-linked immuno 
sorbent Assay (ELISA). 96-well plates were coated overnight with 5 µg KLH /mL in 
carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3; pH 9.6). A positive and negative 
control serum pool was included on each plate to check assay reproducibility. Plates were 
incubated (1h) with serially diluted sera in PBS (137 mM NaCl, 3 mM KCl, 8 mM 
Na2HPO4*2H2O, 1 mM KH2PO4, pH 7.2) containing 0.01% Tween (PBS-T). Then, 
incubated (1h) with anti-IgG1 (1:20000) or anti-IgM (1:16000) antibodies in PBS-T (anti-
IgG1: horseradish peroxidase (HRP)-mouse-anti-rat IgG1(3060-05), anti-IgM: HRP-goat-
anti-rat IgM (3020-05). Both from Southern Biotech, Birmingham, AL, USA). Develop-
ment was performed with TMB-one (Kem-En-Tec, Copenhagen, Denmark) for 12 min in 
the dark and stopped with 0.2 M H2SO4. Absorbance was measured at 450 nm with a 
reference wavelength of 630 nm, using a microtitre reader (Gen5, BioTek Instruments). 
Levels of IgG1 and IgM are expressed as titers on a Log2-scale with cutoff determined 
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according to the negative control for IgG1 and IgM assays. The positive control was used 
to check reproducibility of the assay. 
 
Avidity 
For measurement of the strength of binding between KLH and IgG1 antibodies a thiocya-
nate inhibition ELISA based on the method described by El-Khouly et al. was conducted 
(El-Khouly et al., 2007). Overall assay, coating and reagents as described for above for the 
specific IgG1 assay. Serum samples were diluted in PBS-T to give an OD between 0.5 and 
1, 50 µl added to each well and incubated (1h). Then, incubation (30 min) with potassium 
thiocyate (KSCN, Sigma, St. Louis, MO, USA) in increasing concentrations (0, 0.1, 0.2, 
0.5, 1 and 2 M in PBS-T, quadruplicate determinations for each concentration). For 
detection, incubation (1h) with anti-IgG1 (see specific IgG1 assay). Reaction was visual-
ised by adding 100 µL/well of TMB-one for approximately 12 min and stopped with 100 
µL/well of 0.2 M H2SO4.  
Under the given assay conditions, it was determined that KSCN did not influence the 
binding of antigen to the plates. 
Avidity is expressed as the concentration of KSCN inhibiting 50% (IC50) of the antigen-
antibody interaction. The higher the concentration, the stronger is the interaction between 
antigen and antibody.  
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Delayed type hypersensitivity 
In Study 1 and 2, the day prior to necropsy (PND 43 and 49, respectively), animals were 
mildly anesthetized with hypnorm/dormicum. One ear was challenged intradermally with 
injection of 20 µl of a 5 mg/ml KLH solution and the other ear was injected with 20 µl 
0.9% sterile saline solution. To avoid bias, left and right ear was alternated to receive the 
challenge. Necropsy was performed approximately 24h after the ear injection. Immediately 
after decapitation the thickness of both ears was measured with a micrometer caliper at the 
site of injection and a biopsy was taken with a 6 mm biopsy puncture and weighed. The 
saline ear served as control ear of each animal and the change in ear thickness and weight 
was calculated by subtracting the thickness/weight of the saline ear from the KLH 
challenged ear. 
 
Statistical Analysis 
Data from continuous endpoints were checked for normal distribution and homogeneity of 
variance and then analyzed by analysis of variance (ANOVA). If assumptions were not 
fulfilled, data was transformed accordingly. Body weight was included as covariates in 
data analyses when considered as relevant. Antibody titer levels were analyzed by Kruskal-
Wallis. Litter effects were accounted for by not assessing more than one pup per sex per 
litter in all analyses except the weaned cohort in Study 1. Here, due to limited group sizes 
up to two siblings per sex were included resulting in n = 8 representing 5-7 litters. The 
global Type I error was controlled by the two-tailed Dunnett’s test or Dunn’s multiple 
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comparison, with the alpha level for statistical significance always set to 5%. SAS 
Enterprise Guide 4.3 (2010), SAS Institute Inc, Cary, NC 27513, USA, and GraphPad 
Prism 5.00 (2007) GraphPad Software, Inc, La Jolla, CA 92037, USA were used for 
statistical analyses. 
 
 
Results 
Organ weights 
Organ weights from Study 1 are shown in Table 1. On PND 16 male offspring popliteal 
lymph node weight was reduced nearly 50% at both 5 and 25 mg/kg PFHxS (p = 0.0277 
and p = 0.0205, respectively) but no effects were seen in female offspring. There were no 
effects, in any sex, on bodyweight, thymus and spleen. At PND 44 the only effect was 
reduced adrenal gland weight in 5 mg/kg PFHxS male offspring (p < 0.001). 
In Study 2 no statistically significant effects on body weight, popliteal lymph nodes, spleen 
and thymus for either male or female offspring PND 16/17 were found (Table 2). Body 
weight, liver and adrenal gland weights from PND 16/17 Study 2 were reported previously 
(Ramhøj et al., 2018). The only effects observed was an increase in female liver weight 
and in male adrenal gland weight in the 25-PFHxS group. At autopsy of the immunized 
cohort PND 50, no effects were found on body weight, adrenal glands, liver or immuno-
logical organs (Table 2). 
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In the cyclophosphamide study, cyclophosphamide had no effects on spleen, thymus or liver 
weight (Table 3). Likewise, there were no statistically significant effects on body weight 
PND 64 in the two cyclophosphamide groups that completed the study. The high dose 
group (10 mg/kg bw/day) was terminated early due to toxicity and body weight loss of 
approximately 20% compared to control. In the 5 mg/kg PFHxS group there were no 
effects on body weight, spleen or thymus weight, but the weight of the liver was increased 
with approximately 25% compared to control (p < 0.001).  
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Table 1. Absolute organ weights Study 1 (PFHxS range-finding study).  
Analysis performed with body weight included as covariate. 
 Control 25-Px 45-Px  
PND 16 male, n 5 5 5  
Body weighta (g) 35.8 ± 5.8 30.5 ± 1.2 33.4 ± 9.3  
Popliteal lymph nodes (mg) 3.9 ± 0.8 2.3 ± 0.7* 2.4 ± 0.8*  
Spleen (mg) 143.5 ± 47.7  106.6 ± 25.8 128.8 ± 58.8  
Thymus (mg) 133.5 ± 34.7 106.3 ± 8.9 108.9 ± 50.7  
PND 16 female, n 5 6 7  
Body weighta (g) 33.7 ± 8.0 31.8 ± 3.2 32.7 ± 8.5  
Popliteal lymph nodes (mg) 3.0 ±1.0 2.9 ± 0.6 3.1 ± 0.9  
Spleen (mg) 142.1 ± 75.5 129.9 ± 32.7 146.7 ± 61.1  
Thymus (mg) 119.9 ± 51.2 118.1 ± 23.3 122.9 ± 32.1  
PND 44 male, n (litters) 8 (5) 8 (6) 8 (7)  
Body weight (g) 166.4 ± 15.8  150.3 ± 20.8 154.1 ± 18.7  
Popliteal lymph nodes (mg) 8.6 ± 1.4 10.3 ± 3.5 10.0 ± 3.1  
Left lateral mediastinal lymph node 
(mg) 4.3 ± 2.7 3.2 ± 1.3 3.3 ± 1.7  
Spleen (mg) 628.0 ± 87.3 643.6 ± 93.7 622.1 ± 106.2  
Thymus (mg) 505.8 ± 74.0 508.5 ± 64.2 522.0 ± 112.3  
Adrenals (mg) 43.0 ± 6.8 35.5 ± 4.2 * 37.9 ± 4.8  
Liver (g) 7.23 ± 0.63 6.74 ± 0.80 7.27 ± 1.20  
PND 44 female, n (litters) 8 (5) 8 (6) 8 (7)  
Body weight (g) 133.1 ± 12.9 146.1 ± 25.7 136.8 ± 14.0  
Popliteal lymph nodes (mg) 8.5 ± 1.8 9.2 ± 1.2 8.0 ± 1.0  
Left lateral mediastinal lymph node 
(mg) 2.6 ± 1.4 3.7 ± 1.1 3.7 ± 2.1  
Spleen (mg) 467.5 ± 48.9 490.3 ± 72.1 473.8 ± 63.7  
Thymus (mg) 466.9 ± 48.4 488.9 ± 60.2 434.6 ± 96.0  
Adrenals (mg) 42.6 ± 7.9 43.5 ± 5.1 45.3 ± 9.1  
Liver (g) 5.45 ± 0.51 5.64 ± 0.73 6.01 ± 0.86  
Mean ± SD 
aBody weight reported previously (Ramhøj et al., 2018). Included here for reader discretion. 
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Table 2. Absolute organ weights Study 2 (PFHxS main study).  
Analysis performed with body weight included as covariate. 
 Control 0.05-Px 5-Px 25-Px 
PND 16 male, n 16 14 14 14 
Body weighta (g) 33.7 ± 4.8 34.1 ± 5.6 32.4 ± 3.5 30.5 ± 4.7 
Popliteal lymph nodes (mg) 3.0 ± 0.5 3.5 ± 0.9 2.6 ± 0.8 2.4 ± 0.6 
Spleen (mg) 135.7 ± 41.1 127.7 ± 38.6 117.6 ± 33.8 103.7 ± 25.2 
Thymus (mg) 122.3 ± 23.2 135.5 ± 39.4 117.6 ± 20.6 110.9 ± 23.2 
PND 17 female, n 16 11 16 16 
Body weighta (g) 35.7 ± 5.6 33.9 ± 4.9 34.5 ± 5.1 33.3 ± 4.6 
Popliteal lymph nodes (mg) 3.2 ± 1.0 3.3 ± 0.9 3.3 ± 0.7 3.0 ± 0.8 
Spleen (mg) 145.5 ± 52.3 122.1 ± 26.3 128.8 ± 6.6 128.6 ± 34 
Thymus (mg) 142.7 ± 25.3 124.6 ± 34.0 135.1 ± 26.8 125.5 ± 29.1 
PND 22 male, n 17 12 15 14 
Body weighta (g) 51.0 ± 6.3 50.8 ± 8.0 50.3 ± 5.4 48.6 ± 6.5 
Spleen (mg) 246.0 ± 77.1 254.5 ± 93.2 229.5 ± 53.4 223.8 ± 75.9 
Thymus (mg) 207.4 ± 30.1 208.8 ± 46.0 203.0 ± 32.9 193.8 ± 33.4 
PND 22 female, n 17 11 16 15 
Body weighta (g) 49.6 ± 4.6 49.4 ± 6.9 49.5 ± 5.8 49.2 ± 6.0 
Spleen (mg) 253.1 ± 67.3 229.8 ± 58.2 233.8 ± 48.7 230.7 ± 75.2 
Thymus (mg) 187.8 ± 36.3 215.3 ± 50.0 201.5 ± 28.8 198.1 ± 28.7 
PND 50 male, n 16 14 16 16 
Body weight (g) 192.6 ± 15.4 201.0 ± 19.0 196.6 ± 15.2 192.1 ± 14.8 
Popliteal lymph nodes (mg) 11.8 ± 6.0 11.7 ± 5.0 10.2 ± 3.6 10.7 ± 4.0 
Left lateral mediastinal lymph node 
(mg) 4.5 ±3.7 4.6 ± 1.6 4.7 ± 3.1 4.6 ± 2.8 
Spleen (mg) 685.5 ± 88.6 714.0 ± 121.0 698.0 ± 98.5 662.4 ± 97.4 
Thymus (mg) 552.4 ± 78.6 616.1 ± 97.2 560.1 ± 115.4 568.9 ± 74.5 
Adrenals (mg) 41.2 ± 6.2 42.4 ± 8.2 40.5 ± 7.0 41.8 ± 6.0 
Liver (g) 8.76 ± 0.88 9.25 ± 1.30 8.86 ± 0.87 8.54 ± 1.39 
PND 50 female, n 16 14 16 16 
Body weight (g) 150.7 ± 8.2 160.4 ± 13.0 168.3 ± 34.3 153.9 ± 12.3 
Popliteal lymph nodes (mg) 9.8 ± 3.4 11.2 ± 3.9 8.9 ± 3.2 9.8 ± 3.0 
Left lateral mediastinal lymph node 
(mg) 4.5 ± 3.0 3.3 ± 1.1 3.4 ± 1.7 4.6 ± 2.9 
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Spleen (mg) 471 ± 57.4 505.1 ± 69.7 490.2 ± 67.5 482.9 ± 77.9 
Thymus (mg) 444.0 ± 80.7 494.9 ± 93.4 452.4 ± 54.9 448.3 ± 79.6 
Adrenals (mg) 48.2 ± 5.2 50.3 ± 5.8 50.4 ± 6.8 49.2 ± 5.2 
Liver (g) 6.44 ± 0.47 6.88 ±0.67 6.32 ± 0.50 6.55 ± 0.80 
Mean ± SD 
aBody weight reported previously (Ramhøj et al., 2018). Included here for reader discretion. 
 
 
 
 
 
 
 
Table 3. Absolute organ weights cyclophosphamide study. 
Analysis performed with body weight included as covariate. 
 Control 5-Px CY 1 mg CY 3 mg 
PND ~64 male, n 8 8 8 8 
Body weight (g) 350.0 ± 19.4 348.2 ± 22.0 364.08 ± 31.1 333.6 ± 11.7 
Spleen (mg) 866.0 ± 134.8 902.0 ± 121.2 1002.4 ± 136.5 731.1 ± 95.1 
Thymus (mg) 599.4 ± 80.2 614.5 ± 156.9 674.8 ± 100.0 578.9 ± 75.0 
Liver (g) 13.61 ± 0.90 17.06 ± 1.53 *** 15.03 ± 1.83 13.33 ± 1.21 
Mean ± SD 
***p < 0.001 compared to control 
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Antibody responses 
Developmental exposure to PFHxS 
Antibody levels for Study 1 are depicted in Fig. 1. Primary IgM titers in Study 1 were quite 
low but detectable in most animals, they had risen in the secondary response in most 
animals, but no statistically effects were observe in either sex. Likewise, the primary IgG1 
response was quite restricted with signs of increased response in the 45 mg/kg PFHxS 
males. Again, the secondary titers were increased compared to the primary response. In the 
male offspring some low responders were observed in the control group, and the 45 mg/kg 
group had serum IgG1 levels significantly elevated compared to controls. For the females, 
the same tendency of increase was apparent at 25 mg/kg PFHxS, however at 45 mg/kg four 
animals were non-responders, hence reducing mean value below control level. Overall, 
interpretation of results is significantly hampered by a very large variation within groups. 
In an attempt to reduce variation, potentially caused by increased stress after weaning of 
the offspring, time of immunization in Study 2 was postponed 5 days to PND 29. No 
statistically significant effects were found in offspring in this study (Fig. 2). Primary IgM 
responses show a  
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Fig. 1. Specific serum IgM and IgG1 responses after immunizations with KLH and developmental 
exposure to PFHxS, Study 1. Immunizations performed on PND 23 and PND 37. PND: postnatal 
day. Individual animals represented by symbols. Lines and whiskers represent median ± range. n = 
8 representing 5-7 litters. 
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high variability in both sexes whereas the variation is lower  in the secondary and IgG1 
responses, although still with some animals being poor responders and primary IgG1 levels 
in high dose males (25 mg/kg) being quite variable. Generally, antibody levels are 
increased compared to Study 1 and means are quite similar over exposure groups. The 
distribution pattern potentially indicating that maximal titer levels have been reached in the 
animals. 
 
Cyclophosphamide and direct exposure to PFHxS 
The cyclophosphamide study included a group of young males dosed with PFHxS. In this 
group there was no effect on IgM or IgG1 responses (Fig. 3). Cyclophosphamide had no 
statistically significant effect on primary IgM, and primary and secondary IgG1 responses. 
However, only primary IgM titers are available from the high dose group (10 mg/kg) as the 
animals were terminated prematurely for welfare reasons. No animals in the high dose 
group had a measurable primary IgM titer while 3 controls where above detection limit and 
5, 4 and 3 animals were above detection limits in the 5-Px, CY 1 mg and CY 3 mg groups, 
indicating an impaired primary IgM response at 10 mg/kg Cyclophosphamide. The primary 
IgG1 response appeared to be dose-dependently increased by cyclophosphamide, however 
not statistically significant and the trend was less pronounced in the secondary response. 
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Fig. 2. Specific serum IgM and IgG1 responses after immunizations with KLH and developmental 
exposure to PFHxS, Study 2. Immunizations performed on PND 29 and PND 43. PND: postnatal 
day. Individual animals represented by symbols. Lines and whiskers represent median ± range. n = 
14-16. 
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Fig. 3. Specific serum IgM and IgG1 responses after immunizations with KLH during exposure to 
PFHxS or Cyclophosphamide from PND 30, cyclophosphamide study. Immunizations performed 
on PND 44 and PND 58. PND: postnatal day. Individual animals represented by symbols. Lines 
and whiskers represent median ± range. n = 8, all males. 
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Fig 4. IgG1 Avidity in male and female offspring after immunizations with KLH and developmen-
tal exposure to PFHxS, Study 2. Immunizations performed on postnatal day (PND) 29 and PND 43 
and avidity determined on PND 50. Data shown as mean + SEM. n = 14-16. 
 
 
Avidity 
No statistically significant effects were found on avidity of IgG1 antibodies in the PND 50 
offspring from Study 2 (Fig. 4).  
 
 
A  IgG1 Avidity
     male
Co
ntr
ol
0.0
5-P
x
5-P
x
25
-P
x
0.0
0.2
0.4
0.6
0.8
1.0
M
 K
C
N
B  IgG1 Avidity
 female
Co
ntr
ol
0.0
5-P
x
5-P
x
25
-P
x
0.0
0.2
0.4
0.6
0.8
1.0
M
 K
C
N
124 
 
 
Fig 5. Delayed type hypersensitivity in male and female offspring after immunizations with KLH 
and developmental exposure to PFHxS, Study 1. Immunizations performed on postnatal day (PND) 
23 and PND 37 and challenge with KLH and saline on PND 34 followed by ear measurements 24h 
later. Data shown as mean + SEM. n = 8 representing 5-7 litters. 
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Figure 6. Delayed type hypersensitivity in male and female offspring after immunizations with 
KLH and developmental exposure to PFHxS, Study 2. Immunizations performed on postnatal day 
(PND) 29 and PND 43 and challenge with KLH and saline on PND 49 followed by ear measure-
ments 24h later. Data shown as mean + SEM. n = 14-16. 
 
 
Delayed Type Hypersensitivity 
No statistically significant effects were found on delayed type hypersensitivity as measured 
via ear thickness and ear biopsy weight after challenge with KLH (Fig. 5, Study 1 and Fig. 
6 ,Study 2). The measure showed high variability, hence low power. In both studies strong 
correlations between the 3 measures of ear thickness (DTH) were observed. The results 
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also revealed correlations between primary and secondary IgG1 responses and DTH 
suggesting activation of both Th1 and Th2-type responses after the immunization with 
KLH.  
 
 
Discussion 
 
The functional immunotoxic potential of PFHxS in animal studies is unknown, whereas 
multiple epidemiological studies have found associations with effects in humans (Dong et 
al., 2013; Goudarzi et al., 2017; Granum et al., 2013; Looker et al., 2014; Mogensen et al., 
2015; Timmermann et al., 2017; Zhou et al., 2017). The studies presented here aimed at 
investigating a relationship between developmental immunotoxicity in animals and 
exposure to PFHxS. However a high variation in study parameters and the failure of a 
positive control study precludes conclusions based on the studies. In the following we will 
discuss the model, the few results we can draw conclusions on, and suggest improvements 
to design of future studies. 
 
Positive control study with cyclophosphamide 
The positive control study with cyclophosphamide suffers from multiple severe limitations, 
most noticeably the lack of effect on serum antibody titers, effectively rendering our 
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studies useless. Regrettably, for practical reasons, the study had to be performed after the 
studies of PFHxS and it was carried out in a new facility at DTU Lyngby (although still 
with similar standard conditions in the new facility). This timeline is the reason that the 
animal model was not adjusted accordingly and validated again after the failed cyclophos-
phamide study. No apparent explanation exist for the lack of effects on antibody titers after 
exposure to cyclophosphamide where others have found effects (Hou et al., 2007; Kawai et 
al., 2013; Loveless et al., 2007), although the literature does suggest that positive control 
studies in immunotoxicology may not always produce significant results in all laboratories 
(section 2.6.2) In one of the validation studies Richter-Reichhelm et al.,(1995) compared 
five labs in a 28-day study of cyclosporine A with additional immunotoxicity endpoints 
(Richter-Reichhelm et al., 1995). Interestingly, at the highest dose, specific IgG was 
reduced in females but increased in males. In two labs out of five, specific IgM titers were 
decreased in male rats. These results seem to resemble our findings in the cyclophospha-
mide and PFHxS range-finding study and suggest that detection of effects even with 
positive control compounds may not always be as expected. Furthermore, it indicates the 
importance of sex in immunotoxicology studies and shows that the different endpoints 
reflect effects on different components of the immune system. These components may all 
be affected in dissimilar ways and examination of them all could be necessary to correctly 
predict the immunotoxic potential of a given compound.  
Other studies suggests that cyclophosphamide may not always function as an overall 
immune suppressing agent but that certain circumstances and dosing schemes rather result 
in an immune potentiation, possibly even increasing immune responses, as our cyclophos-
128 
 
phamide study could also suggest (Brode et al., 2008; Sistigu et al., 2011; White et al., 
2007). On the other hand we simply may not have been able to use a dose high enough to 
aquire enough sensitivity; the highest dose should cause a 10 % decrease in body weight 
(Dayan et al., 1998). However, this was not the case for our studies of either PFHxS or 
cyclophosphamide where the highest dose group surviving until the end of the experiment 
had a reduction of 4.9% possibly indicating a low sensitivity of our studies (Hou et al., 
2007).  
While unreliability and differential mechanisms may be the explanation for our negative 
findings, other potential sources of variation between the cyclophosphamide and PFHxS 
studies also deserve scrutiny and severely impair comparability between studies. Wistar 
rats were used for all studies, but for the cyclophosphamide study, the Danish breeder had 
suddenly discontinued the Wistar strain, hence the rats had to be delivered from Charles 
River, Germany. Therefore, the rats were from the same strain but originated from 2 
different breeding populations, potential source of variation. Another potential source of 
variation arises in the timing of the cyclophosphamide study. While the first immunization 
in Study 1 and 2 took place on PND 23 and 29, respectively, the first immunization in the 
cyclophosphamide study took place on ~PND 38. Possibly even later as the rats ordered as 
PND 24 rats upon delivery weighed 90 grams on average, a bit more than the ca 55 gram 
they weigh at the same age when they are born in our facility. 
All of the above factors may have influenced the results and contributed with variability, 
however, we should still have been able to detect effects in a positive control study. 
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Antibody responses after immunization with KLH as an animal model to detect devel-
opmental immunotoxicity 
CoV 
The immunization scheme to be employed in the PFHxS studies was optimized for KLH 
dose and immunization route in two pilot studies in young adult Wistar rats (Taconic, 
Denmark). A dose of 0.3 mg/kg KLH administered intraperitoneally was found optimal for 
detection of both increased and decreased antibody responses and on both primary and 
secondary IgM and IgG1 responses with coefficient of variations (CoV) between 10.4 and 
16.5%. However, when this model was applied to the cohorts of pups from the develop-
mental toxicity studies the CoVs for the antibody responses in the controls were between 
7.0% and 59.8%, significantly decreasing the power and reliability of the studies.   
 
Baseline 
The absolute antibody titers vary considerably between the two PFHxS studies; whereas 
the titers in the primary responses of Study 1 are so low that it effectively impedes 
detection of immunosuppression, the levels of the secondary responses and potentially also 
primary IgG1 from Study 2 could have reached maximum, precluding detection of 
increased responses and having activated the immune response so effectively that even the 
detection of immunosuppression would be with low sensitivity due to the strength of the 
induced response (and hence high potency required to revert the induced response). This 
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could also (partly) be the explanation for our failed cyclophosphamide study; the KLH i.p. 
immunizations may have been activating the full capacity of the immune system, effective-
ly compensating for the presumed cyclophosphamide induced immune suppression.  
Changes to baseline could also be due to changes in the antigen, where subunit confirma-
tion and sources of KLH has shown differential antigenicity (Lebrec et al., 2013). The 
same lot of KLH was used for all studies, although the KLH for the cyclophosphamide had 
been stored up until the end of its shelf life. 
 
Inter-studies variability 
Direct comparison between absolute titer values from different studies should be done with 
caution due to possible variation in the ELISA assay employed. We tried to overcome this 
by using the positive control to test the stability of the assay; still, comparisons to the 
concurrent control group are the most reliable. In our studies this mostly gives rise to the 
conclusion of no effect. However, the considerable difference between the studies suggest 
a need for further refinement of the animal model to ensure adequate possibility for 
detection of both increasing and decreasing effects on the antibody responses at the 
different phases of both IgM and IgG1 responses. If the marked differences observed 
between studies is representative, it may even be necessary with different immunization 
protocols for different immune effects and potentially also with a concurrent positive 
control group in every study.  
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Study design 
We attributed some of the variation in the range-finding study to potentially be due to 
increased stress in the animals who had been weaned the day prior to the first immuniza-
tion; hence immunizations in the main study were delayed 5 days, also allowing for further 
discrimination between true developmental effects and effects due to the internal dose of 
PFHxS. This shift in developmental age may provide some of the explanation for the 
differences in response profiles in the two PFHxS studies, as it can be assumed that the 
immune system is more mature in the older animals studied in the main study, although 
both studies took place during a time of rapid change in the immune system of these 
pubertal rats (Boverhof et al., 2014; Holsapple, 2005; Tonk et al., 2010, 2012). The 
significance of accurate timing of immunizations should be studied further also with the 
prospect of reducing variation within groups. 
 
The immune system over a lifetime 
Our studies, as well as OECD guideline studies, fail to adequately test the immune system 
over the lifetime of the animal with termination around day 50. For the OECD guideline 
studies the assessed time window is even narrower with continued exposure of pups after 
weaning and termination day 56 (± 3 days) with immunization 4 to 5 days before (OECD, 
2011). Effects on the immune system due to developmental exposure may arise later in life 
for example in the form of skewing of immune responses and increased risk of non-
communicable diseases (Dietert et al., 2009; IPCS, 2012). Immunotoxicity studies should 
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therefore assess these possibilities in addition to effects during development and matura-
tion of the system (Dietert, 2014). 
 
Additional endpoints 
Maturation of antibody responses is an important functionality of the immune system. 
Here, both the measures of primary and secondary responses and determination of avidity 
of the antibodies can serve for evaluation of this part of the immune system. The level of 
specific antibody as measured by ELISA may not be the most sensitive endpoint for 
antibody response (Bøgh et al., 2013; Kroghsbo et al., 2011). We therefore chose to 
include the binding strength (avidity) of the response, as it is a measure of the maturation 
of the specific response. There were no effects on avidity hence on the maturation of 
response between groups. 
Delayed type hypersensitivity was included in our PFHxS studies to expand our studies to 
also include a more Th1-cell dependent response. It was assessed as increase in ear 
thickness and weight of ear biopsy 24h after a KLH challenge. We saw a high degree of 
correlation between the two measures and also to IgG1 responses. This suggests an equal 
degree of T and B-cell activation by i.p. KLH. It is also worth noting that the high variabil-
ity within groups for the DTH response results in a low power, even with large nominal 
effects, statistical significance is unlikely with the current setup. Hence, nominal effects on 
DTH could function as circumstantial additional evidence to support a significant effect on 
antibody responses. 
133 
 
Conclusion 
 
Effects on the immune system after exposure to PFHxS were scarce; however a faulty 
study design impedes conclusions on especially functional immune endpoints, which in 
theory should be the most sensitive endpoint in immunotoxicology. At a high dose (45 
mg/kg) PFHxS may reduce immune organ weights, but this could not be replicated in the 
main study investigating doses up to 25 mg/kg. Hence further studies of immunotoxicity of 
PFHxS are warranted. 
 Other studies have shown that perfluorinated compounds are a threat to healthy immune 
function amongst humans and animals. While the evidence is strongest for PFOA and 
PFOS other perfluorinated compounds could possess similar properties and the effects of 
mixed exposures constitute a potential risk which should not be underestimated.  
While inclusions of immune related endpoints in OECD guidelines is an important step 
forward in protection of both the mature and developing immune system of wildlife and 
humans there still seem to be a need for tests that adequately test for dysregulated immune 
responses and late-life effects (Dietert et al., 2007; IPCS, 2012). Future research should 
address these needs for knowledge of both potential effects on the immune system by 
environmental chemicals, the similarities and differences between species, sexes and in 
particular characterization of the developing immune system including the role and 
importance of the complex network of cells and their communication with each other, with 
immune organs and the rest of the organism. 
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6 Discussion 
 
This chapter contains a discussion of perfluorinated compounds and the immune system 
(6.1), thyroid hormone disruption (6.2), thyroid hormone disruption by environmental 
chemicals and model compounds (6.3) and protection of human brain development (6.4). 
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6.1 Perfluorinated compounds and the  
developing immune system  
 
In this project, acute and developmental immunotoxicity induced by PFHxS was investi-
gated (chapter 5). Surprisingly, almost no effects on functional immune endpoints were 
observed. However, the animal models needs optimization, as the positive control study 
also resulted in no convincing effects, leaving the study partially void. At the highest tested 
dose, PFHxS may reduce immune organ weights, but this could not be replicated in the 
main study that investigated lower doses. Hence, further studies of immunotoxicity of 
PFHxS are warranted.  
Despite the limited effects in this project, both human and animal studies have previously 
shown that perfluorinated compounds can induce immunotoxic effects (section 2.6). In 
humans, effects on vaccine serum antibodies are convincing, whereas effects on other 
endpoints such as asthma or susceptibility to infections are more equivocal, especially with 
regards to PFHxS. Still, despite a limited number of studies, they suggest that current 
human exposure levels affect the immune system of the general population.  
The fact that MMR vaccinations appear to modulate the effects of PFAS for asthma 
[Timmermann et al., 2017] indicate that the compounds have complex effect activities, not 
only on vaccine antibodies,  but also in that they may cause a skewing of the immune 
system [G.-H. Dong et al., 2011, 2013; Zhu et al., 2016]. Hence, future research should 
focus on understanding the underlying mechanisms of PFAS mediated immunotoxicity and 
the potential implications for both the developing immune system and its long-term 
function. The combined effects of chemical exposures and other events impacting the 
immune system, for instance vaccinations and infections, should also be accounted for. In 
light of PFAS effects the endocrine systems also potential crosstalk-effects between the 
endocrine and immune systems should be investigated [WHO/UNEP, 2013]. Finally, 
bearing in mind the potential high human sensitivity to PFAS-mediated immune effects, in 
vitro tests using primary human immune cells could prove a beneficial addition to rodent 
models in understanding the molecular mechanisms driving the effects on the functional 
immune endpoints.  
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6.2 Perfluorinated compounds and thyroid 
hormone disruption 
 
The effects of PFHxS on the thyroid hormone system (chapter 3 and 4) resemble effects 
observed for other perfluorinated compounds that consistently affect circulating levels of 
thyroid hormones in animals. Evidence from human studies is less consistent (section 2.5); 
however, the importance of thyroid hormone levels for brain development and the 
limitations of the epidemiological studies on thyroid function, in connection with ubiqui-
tous exposure to PFAS warrants further investigations of the effects of PFAS exposure on 
the thyroid hormone system.  
We observed a reduction in T4 following PFHxS exposure, but cannot deduce how much 
of the effect derives from TTR-binding or enzyme induction. This is in general a challenge 
for thyroid hormone disruption caused by increased hormone metabolism, as our under-
standing of causality and quantitative relationships still is very limited. Thus, future 
research should aim to determine what exactly the effects are when a chemical binds to 
TTR.  In particular, determine how much T4 is displaced by a compound with a certain 
affinity and where this unbound T4 is subsequently dispositioned. In this context the liver 
response is especially relevant, as it remains unclear what the short- or long-term responses 
to unbound T4 are and to what degree T4 in itself can induce enzyme induction compared 
to what is induced by chemical exposure itself [Haberkorn et al., 2003]. Likewise, further 
studies of enzyme induction by compounds that do not affect distributor proteins are 
needed, as interpretations of results are currently impaired by the use of chemicals with 
multiple targets and differential effects. Through such studies, an AOP for increased 
metabolism of thyroid hormones could be further developed [Friedman et al., 2017] and 
understanding of the reasons and adverse effect implications for differential HPT axis 
activation after thyroid hormone disruption could be improved. 
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6.3 Thyroid hormone disruption by environ-
mental chemicals and model compounds   
 
Both drugs and environmental chemicals can affect thyroid homeostasis by acting on 
different different molecular targets. We are now characterizing which environmental 
chemicals might be thyroid hormone disruptors and if so, their potential downstream 
effects. And it is becoming increasingly clear that we need to adjust our assumptions, 
animal models and assays to fit a reality in which the environmental chemicals do not 
affect the thyroid hormone system similarly to the model compounds that shaped our 
understanding of the system in the first place.  
To exemplify, the following section will discuss in more detail PFHxS- and PTU-induced 
thyroid hormone disruption, its downstream consequences and our ability to detect the 
adverse effects in a regulatory context. Finally, ending with recommendations for some of 
the considerations needed when evaluating thyroid hormone disruptors.  
 
 
6.3.1  Contrasting downstream effects of the model compound 
propylthiouracil (PTU) and PFHxS mediated thyroid hor-
mone disruption  
 
As most of our knowledge of the thyroid system is derived from PTU studies, our studies 
on PFHxS were tailored for comparison with two PTU rat studies. One study from our own 
research group on behavioral effects [Axelstad et al., 2008] and another study from a 
collaborator [O’Shaughnessy, Wood, et al., 2018] on cortical gene expression (data from 
the study has also been published in [Gilbert et al., 2014, 2016, 2017; Johnstone et al., 
2013; Wood et al., 2014]. Axelstad et al., (2008) used a study design similar to our PFHxS 
study with oral gavage exposure, while O’Shaughnessy et al., (2018) administered PTU in 
the drinking water from GD 6 at doses of 1, 2, 3 and 10 ppm PTU [Gilbert et al., 2014; 
Johnstone et al., 2013]. Some of the results are summarized in Table 2. 
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Table 2. Thyroid hormone profiles and effects after developmental exposure to PFHxS and 
PTU in similar studies. 
*Indicates a statistically significant effect according to the paper. 
aPup serum T4 assessed on PN 14 in [O’Shaughnessy, Wood, et al., 2018]/[Johnstone et al., 2013] and PND 
16 in other studies. 
bNo further effects on serum hormone levels in dams or offspring expected up to 45 mg/kg, according to 
range finding study, Ramhøj et al., 2018. 
cTSH not measured. 
dDosing regimen described as “moderate” in the publication 
 
 
Thyroid hormone profiles 
PTU [Johnstone et al., 2013] and PFHxS caused differential serum hormone profiles (table 
2 and chapter 4). While 25 mg/kg PFHxS and 1 ppm PTU both decreased T4 to 55% of 
control, T3 was decreased by PFHxS and increased by PTU. Additionally, PTU caused an 
increase in TSH while there were no effects by PFHxS. For PTU a dose of 3 ppm was. 
required to reduce T3. However, 3 ppm had also reduced T4 to 18% of control levels and 
increased TSH to 660%. Possibly, some of the differences were due to activation of the 
HPT axis caused by PTU; serum TSH goes up to maintain serum T3 levels, but at the 
Exposure,  
grouped according to effect 
on pup serum T4a 
T4, % of 
control 
T3 % of 
control 
HPT axis 
activation 
Reference 
app. 50% of control    
25 mg/kg PFHxSb 55* 84* ↔ 
Ramhøj et al., 2018 & Ramhøj et 
al., manuscript 
1 ppm PTU 54* 112 234%* ↑TSH Johnstone et al., 2013 
0.8 mg/kg PTU 50* - ↑gland weight*c Axelstad et al., 2008 
20-40% of control     
2 ppm PTU 35* 108 448%*↑TSH Johnstone et al., 2013 
1.6 mg/PTU 23* - ↑gland weight*c Axelstad et al., 2008 
0-20% of control     
3 ppm PTU 18* 82* 660%*↑TSH Johnstone et al., 2013 
10 ppm PTUd 8* 40* 392%*↑TSH Johnstone et al., 2013 
2.4 mg/kg PTU 16* - ↑gland weight*c Axelstad et al., 2008 
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higher doses the compensation cannot maintain T3. Hence there are marked differences in 
the effects on serum hormones achieved in the O’Shaughnessy et al., PTU study and the 
PFHxS study, which could indicate differences in downstream effects of the compounds. 
Cortical gene expression 
The primary function of thyroid hormones is regulation of gene transcription. Thus, 
transcription of TH regulated genes could be a downstream effect of thyroid status in 
specific tissues at specific times [Bernal, 2007, 2017; Crofton et al., 2018; Royland et al., 
2008]. In other words, cortical gene transcription should be affected if low serum T4 
correlates with low cortical T4, as is the case in some models [Gilbert et al., 2013; 
Morreale de Escobar et al., 1988; Porterfield & Hendrich, 1993; Ruiz de Oña et al., 1988; 
Schwartz et al., 1997].  
O’Shaughnessy et al., showed dose-response relationships between cortical gene transcrip-
tion at PN 14 and reduced serum T4 after developmental exposure to PTU in drinking 
water (table 2) [O’Shaughnessy, Wood, et al., 2018]. Seven genes were significantly 
affected at 1 ppm PTU where brain T4, but not T3, was affected. Gene transcripts were 
decreased with decreasing levels of T4, down to below 0.1 fold of control expression, 
providing a compelling case for their transcriptional regulation being influenced by thyroid 
hormones [Bastian et al., 2012; Bernal, 2017; Gil-Ibañez et al., 2017; O’Shaughnessy, 
Wood, et al., 2018; Royland et al., 2008]. Unfortunately, at the low dose of 1 ppm PTU 
(T4 at 54% of control) a reduction of only 0.3 fold is observed, arguably falling within the 
inherent variability of the assay. Hence, reductions of this magnitude, despite statistical 
significance, are only confirmed by the remainder of the dose-response relationship. 
Extrapolating this observation to studies of environmental chemicals, which might only 
produce reductions of about 50% in circulating T4 in the pups on PN 14, it would result in 
an expression level at 0.7 fold compared to the control – in most cases not enough to be 
deemed significant and reliable. This is exactly what was observed in the PFHxS study 
where some of the same genes were investigated (chapter 4). The submaximal T4 reduc-
tion by PFHxS is not the more severe hypothyroxinemia that would be necessary to verify 
whether transcription of the thyroid sensitive genes examined by O’Shaughnessy et al. 
were affected. 
Cortical gene transcription as a downstream endpoint could possibly be enhanced by 
dosing pups directly with the thyroid hormone disruptor to induce a severe hypothyrox-
inemia for better comparison with PTU studies. This would exploit the nature of the direct 
relationship between concurrent TH levels and downstream gene transcription in the 
postnatal pups. And simultaneously be in contrast to other downstream effects which are 
assessed later in life and represents readouts of thyroid function over time (fig. 6). 
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Figure 6 | Conditions of thyroid hormones and downstream endpoints during development. Chemical interference with 
thyroid hormones should be assessed in light of the distinct features characterizing the developmental periods of the 
rat. In the beginning of gestation dam thyroid hormone balance is determining for the fetal supply, later follows gradual 
onset of fetal thyroid function and thyroid hormone balance in both maternal and fetal compartments have an 
influence on fetal TH supply. Birth denotes a sharp transition to new compartmental conditions with rapid changes in 
neonate HPT axis and hormones. In the postnatal period disruption of pup thyroid hormones can only take place with 
sufficient lactational transfer of the chemical. After PND 16 dosing through the drinking water can be efficient as direct 
exposure route. Hence, many factors determine the induction of severe hypothyroxinemia during brain development 
and the presence of hypothyroxinemia during the critical window of an effect. The outcomes of downstream endpoints 
are determined by thyroid hormone balance during the endpoint-specific critical windows, e.g. Heterotopia formation is 
dependent upon T4 deficiency from GD 20 to approximately PND 4, a critical window which spans two distinct 
developmental conditions and which is compromised with adequate T4 supply during one of them. GD: Gestational day, 
PND: Postnatal day. 
 
 
Behavior, learning and memory 
Effects on behavior, including learning and memory, represent functional defects caused 
by impaired brain development and assessment can take place later in life, long after 
exposure cessation. Accordingly, the relationship with brain hormones may be more 
complex, as effects may depend on a certain TH deficit during a particular developmental 
period; but perhaps more often during the entire period of brain development (fig. 7) 
[Crofton, 2000; O’Shaughnessy, Kosian, et al., 2018; Zoeller et al., 2007; Zoeller & Rovet, 
2004]. However, Axelstad et al., (2008) showed reasonable correlations between PTU-
induced decreased pup (PND 16) and dam (GD 15) hormones and effects on brain 
development. These effects were observed in the radial arm maze and on motor activity 
levels after T4 reductions to 23 and 16% of control on PND 16, respectively, and there 
were no effects at T4 at 50% (Table 2) [Axelstad et al., 2008]. Therefore, the sensitivity of 
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the employed behavioral assays to detect developmental thyroid hormone disruption is 
limited to very severe T4 reductions and it is not surprising that the high dose PFHxS (T4 
at 55% of control) did not result in TH mediated effects (chapter 4). 
 
 
6.3.2  Sensitivity of assays for downstream effects of thyroid 
hormone disruption 
 
Adverse effects on human brain development after developmental hypothyroxinemia 
typically manifest with complex functional parameters such as IQ and language [Berbel et 
al., 2009; Gyllenberg et al., 2016; Haddow et al., 1999; Henrichs et al., 2010; Korevaar et 
al., 2016; Román et al., 2013]. Yet, the testing of chemicals for effects on the developing 
nervous system relies on rather simple behavioral tests in rodents [Hass, 2006]. We are 
thus faced with two primary problems. Firstly, there is a discrepancy between the complex-
ities of the human brain and rodent brain, and consequently parameters that can be 
evaluated in rodents. Adverse effects in rodents are typically only detected at severely 
reduced T4 levels, whereas smaller reductions in T4 may cause adverse effects in humans. 
To the former, studies have shown similar picture of limited adverse effects correlated to 
submaximal thyroid hormone reduction after chemical exposure [Axelstad, Boberg, 
Hougaard, et al., 2011; Axelstad, Boberg, Nellemann, et al., 2011; Crofton, 2004; Gilbert 
et al., 2013; Gilbert & Lasley, 2013; Gilbert & Sui, 2008; Harry et al., 2014; Kodavanti et 
al., 2010; Kortenkamp et al., 2017; Noda et al., 2005]. Unfortunately, in animal studies of 
PFHxS and other environmental chemicals there is a limit to the maximal obtainable effect 
on T4 levels during the specific developmental stages: lower chemical potency, limited 
chemical transfer to pups or excessive pup or maternal toxicity at higher doses not related 
to thyroid effects, all limit the T4 reductions [Axelstad et al., 2013; Axelstad, Boberg, 
Hougaard, et al., 2011; Axelstad, Boberg, Nellemann, et al., 2011; Crofton et al., 2000, 
2005; Kodavanti et al., 2010]. Hence, due to assay insensitivities it is often not possible to 
distinguish between absence of effect, no effect due the existence of adequate brain 
hormones, and no effects as a result of only mild TH reductions in the fetal or pup 
compartments. Overall, after submaximal thyroid hormone disruption in animal studies, we 
have no reliable downstream endpoint in the brain. At reductions of 0-50% in circulating 
thyroid hormones there is virtually no potential candidates for such a reliable endpoint (fig. 
7). Some genes, and potentially periventricular heterotopias may be affected around a 
50%-ca.75% reduction in the offspring and the fetus, respectively (see below). This 
therefore leaves only a putative threshold at about 50% for detection of adverse 
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Figure 7 | Schematic correlations between decreased T4 levels during development and effects in humans and rats. 
While effects on functional brain endpoints appear in humans  when the maternal fT4 levels are in the lower end of the 
population reference interval, current endpoints in rats are only affected after T4 levels at less than 50% of control 
levels as assessed postnatally in the pups. Note that potentially both heterotopia and behavior may be dependent on 
thyroid hormone insufficiency during critical windows earlier in development. IQ: Intelligence quotient  TH: Thyroid 
hormones. 
 
 
effects on rat brain development after thyroid hormone disruption. This prominent lack of 
endpoints suitable for regulatory evaluation of thyroid hormone disruption presents a 
serious challenge for testing of thyroid hormone disrupting chemicals and thereby the 
protection of human health. 
 
Currently, the best candidate for an adverse effect suitable for large scale toxicological 
studies may be periventricular heterotopia, a structural effect (adverse effect in terms of 
toxicological regulation) observable at  around 50% decrease in T4 relative to control at 
PN14, [Gilbert et al., 2014; Goodman & Gilbert, 2007; Hassan et al., 2017]. Heterotopia 
seems to be dependent upon a small critical window around birth, however. Late during 
gestation, a dose of 1 ppm PTU decreases fetal T4 to around 40% of control levels and the 
heterotopia was just detected [Gilbert et al., 2014; Spring et al., 2016]. So far, heterotopia 
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has been observed after exposure to methimazole, PTU, and perchlorate, all sharing an 
intrathyroidal mode of action [Berbel et al., 2001; Gilbert et al., 2014, 2018; Goodman & 
Gilbert, 2007; Powell et al., 2012; Shibutani et al., 2009; Shiraki et al., 2012; Spring et al., 
2016]. Further studies are needed to assess both the exact sensitivity of the assay and the 
presence of effects after thyroid hormone disruption through extrathyroidal modes of 
action.  
 
6.3.3  Considerations for testing of environmental chemicals in 
contrast to model compounds  
 
Our knowledge of the thyroid system has relied heavily on animal models of severe 
hypothyroidism. As data on environmental chemicals is now emerging, a number of 
outstanding challenges remain to be addressed.  
 First, as described, development of a reliable endpoint that can be applied with-
in the framework of toxicological studies, e.g. not scanning of the brain or very 
specific counting of cell migration. Of special interest is an endpoint sensitive 
to decreases in T4 of less than 50%.  
 
 Second, model compounds and thyroid hormone disruptors affect TH serum 
hormone profiles in dams, fetus and offspring differently. Knowledge of the ki-
netics over time in different compartments and potential compensatory mecha-
nisms will be crucial for interpretation of the significance of the pres-
ence/absence of an adverse effect after chemical exposure.   
 
 Third, characterization of how different modes and mechanisms of perturbing 
the thyroid system affect circulatory TH and the peripheral tissue TH status, es-
pecially brain thyroid hormone concentrations and the derived effects.  
 
 Fourth, knowledge about local peripheral compensatory mechanisms is lacking. 
For example, an understanding of the compensatory capacity of D2 induction in 
the brain and its implications for adverse effects would be relevant. 
 
 Fifth, one specific and puzzling finding remains; the source of the lack of a 
compensatory TSH increase in response to thyroid hormone disruption by some 
environmental chemicals. The source(s) and downstream consequences of this 
type(s) of thyroid hormone disruption are still elusive.  
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6.4 Protection of human brain development 
 
The challenge of safeguarding human brain development from exposure to xenobiotic 
chemicals disrupting thyroid hormone system is complex. Currently, it relies on the 
development of tests and endpoints for thyroid hormone mediated adverse effects. As this 
approach has limitations and may be prolonged, this section will discuss more recent 
epidemiological data indicating the need for an alternative and timely approach to ensure 
optimal human brain development of future generations.  
 
 
6.4.1  Defining a threshold for adverse effect of developmental 
hypothyroxinemia in humans 
 
Thyroid hormones are necessary for human brain development, yet we do not know the 
lower (or upper) threshold for an adverse, suboptimal brain development due to develop-
mental thyroid hormone insufficiency. It seems that the variation within populations and 
analytical methods (section 2.4.3) impedes the setting of an absolute limit for thyroid 
hormone sufficiency. Furthermore, we are lacking knowledge of the consequences of a 
dynamic T4 reduction in an individual as opposed to the effects that are linked to having a 
low fT4 within the reference interval. However, what can be derived from the epidemio-
logical studies is knowledge about the impact on brain development of even very small 
differences in pregnancy T4 levels. 
Per definition, studies of developmental hypothyroxinemia deals with pregnant women that 
have T4 levels within the reference interval of the population, often studying differences 
between the lowest 5th and/or 10th percentile and the rest of the population (section 2.4.2). 
In Berbel et al., (2009) the lowest 10th percentile had an upper fT4 limit 15.4% above the 
lower limit of the reference interval. Thus effects on neurodevelopment were found for 
children of mothers within this 100-115.4% T4 (compared to lower reference boundary) 
[Berbel et al., 2009]. Another study found divergent results between mild and severe 
hypothyroxinemia compared to the rest of the population. Hence a reduction of 6.8% of 
fT4 from the upper limit had significance for the outcome, as expressive language was 
affected in both groups but only severe maternal hypothyroxinemia predicted a higher risk 
of nonverbal cognitive delay [Henrichs et al., 2010]. These studies have indicated the 
importance of very small differences in fT4 during gestation. Further supporting this 
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notion is an inverted U-shaped curve for IQ as a function of fT4, and also a clear dose 
response relationship between the lowest ca. 10th percentile of fT4 levels and IQ [Korevaar 
et al., 2016]. This dose response relationship suggests that even small decrements in the 
availability and function of TH have an effect on human brain development and the effect 
has proven clinically relevant in other studies. Similar dose response relationships have 
been seen for neurobehavioral development [Gyllenberg et al., 2016; Pop et al., 2003]. 
It is thus evident that, although the exact threshold for adverse effect on neurobehavioral 
development is yet unknown, very small differences in fT4 levels has an impact on brain 
development. At least in the lower end of the reference interval this impact takes place in a 
dose-response like manner, potentially with a threshold effect for the start of the dose 
response relationship. Absolute T4 levels for both threshold and dose-response curve are 
probably dependent on both the population investigated and analytical method at hand and 
they are influenced by other factors as iodine status and TPO-ab+ (section 2.4.3). If 
environmental chemicals also have an impact on TH of populations they may cause a shift 
of the population normal distribution and transfer more people into the dose-response area 
for neurobehavioral effects.  
Despite these unknowns, our current knowledge shows that human brain development is 
sensitive to thyroid hormone disruption also in the range below 10% changes in fT4. This 
indicates the need for an alternative approach in the evaluation of thyroid hormone 
disrupting chemicals. 
 
 
6.4.2  T4 as a marker and adverse effect outcome in 
 in vivo studies 
 
Presently, a sensitive assay to detect adverse effects caused by developmental T4 insuffi-
ciency is lacking. With the recognized importance of fT4 to human development and 
health, there is a strong need to change how we currently asses chemicals for thyroid 
disruption. Therefore, based on current knowledge, I would propose directly using serum 
T4 levels as adverse effect outcome instead of downstream effect markers.  
Arguments for adopting serum T4 levels as an adverse effect outcome for risk assessment 
purposes are: 
 Serum T4 levels are currently used as marker of thyroid function both in hu-
mans and in OECD guideline studies on rats. 
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 In human epidemiological studies, it is small changes in serum T4 and not T3 
nor TSH that display strongest correlation with effects on child neurobehavior. 
 
 Assessment of serum T4 is an established clinical method to diagnose and man-
age thyroid disorders with obvious advantages; e.g. ease of routine sampling 
and automated analyses.  
 
 Serum T4 levels are directly translatable between humans and rats when used as 
a marker of thyroid function. The potential sensitivity of the rat thyroid system 
can be taken advantage of to account for the sensitivity of human brain devel-
opment. 
 
There are, however, some shortcomings with respect to serum T4 levels as a biomarker 
that must be considered. They include: 
 Measurements of circulating T4 levels do not necessarily reflect changes at the 
local tissue levels, where T4 exert its functions.   
 
 In developmental toxicity studies, T4 levels are measured in dams and not in 
the fetal compartment. Although dam serum hormones are very important for 
fetal brain development, fetal thyroid hormones can be more sensitive than dam 
thyroid hormones.  
 
 Chemicals with MIEs in peripheral tissues, e.g. inhibition of deiodinases, mem-
brane transporters or interference with thyroid hormone receptors, may not be 
detected by assessment of serum T4 levels. 
Despite these limitations, serum T4 is presently the best option for assessing thyroid 
hormone status in animal toxicity studies, not least since even slight effects on circulating 
T4 level has been shown to have serious effects on human brain development. But efforts 
should still be made at developing even better and more sensitive test methods for thyroid 
disruption, as a golden standard test, or test battery, remains needed. To account for the 
potential insensitivity of T4 levels as adverse outcome readout, safety factors should, for 
the time being, be applied to account for potential specific effects in the sensitive fetal 
compartment and for peripheral targets of thyroid disrupting chemicals.  
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7 Conclusions 
 
This chapter contains the conclusions on the work presented in this thesis  
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Conclusions 
 
The overall aim of this PhD project was to better define to what degree early-life exposure 
to perfluorinated chemicals can affect thyroid hormone signaling and in extension, brain 
development. A sub-aim was also to examine potential effects on the immune system. To 
achieve this, we exposed pregnant rats to PFHxS and examined appropriate effect end-
points in a series of experiments.  
The presented developmental toxicity studies have extended our knowledge on how 
perfluorinated chemicals, in this case PFHxS, can disrupt normal development. We saw 
clear signs of effects in the liver, but also indications that PFHxS, when combined with a 
background exposure to endocrine disrupting chemicals, can disturb fetal hormone 
signaling and thereby affect sexual differentiation of the brain. 
This thesis also shows how PFHxS exposure can reduce circulating T4 and T3 in both 
dams and offspring without a compensatory increase in TSH levels. And, although we 
could not correlate developmental thyroid hormone insufficiency to effects in our behav-
ioral tests, comparisons to PTU studies show that this is not unexpected since the magni-
tude of changes to thyroid hormone levels induced by PFHxS were moderate compared to 
the maximal effect sizes induced by PTU. The effects on circulating thyroid hormone 
levels were nevertheless of a magnitude that raises concern for human brain development, 
as changes of just a few percent in maternal fT4 levels are associated with impaired 
cognitive and neurobehavioral development in their children; but also because current 
human exposures include other thyroid hormone disrupting compounds. 
Our understanding of the thyroid system and compensatory mechanisms is improving, but 
when it comes to effects caused by xenobiotics, our knowledge is still limited. Worryingly, 
the presented work has highlighted that current behavioral assays are not sensitive enough 
to detect adverse effects of developmental thyroid hormone disruption. It is critical that we 
become capable of detecting adverse effects caused by less than a 50% reduction in thyroid 
hormone levels.  It is well known that even small reductions in available thyroid hormones 
in humans can have negative consequences for the children’s brain development. Then, as 
environmental chemicals can cause T4 reductions, there is a strong need for implementing 
serum T4 levels as an adverse outcome in itself. A suggestion for effect size could be 
statistically significant effects at a magnitude of 10-20% from control levels. 
Due to technical difficulties, we were unable to establish a clear link between PFHxS 
exposure and immunotoxicity.  However, available literature on PFHxS and other PFASs 
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suggests that they are immunotoxic in humans at current exposure levels. Therefore, it is 
imperative that this work continues and that we establish with more certainty what the 
long-term consequences of PFAS exposure to human health may be.  
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